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GENERAL INTRODUCTION AND OUTLINE OF THESIS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Based on:  
“Important factors in diagnosis and staging of testicular germ cell tumours” by J.R. Spermon, 
F.M.J. Debruyne and J.A.Witjes in Current Opinion in Urology 2002 and “The management 
of testicular germ cell tumours” by J.R. Spermon and F.M.J. Debruyne in Annual European 
Course in Urology 2002, Rome, Italy. 
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I. Epidemiology and classification of testicular germ cell tumours 
 
Introduction 
Testicular germ cell tumours (TGCT), although an uncommon malignancy, evokes 
widespread interest in healthcare. Three decades ago, it was the most common solid tumour 
cause of death in young males. The development of a multi-modal treatment policy has 
resulted in revolutionary changes in the cure rate. Today, TGCT is one of the most curable 
solid malignancies and serves as a paradigm for the treatment of cancer.  
 
Incidence 
Testicular germ cell cancer represents 1% of all male neoplasms. The age-related incidence 
curve of testicular germ cell cancer has a bimodal distribution. The major peak occurs 
between the ages of 15 and 35. Non-seminomatous germ cell tumours represents the 
predominant histopathologic diagnosis up to the age of 35, while the peak age for 
seminomatous germ cell tumours is approximately 10 years older. The rates declining more 
rapidly beyond the age of 40 for nonseminomas compared to seminomas.1 As a result, 
virtually all testicular tumours among older men are seminomas. 
The incidence of the disease varies markedly based on geographic distribution, with the 
highest incidence in northern Europe and North America and the lowest in Africa and Asia.2,3 
Race is also of importance, with the highest incidence in Caucasian compared to black and 
Hispanic males.4 
The incidence is rising in the United States and in parts of Western Europe.2,3  Between 1973 
and 1995 the incidence of testicular cancer in the United States increased 51% (3.6 to 
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5.4/100,000).5 In the Netherlands the age-adjusted incidence increased from 4.8 to 6.6 per 
100,000 between 1991 and 2002.6 
 
Risk Factors 
Risk factors can be classified into Epidemiological, Pathological and Clinical risk factors as 
shown in Table I. The strongest proven risk factor for developing testicular cancer is 
cryptorchism with a risk ratio between 2.5 and 11.4 in case-control studies. Approximately, 7-
10% of testicular cancers develop in patients with a history of cryptorchism.1 
 
Table I. Classification of risk factors for germ cell tumours  
     
Epidemiological 
  Cryptorchism 
  Contralateral tumour 
  Geographic distribution 
  Race 
  Familial predisposition 
  Infertility 
  Klinefelter’s syndrome 
 
Pathological predictors for occult metastatic disease in clinical stage I disease1 
  Histopathological subtype  
  Vascular/Lymphatic invasion (only for non-seminoma testis) 
  Tumour size (only for seminoma testis) 
 
Clinical prognostic markers for survival in metastatic disease2 
  Primary histology 
  Primary location 
  Elevation of serum tumour marker levels 
  Presence of non-pulmonary visceral metastases 
     
1. See also Treatment of low stage testicular germ cell tumours pg 21-23. 
2. See also Table V, pg 20. 
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For clinical stage I non-seminomatous disease, the most important predictors for 
micrometastatic disease are the presence of vascular invasion in the primary non-
seminomatous tumour.7 In contrast, in seminomatous disease, the size of the primary tumour 
at presentation is predictive for metastatic disease.8 
Recently, the International Germ Cell Collaborative Consensus Group (IGCCCG) identified 
some clinical independent adverse factors for metastatic disease.9 A prognostic based staging 
system was generated out of these data, in which a combination of histology, stage of disease 
and degree of elevation of serum tumour markers determined subgroups of good, intermediate 
and poor prognostic risk groups for NSGCT, and good and intermediate risk groups for SGCT 
(see also Table V). 
 
 
Classification 
The histological type of testicular tumours varies, although there is a clear predominance of 
germ cell tumours (Table II).10 All germ cell tumours of the testis, with the exception of 
spermatocytic seminoma, are expected to originate from “intratubular germ cell neoplasia”, 
otherwise called “carcinoma in situ” of the testis.11 It is usually a diffuse disease, that might 
progress to invasive TGCT in as much as 50 % of cases within 5 years.12 
Testicular germ cell tumours are divided into seminoma and nonseminoma types. There are 
four subtypes of nonseminomas: embryonal cell carcinomas; yolk sac tumours; 
choriocarcinomas and teratomas. These nonseminomas can sometimes occur in combination, 
and are then called mixed tumours. The combination of seminoma and one or more non-
seminomatous components is considered a non-seminomatous tumour, because 
nonseminomas are generally more aggressive than seminomas. At the University Medical 
Centre Nijmegen, the modified classification of the World Health Organisation is used (Table 
II). 
  General introduction 
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Table II. Histological Classification of Testicular Tumours 
     
1. Germ cell tumours (96%) 
- Intratubular germ cell neoplasia (IGCN)     5 % 
- Seminoma        35 % 
- Spermatocytic Seminoma      5 % 
- Anaplastic Seminoma      5 %  
- Embryonal cell carcinoma      5 % 
- Yolk sac tumour        5 %  
- Choriocarcinoma       1 % 
- Teratoma (mature, immature, with malignant transformation)  4 % 
- Mixed germ cell tumours       31 % 
 
2. Sex Cord-Stromal Tumours (3.5%) 
- Leydig Cell Tumour      2 % 
- Sertoli Cell Tumour      1 % 
- Granulosa (adult and juvenile)     0.5 % 
 
3. Gonadoblastoma (0.5%) 
     
 
 
Seminoma germ cell tumours (SGCT) occur generally in older individuals than do most other 
germ cell tumours.1,10 SGCT usually spread via lymphatics, mainly to the para-aortic nodes 
and sometimes to mediastinal and supraclavicular nodes. Haematogenous spread is rare. The 
tumour is extremely responsive to both radiotherapy and chemotherapy. Two other histologic 
subtypes of seminoma have been described: anaplastic seminoma and spermatocytic 
seminoma.  
In 4 to 5% of seminomas, areas of anaplasia have been found and were thought to be associate 
with a lower overall survival rate.13 However, it has been demonstrated that the difference in 
survival reflected a tendency for the anaplastic variant to present at advanced stages, but that 
stage by stage there is no prognostic difference with pure seminoma.  
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Spermatocytic seminoma is a unique entity among testicular germ cell neoplasms. It never 
occurs mixed with other germ-cell elements but only occurs in its pure form. Other important 
clinical features further distinguish it from classic seminoma, including an average age at 
diagnosis above 50 years, a higher frequency of bilaterality and a rare occurrence of 
metastasizes.14 
 
Non seminoma germ cell tumours (NSGCT) occur most often in men between 20 and 35 
years. NSGCT are extremely heterogeneous. They metastasize via both the lymphatics and 
blood stream, especially to the lung. Liver, brain and bones are much less involved. 
a) Embryonal cell carcinoma is the most undifferentiated tumour, and the purer it is, the 
more aggressive it is.7 It is very responsive to chemotherapy. This tumour may be 
associated with an elevation in serum alpha-fetoprotein (αFP) and/or betachorion-
gonadotropin (β-HCG). 
b) Yolk sac tumour is the most frequent testicular tumour in children. In children, the tumour 
almost invariably occurs as a histological pure lesion, whereas in adults it occurs in 
combination with other elements. Also the natural behaviour is different between 
childhood and adult yolk sac tumours. Prior to the introduction of effective chemotherapy, 
the presence of yolk sac elements in adult tumours conferred a poor prognosis.15 
Similarly, children older than two years with yolk sac tumours had a poorer prognosis 
than children younger than 2 years.16 Metastases from yolk sac tumours occur via both 
lymphatic and haematogenous routes. Distant metastases most often involve the lungs and 
liver. It produces αFP. 
c) Pure choriocarcinoma is extremely rare. It occurs almost exclusively in young adults. 
Choriocarcinoma has the highest potential for organ confined metastases and yields a very 
poor prognosis.10 It metastasizes diffusely via the blood stream, often skipping the 
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retroperitoneum. When it is mixed with other histologies, it becomes a potentially curable 
disease, in contrast to pure choriocarcinoma which is very difficult to cure. It produces β-
HCG. 
d) Teratoma is a germ-cell tumour which underwent somatic differentiation from all three 
germ cell layers: ectoderm, mesoderm and endoderm. Incomplete differentiation leads to 
immature teratoma and complete differentiation leads to mature teratoma. The degree of 
maturity is closely linked to both the patient age at time of presentation and to clinical 
behaviour, specifically malignant potential.10 In early childhood, teratomas are almost 
invariable mature and carry a uniformly benign prognosis, even in the rare instances that 
immature elements are detected.17 In adults, on the other hand, the presence of mature and 
immature elements have a metastatic potential and may undergo malignant transformation 
also into non germ-cell cancers (e.g., sarcoma, adenocarcinoma). Because teratomas are 
poorly responsive to both chemotherapy and radiotherapy, surgical removal is necessary.18 
Serum tumour markers are normal in patients with pure teratoma. 
 
 
II. Signs, diagnosis and staging of testicular germ cell tumours 
 
Signs and Symptoms 
Testicular cancer generally occurs in young men. The most common sign of testicular cancer 
is a painless unilateral mass in the scrotum. In 20% of the cases the first symptom is scrotal 
pain, followed by back and flank pain in 11%. Gynaecomastia appears in 7% of the cases and 
is more common in non-seminomatous tumours.19 Differential diagnosis must be established 
with any other intrascrotal mass or disease, but scrotal complaints at young age need to be 
thoroughly investigated to rule out cancer.   
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Diagnosis 
The first step in diagnosing testicular cancer is usually made by self-examination. Ultrasound 
will confirm the presence of a testicular mass and can explore the contralateral testis.20 The 
sensitivity of ultrasound in detecting testicular tumours is almost 100%.21 Furthermore, 
ultrasound is able to distinguish intra-testicular from extra-testicular lesions and is able to 
detect microlithiasis. Microlithiasis should at least be cautiously followed up, or subjected to 
biopsy since it can be associated not only with intra-tubular germ cell neoplasia but also with 
testis cancer.22 
Serum tumour markers not only contribute to the diagnosis, but also to staging, prognosis and 
follow-up.23 Tumour markers are especially helpful to differentiate germ cell tumours from 
each other and from other malignancies. In clinical practice the most common markers for 
testis cancer consist of αFP, β-HCG and lactate dehydrogenase (LDH). AFP and β-HCG are 
produced by yolk sac elements and syncitiotrophoblasts, respectively. AFP has been increased 
in 50-70 % of NSGCT to β-HCG in 40-60 %. 
Over all, 90% of non-seminomatous tumours present a rise in one or both markers. In 8 to 
10% of patients with seminoma an elevated β-HCG is found because of the presence of 
syncitiotrophoblasts in the tumour. LDH is a non-specific marker, being an expression of 
tissue destruction grossly proportional to tumoural volume. It can be elevated in 80% of 
patients with advanced testis tumour. Importantly, negative markers do not exclude the 
diagnosis of germ cell tumour, and normalization of markers after treatment does not 
necessarily mean cure. 
After a testicular tumour has been clinically diagnosed, the ablation of the testis is indicated. 
The incision is high inguinal and the whole spermatic cord should be removed up to the 
internal ring with separation of ductus deferens and gonadal vessels. In case of bilateral 
tumour (synchronous or metachronous) an organ-preserving procedure should be considered. 
  General introduction 
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The operation should be performed in cold ischemia and biopsies must be taken from the 
tumour ground and periphery.24 
 
Staging 
As soon as the diagnosis of germ cell cancer has been confirmed, further staging 
examinations are warranted to examine the extent of disease. Clinical staging describes the 
extent of disease based on nonsurgical diagnostic modalities. Computerized tomography (CT) 
of abdomen and chest is the standard routine radiological staging technique. 
The abdominal CT-scan offers a sensitivity of 30-35% in the evaluation of retroperitoneal 
lymph nodes in the landing zone by using a threshold of 1 cm.25 Lowering this threshold 
results into an increased sensitivity, but a decreased specificity.25,26 New generation CT scans 
do not seem to improve the sensitivity.27 
Chest CT-scan is the most sensitive way to evaluate the chest. Although it is able to detect 
pulmonary lesions as small as 2 mm in size, up to 70% of these small lesions seem to be 
benign. When abdominal CT scan is positive, all patients should undergo a chest CT-scan.28 
Anteroposterior and lateral Chest X-rays can be considered as the only mandatory exploration 
when retroperitoneal and pelvic CT scans are normal.28 
CT examination of the brain, bone scan or liver ultrasound are advised only if there is any 
clinical suspicion of metastases.29 
In Europe, the most commonly used staging system for the primary tumour is the TNM 
classification (Table III),30 while the Royal Marsden Hospital Classification is used for the 
staging of dissemination (Table IV).31 Today, staging represents the cornerstone on which 
treatment is based. Low stage disease refers to clinical stages I and IIA disease, whereas high 
stage disease encompasses stages >IIA disease. This distinction between low and high stage 
General introduction 
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disease is important, as it determines, to a large degree, the adjuvant therapy that the patient 
receives. 
 
Table III.  The  TNM staging system for testicular cancer (1997)30 
     
Primary Tumour (only pathologically defined) 
pTx   Radical orchiectomy not performed 
pT0   Histological scar or no evidence of primary tumour 
pTis   Intratubular germ cell neoplasia 
pT1   Tumour limited to testis, including rete testis and albuginea 
pT2        Tumour limited to testis with evidence of vascular (hematic or lymphatic) invasion; or tunica 
        vaginalis involved by tumour 
pT3  Tumour involving spermatic cord, with or without vascular invasion 
pT4   Tumour involving scrotum, with or without vascular invasion 
 
 
 
Table IV. The Royal Marsden Hospital Classification system for germ cell tumours31  
     
Stage I  Tumour limited to testis 
   
Stage II  Infradiaphragmatic lymph node involvement 
 IIA Metastases <2 cm in diameter 
 IIB Metastases 2-5 cm in diameter 
 IIC Metastases 5-10 cm in diameter 
 IID Metastases >10 cm in diameter 
   
Stage III  Supradiaphragmatic lymph node involvement 
 A-D See stage II 
   
Stage IV  Extralymphatic involvement of lung (L), liver (H), brain and bone 
 L1 ≤ 3 metastases; ≤2 cm in diameter 
 L2 multiple metastases; ≤2 cm in diameter 
 L3 multiple metastases; ≥2 cm in diameter 
 H1 less than four, <2 cm in diameter 
 H2 more than four, <2 cm in diameter 
 H3 more than four, >2 cm in diameter 
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In addition, a prognosis based staging system has been developed to classify all patients with 
advanced disease into different risk groups, based on histology, extent of disease and level of 
tumour markers after orchiectomy. The International Germ Cell Cancer Collaborative Group 
(IGCCCG) determines subgroups of good, intermediate or poor prognosis for NSGCT and of 
good and intermediate risk for pure seminoma (Table V).9 
 
Table V. A prognostic factor-based staging system for metastatic germ cell cancer9 
 
Good prognosis group 
 
Non-seminoma: 
 
56% of cases 
5 year PFS* 89% 
5 year survival 92% 
  
Seminoma:   
 
90% of cases 
5 year PFS 82% 
5 year survival 86% 
with all of 
  testis/retroperitoneal primary 
  no non-pulmonary visceral metastases 
  AFP< 1,000 ng/ml and 
       HCG < 5,000 mIU/I (1000 ng/ml) and 
       LDH < 1.5 x upper limit of normal 
 with all of 
  any primary site  
  no non-pulmonary visceral metastases 
  normal AFP 
       any HCG  
       any LDH 
  
 
Intermediate prognosis group 
 
Non-seminoma: 
 
28% of cases 
5 year PFS 75% 
5 year survival 80% 
  
Seminoma:   
 
10% of cases 
5 year PFS 68% 
5 year survival 73% 
with all of 
  testis/retroperitoneal primary 
  no non-pulmonary visceral metastases 
  AFP ≥ 1,000 and ≤ 10,000 ng/ml or  
       HCG ≥ 5,000 and ≤ 50,000 mIU/l or 
       LDH ≥ 1.5 and ≤ 10 x upper limit of normal 
 with all of 
  any primary site  
  non-pulmonary visceral metastases 
  normal AFP 
       any HCG  
       any LDH 
     
 
Poor prognosis group 
 
Non-seminoma: 
 
16% of cases 
5 year PFS 41% 
5 year survival 48% 
  
Seminoma:   
 
no patients classified as 
poor prognosis 
with all of 
  mediastinal primary 
  non-pulmonary visceral metastases 
  AFP ≥ 10,000 ng/ml or  
       HCG ≥ 50,000 mIU/l (10,000 ng/ml) or 
       LDH > 10 x upper limit of normal 
  
     
* PFS = Progression-free survival 
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III. Treatment of low stage testicular germ cell tumours 
 
Treatment of low stage testicular disease results in an extremely high survival rate up to 
100%, independent on the choice of treatment.  
 
Low stage Seminomatous Germ Cell Tumour  
Patients with low seminoma germ cell tumour (SGCT) have traditionally been treated by 
orchiectomy followed by adjuvant abdominal radiotherapy. Only 5% of these patients relapse 
post-radiotherapy and the majority of them can be salvaged by chemotherapy.32 
To date, surveillance for stage I seminomatous disease is also possible. Surveillance studies 
have shown subclinical metastatic disease in 15%-20% of stage I seminoma patients, usually 
occurring in the retroperitoneum.32-35  About 15% of the relapsed patients require salvage 
radiotherapy and 5% salvage chemotherapy.32 The main advantage of preventing needless 
radiotherapy in 80% of the patients must be balanced against intensified cancer treatment at 
relapse and cost of long-term follow-up. Furthermore, good patient compliance is mandatory 
to surveillance policy. 
Seminoma cells are also clearly responsive to chemotherapy. Efforts are currently made to 
assess the use of prophylactic chemotherapy (two courses of carboplatin) as a treatment 
alternative. Two courses of carboplatin reduces the relapse rate to 0-1%.36-38 Despite this 
favourable outcome, controversy exists, because the majority of patients are overtreated and 
the late sequelae of carboplatin treatment and quality of life compared to surveillance or 
radiotherapy are not known. To date, the prophylactic chemotherapy regimen should be 
investigated in randomized trials, before definitive incorporation into daily practice.  
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Low stage Non-Seminomatous Germ Cell Tumour 
Patients with clinical stage I tumours have disease that is confined to the testis. However, 
approximately 30% of the clinical stage I non-seminoma germ cell tumour (NSGCT) patients 
are understaged by radiological imaging and are found to have metastatic disease at 
retroperitoneal surgery.39 Primarily two strategies have been applied to treat clinical stage I 
NSGCT: primary retroperitoneal lymphadenectomy (RPLND) with or without adjuvant 
chemotherapy or watchful waiting with close surveillance and chemotherapy on relapse. The 
certainty of accurate staging by surgery must be balanced against overtreatment in 70% of the 
patients. Therefore, some advocate surveillance and only treat patients who develop 
metastatic disease. Currently, two courses of primary chemotherapy have also been used in 
treatment for clinical stage I NSGCT. 
Today, treatment can also be adapted to prognostic factors for metastatic disease. The best 
predictor for metastatic disease is the presence of vascular invasion (VI) in the primary 
tumour.40 For patients at high risk for metastases some investigators39 advocate a RPLND 
with adjuvant chemotherapy in pathological stage (PS) II, whereas others recommend 
chemotherapy only.41,42 In contrast, patients at low risk (absence of prognosticators) will enter 
a surveillance protocol. Independent of initial treatment, the survival rate for stage I NSGCT 
patients is near 100%.43 So far, no consensus has been achieved about preferred treatment 
policy. The choice of treatment depends on a number of factors, such as risk factors for 
disease relapse, patient compliance and local expertise with respect to performance of the 
surgical procedure. Improving the clinical staging will ultimately result into better defined 
subgroup of patients and facilitates the choice of treatment. 
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Summary of primary treatment of low stage disease: 
 
radiotherapy surveillance chemotherapy
(trial)
seminoma
surveillance
absence of
vascular invasion
RPLND cisplatin based
chemotherapy
(trial)
presence of
vascular invasion
non-seminoma
Low Stage disease
 
 
 
IV. Primary treatment of high stage testicular germ cell tumours 
In general, high stage disease will be treated primarily with chemotherapy. The extent of 
treatment depends on the histology of the primary tumour and the prognostic risk groups as 
defined by the IGCCCG (Table V). The primary treatment of choice in high stage disease is 
combination of cisplatin based chemotherapy (BEP: Bleomycin, Etoposide, cisPlatin). While 
chemotherapeutic trials were being conducted, it became clear that prognoses varied and that 
patients should therefore be divided into low and high risk categories. The International Germ 
Cell Cancer Collaborative Group uses clinical parameters to divide patients with disseminated 
testis cancer into three risk categories: good prognosis, comprising 60% of germ cell tumours 
(GCT) with a 91% 5-year survival rate; intermediate prognosis, comprising 26% of GCT with 
a 79% 5-year survival rate; and poor prognosis, comprising 14% of GCT with a 48% 5-year 
survival rate.9 Currently, three courses of BEP is the primary treatment for metastatic germ 
cell tumours with good prognosis and four courses remain the choice for intermediate and 
poor risk patients.44  
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High stage Seminomatous Germ Cell Tumours 
Advanced seminoma is highly responsive to chemotherapy. There are often residual masses 
after induction chemotherapy containing residual cancer (10%) or fibrosis (90%). Many 
authors suggest resecting residual masses over 3 cm in diameter, 45 but post-chemotherapy 
surgery in pure seminoma is usually very difficult and dangerous because of intense fibrosis. 
Another less frequently used option is surveillance of residual masses and reserving 
radiotherapy or chemotherapy for those patients who subsequently develop progressive 
disease. 46   
 
High stage Non-Seminomatous Germ Cell Tumours 
Though chemotherapy plays a major role, postchemotherapy surgery has been complementary 
in the overall chance for cure of NSGCT. In general, residual mass after chemotherapy for 
advanced non-seminomatous disease has to be removed.47 Three histological entities can be 
found in the residual mass: residual tumour (10%), teratoma (50%) and fibrosis (40%). 
Resection of fibrosis confers no benefit to the patient, however it is not possible to predict the 
histology of these masses by clinical means. Teratoma has to be removed as it is not sensitive 
to chemotherapy and consequently it may continue to grow or degenerate into non-germ cell 
cancers. The key to success is complete resection with histology being the second most 
imported prognostic factor: 50-70% disease free survival for radically resected residual 
cancer, 70-90% for mature teratoma and over 90% for fibrosis.48 In case of residual 
tumourous disease, it is possible to give two adjuvant courses of chemotherapy. This policy 
is, however, not superior to careful observation and deferred treatment in case of relapse. 49 
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Summary of primary treatment of high stage disease: 
surveillance
no
resection
non-seminoma
<3cm: surveillance >3cm: resection
 diameter
no: surveillance yes: resection
progression during
surveillance
seminoma
yes
residual mass
chemotherapy
High stage disease
  
 
 
V. Follow-up in Testicular Germ Cell Tumours 
Testicular germ cell tumour (TGCT) is unique compared with other urological malignancies 
in that recurrence is highly treatable, especially when detected early. 50,51 As a result, optimal 
follow-up seems critical to the care of TGCT patients. However, no prospective studies have 
been performed so far to justify any particular follow-up schedule. 51 
To date, patients are followed by regular outpatient visits, during which physical examination, 
serum tumour markers and radiological examinations are performed. In most commonly used 
schedules, patients will visit a medical specialist up to 30 times over a period of 10 years. 
Some advocate even lifelong follow-up as late relapses have been recorded.52  
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VI. Fertility aspects in Testicular Germ Cell Tumours 
With the high cure rates in this young male population, fertility related aspects become 
increasingly important. For several reasons, fertility-related problems are common in patients 
with TGCT. Testicular cancer patients demonstrate decreased reproductive potential at 
baseline that might further deteriorate after treatment. Approximately a quarter of the patients 
remain azoospermic after treatment.53 Furthermore, up to half of all the patients undergoing 
surgery may suffer from ejaculatory dysfunction after treatment.54,55  
Today, the most effective way to preserve fertility potential in patients with TGCT is 
cryopreservation of sperm before any treatment is offered.55  
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Outline of this thesis  
From the preceding review, it becomes clear that testicular germ cell tumours represent a type 
of malignancy that can be cured in a large number of patients. This success has become a 
“two-edged sword” in the contemporary urologic oncology. On one hand, the vast majority of 
patients will survive as a result of advances from effective chemotherapy. On the other hand, 
this spectacular success has led to a dichotomy of views in the management of clinical stage I 
nonseminoma germ cell tumours and post-chemotherapy residual masses. Furthermore, some 
complacency has taken place regarding follow-up and fertility related aspects after primary 
treatment. This thesis focuses on the fine-tuning of different aspects in the management of 
testicular germ cell tumours. 
 
In the first part of this thesis, epidemiological risk factors have been evaluated. In daily 
practice, many patients and their relatives ask if testicular cancer is a familial related disease. 
In chapter 1, we evaluated if there is an increased incidence of cancer among relatives of 
testicular cancer patients. Possible familial clustering with other cancers may indicate a form 
of etiologic heterogeneity, which may facilitate the continued search for gene locations.  
In Chapter 2, we compare the survival rate of young and elderly patients with a testicular 
germ cell tumour adjusted for stage and morphology. Data from the population based Cancer 
Registry in the Netherlands suggest that testicular cancer patients older than 50 years of age 
have a worse disease specific survival. We evaluated if the same trend is present in a 
population of 12.881 patients with testicular cancer selected from the public-domain data 
from the Surveillance, Epidemiology and End Results (SEER) registry in the U.S.A.. If so, 
special attention has to be given to treatment and long-term care of elderly patients with 
testicular cancer. 
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The second part of the thesis deals with the management of clinical stage I nonseminoma 
germ cell tumours. In chapter 3, the current treatment options of clinical stage I non-
seminomatous testicular germ cell tumours are reviewed. The choice of management in 
clinical stage I disease is one of the most controversial topics in urological oncology today. 
Interestingly, the different treatment options –surgical versus conservative approach- have 
geographic trends that are influenced by personal choice of the medical specialists. In the 
United States, there is a strong urological surgical tradition. In Europe, the conservative 
approach is generally favoured. In the Netherlands, all but one centre advocate surveillance 
for clinical stage I disease. Chapter 4 presents a comparison of surveillance policy at the 
Antoni van Leeuwenhoek Hospital, Amsterdam versus retroperitoneal lymph node dissection 
at Radboud Nijmegen University Medical Centre, in which the advantages and disadvantages 
of both policies in the Netherlands will be outlined.  
A more rational approach to treatment would be possible if the likelihood of micrometastasis 
could be determined. In case of metastasis surgery is needed, whereas surveillance is the first 
choice of treatment in localised disease. In chapter 5, several prognostic risk factors are 
evaluated to predict the presence of micrometastasis in clinical stage I non-seminomatous 
disease.  
 
The third part of the thesis investigates the value of 18Fluor-Deoxy-Glucose Positron Emission 
Tomography (18FDG-PET) in the management of testicular germ cell tumours. 18FDG-PET is 
a relatively new technique in which the increased metabolic activity of malignant cells is 
visualized by radioactive labelling of glucose. Imaging the cellular glucose uptake by FDG-
PET has proven to be able to visualize tumour masses and seems to be a promising method 
for monitoring treatment response in other solid tumours, like breast cancer, and head and 
neck tumours.56 To study the value of FDG-PET in detection of testicular metastasis, chapter 
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6 introduces and discusses the role of 18FDG-PET in initial staging and restaging after 
chemotherapy for testicular germ cell tumours. In chapter 7, we evaluated if monitoring 
chemotherapy response in patients with high stage testicular germ cell cancer has additional 
value in differentiation of residual masses after chemotherapy. 
 
In the fourth part of this thesis, the efficacy of follow-up examinations for different subgroups 
of patients has been evaluated. The efficacy of follow-up after primary curative treatment has 
been described in chapter 8. A retrospective study was performed to get insight into the 
recurrence rate, the interval between completion of primary treatment and recurrence and the 
way in which recurrence was detected. Recommendations are given to optimize the current 
follow-up strategy at our centre. In chapter 9, special interest was focused on clinical stage I 
NSGCT patients on surveillance. The timely diagnosis of a relapse is important for a 
surveillance protocol. However, no prospective studies have been performed so far to justify 
particular follow-up schedules. In this chapter, we evaluate the efficacy of different follow-up 
strategies by using a simulation method (Markov analysis).  
 
Testicular cancer patients are young and have an excellent chance of survival including a long 
life expectancy, making (late) side effects on important topic. In the fifth part of this thesis, 
the effect of the disease per se and its’ treatment on fertility has been examined. Chapter 10 
reports on the prevalence of (in)fertility in men before and after treatment for unilateral 
testicular germ cell cancer. It is yet not known whether cancer treatment implies an increased 
risk of sperm damage. In chapter 11, the sperm quality including DNA-analysis has been 
analysed in testicular cancer patients before and after chemotherapy. 
 
In the last part of this thesis, all studies are summarised and future directions for the 
management of testicular germ cell tumours are suggested.  
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Abstract 
 
Objectives. To investigate the incidence of malignant tumours in first-degree relatives of 
patients with testicular cancer.  
Material and Methods. Information about the occurrence of cancer in relatives of patients 
treated for testicular germ cell cancer (TC) at the Department of Urology of the University 
Medical Centre Nijmegen from 1986 to 1997 was collected using postal questionnaires from 
379 (72%) of 524 patients. The expected numbers of cancers in relatives were computed from 
age- and sex-specific incidence data in the Netherlands Cancer Registry. The 
observed/expected (O/E) ratios with 95% confidence intervals (CIs) were calculated using 
Byar's approximation of the exact Poisson test.  
Results. The O/E ratio for developing cancer in the families of patients with TC was 1.2 (95% 
CI 1.0 to 1.3). Among first-degree relatives of patients with TC, more TC was observed than 
expected (O/E 3.3; 95% CI 1.4 to 6.9). The risk for brothers of patients with TC increased 
5.9-fold (95% CI 2.2 to 12.8). Both the risk of developing lung cancer (O/E 1.5) and 
malignancy of the female genital tract in sisters (O/E 2.8) was slightly increased. In contrast, 
the risk of urinary tract malignancies (O/E 0.3) and other and unknown primary tumours (O/E 
0.2) had a lower incidence among relatives. However, both the increased and decreased risk 
of nontesticular cancer for first-degree relatives may have been caused by misclassification.  
Conclusions. TC clusters in families were more pronounced among brothers than among 
fathers and sons. This study supports previous reports that families of patients with TC do not 
seem to be prone to nontesticular cancer. Additional investigations in families with TC are 
recommended to map candidate genes for TC. 
 
 
 
 
 
 
  Cancer incidence in relatives of testicular cancer patients 
  
 
 
 
37
Introduction 
 
Nonseminomatous germ cell tumours (NSGCTs) and seminomatous germ cell tumours 
(SGCTs) of the testis are the most common malignant tumours in young adults. The etiology 
is still poorly understood. The incidence of testicular germ cell cancer (TC) has risen 
dramatically during the past century.1 Important risk factors for TC are undescended testes, 
testicular dysgenesis, infertility, and an antecedent contralateral testicular neoplasm.2 Several 
studies have focused on the possibility of a familial predisposition to TC. For brothers of 
patients with TC, a 3 to 12-fold increased risk was calculated.3-7 This familial relative risk is 
much higher than that for most other types of cancer. After earlier inconclusive results,8,9 
recently a candidate gene location for TC was found with linkage analyses.10 Possible familial 
clustering with other cancers may indicate a form of etiologic heterogeneity, which may 
facilitate the continued search for gene locations. Two previous studies have reported an 
increased risk of breast cancer (odds ratio 4.4, P <0.05).11,12 The aim of this study was to 
investigate the risk of malignant tumours in relatives of patients with TC.  
 
Material and methods 
 
Family data were collected using postal questionnaires sent to all patients (n = 524) treated for 
TC at the Department of Urology, University Medical Centre Nijmegen from 1986 to 1997. 
All surviving patients who could be located were asked to complete the questionnaire asking 
for information about the occurrence of cancer in their first-degree relatives. Only first 
cancers occurring in the relatives were considered. When a patient had died (n = 42), the 
patient's partner or close relative was asked to complete the questionnaire.  
We asked the participants to list, if applicable, the date and side of an inguinal hernia, 
undescended testis, and/or orchitis in their history, and to list the year of birth, year of 
diagnosis, type of cancer, and year of death if applicable for all of his first-degree relatives. 
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Only the familial TC, brain tumour, and bone tumour stated in the questionnaires were 
verified by pathology or hospital reports or by contacting the general practitioner. 
At Statistical analysis, the observed numbers of cancers were compared with the expected 
numbers based on the population rates specific for age and sex. To compute the expected 
numbers of a specific type of cancer, we calculated each relative's time at risk as the number 
of years from his date of birth to the date of data collection, cancer diagnosis, or death, 
whichever came first. We then stratified the total person-years at risk by sex and age (5-year 
categories). The expected numbers were obtained by multiplying the person-years at risk in 
each category by the age and sex-specific incidence rates for the type of cancer obtained from 
the Netherlands Cancer Registry (1990 to 1995).13 The incidence rates of cancer in the eastern 
part of The Netherlands are similar to other parts of the country.14 Finally, the 
observed/expected (O/E) ratios with 95% confidence intervals (CIs) were calculated. The 
95% CIs were calculated using Byar's approximation of the exact interval for the Poisson 
distributed variables.15 
 
Results 
In total, 379 (72%) of the 524 questionnaires were returned. Of the remaining 145 patients, 10 
patients refused to take part, 41 patients had moved to an unknown address, and 94 
questionnaires were not returned for unknown reasons.  
The 379 patients had 2270 first-degree relatives and were observed for 85,375 person-years 
(data not shown). Seven (1.8%) of 379 families could be classified as having first-degree 
familial TC (FTC). The O/E ratios for TC among first-degree relatives are given in Table I.  
There were four SGCTs and three NSGCTs among the probands with first-degree TC. Among 
the sporadic cases, 110 (29.6%) of the 372 tumours were SGCTs and 262 (70.4%) were 
NSGCTs. The distribution of the histologic types in the probands with a positive family 
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history was not different from that of the sporadic TC cases (P = 0.20, Fisher's exact test). The 
mean age at diagnosis of the patients with FTC and those with sporadic TC was 36.1 years 
(range 27 to 51) and 32.4 years (range 1 to 77), respectively. The difference in age was not 
statistically significant. 
 
TABLE I Observed/Expected Ratios for first-degree Familial Testicular Cancer 
  
Relatives
(n) 
 
Person years 
at risk 
 
Observed
(O) 
 
Expected 
(E) 
 
 
O/E 
 
 
95% CI 
       
All men    1180   44.352 7 2.12 3.30 1.4-6.9 
Fathers      379   21.877 1 1.04 0.96 0.0-5.4 
Brothers      580   20.007 6 1.02 5.88 2.2-12.8 
Sons      221     2.468 0 0.06 0.00 0.0-61.4 
       
Key: CI = confidence interval 
 
 
In the present study, one of seven probands with FTC (14.3%) had an undescended testis 
compared with 10.5% of the patients with sporadic TC, and two had bilateral disease 
compared with 6 of 372 of the sporadic cases. 
In total, the first-degree relatives of patients with TC had a 1.2-fold increased risk of 
developing any cancer (95% CI 1.0 to 1.3). A statistically significant excess of respiratory 
tract cancer was found Table II. In contrast, other smoking-related cancers, such as urinary 
tract and mouth and pharynx malignancies, were observed less frequently than expected. 
Also, the number of cases in the group of other and unknown primary malignancies was 
observed significantly less frequently than expected. Stratification by histologic groups (i.e., 
SGCT and NSGCT) did not materially change these results, although the risk of TC seemed 
to be somewhat higher among the relatives of patients with SGCTs. 
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TABLE II  Observed/Expected Ratios for selected cancers in all first-
degree relatives of testicular cancer patients 
Site Histologic 
type 
Observed 
(O) 
Expected 
(E) 
O/E 95% CI 
      
Mouth and pharynx NSGCT 0 2.6 0 0.0-1.4 
 SGCT 2 1.4 1.4 0.2-5.2 
 Total 2 4.0 0.5 0.1-1.8 
Digestive tract NSGCT 25 20.1 1.2 0.8-1.8 
 SGCT 13 11.7 1.1 0.6-1.9 
 Total 38 31.8 1.2 0.8-1.6 
Respiratory tract NSGCT 25 17.3 1.4 0.9-2.1 
 SGCT 17 10.2 1.7 0.97-2.7 
 Total 42 27.5 1.5 1.1-2.1 
Bone and soft tissue NSGCT 2 2.0 1.0 0.1-3.7 
 SGCT 1 1.0 1.0 0.0-5.8 
 Total 3 2.9 1.0 0.2-3.0 
Skin NSGCT 10 7.8 1.3 0.6-2.3 
 SGCT 3 4.2 0.7 0.1-2.1 
 Total 13 12.1 1.1 0.6-1.8 
Testis NSGCT 3 1.4 2.1 0.4-6.1 
 SGCT 4 0.7 6.0 1.6-15.3 
 Total 7 2.1 3.3 1.4-6.9 
Prostate NSGCT 11 7.0 1.6 0.8-2.8 
 SGCT 3 4.7 0.6 0.1-1.9 
 Total 14 11.7 1.2 0.7-2.0 
Breast NSGCT 22 18.1 1.2 0.7-1.8 
 SGCT 11 9.1 1.2 0.6-2.2 
 Total 33 27.2 1.2 0.8-1.7 
Female genital system NSGCT 9 6.7 1.3 0.6-2.5 
 SGCT 4 3.4 1.2 0.3-3.0 
 Total 13 10.2 1.3 0.7-2.2 
Urinary tract NSGCT 3 6.0 0.5 0.1-1.5 
 SGCT 0 3.5 0 0.0-1.0 
 Total 3 9.5 0.3 0.1-0.9 
Central Nerve System NSGCT 4 3.0 1.3 0.4-3.4 
 SGCT 1 1.5 0.7 0.0-3.8 
 Total 5 4.5 1.1 0.4-2.6 
Endocrine glands NSGCT 1 1.0 1.0 0.0-5.4 
 SGCT 1 0.5 2.0 0.0-11.1 
 Total 2 1.5 1.3 0.1-4.8 
Haematolymphopoietic system NSGCT 12 9.1 1.3 0.7-2.3 
 SGCT 5 4.8 1.0 0.3-2.4 
 Total 17 13.9 1.2 0.7-2.0 
Unknown primary NSGCT 1 3.9 0.3 0.0-1.4 
 SGCT 0 2.2 0 0.0-1.6 
 Total 1 6.1 0.2 0.0-0.9 
Total NSGCT 128 106.4 1.2 1.0-1.4 
 SGCT 65 59.0 1.1 0.9-1.4 
 Total 193 165.4 1.2 1.0-1.3 
      
Key:  CI= confidence interval; NSGCT= non-seminoma germ cell tumour; SGCT= seminoma germ cell tumour. 
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Sisters, but not mothers, had a significant excess of malignancy of the genital system (data not 
shown). The incidence of other hormone-related cancers, such as breast and prostate cancer, 
was not significantly different. 
 
Discussion 
We found a modest increase of 16% in the total cancer incidence in the families of patients 
with TC. The risk of TC among first-degree relatives was increased. For nontesticular 
tumours, an increase in risk for first-degree relatives was found for respiratory tract cancers 
and female genital system malignancies in sisters. To verify the familial cases of TC, the 
pathology records of all first-degree affected relatives were obtained from the institution at 
which they had undergone orchiectomy. After comparing the obtained pathology records with 
the family questionnaires, no difference in reporting was noticed. Among the nontesticular 
tumours, misclassification could have taken place, because the occurrence of cancer in family 
members was based solely on the questionnaire, with the exception of brain and bone 
tumours. For example, metastasized cancers may have been reported instead of the primary 
tumour, leading to overreporting of, for instance, lung cancer. During the first evaluation of 
the unverified data, we also found a remarkably increased incidence of bone tumours among 
relatives (n = 8). After verification, however, five of eight bone tumours initially reported 
appeared to be metastases of other primary tumours. In addition, the small numbers of 
expected cases of some cancers (e.g., endocrine gland, bone, and soft tissue cancer) make the 
risk estimates highly sensitive to chance effects. Finally, families with TC and other cancers 
were more willing to take part in the study than families without cancer. Consequently, the 
questionnaires of the affected families were more completely filled out than those from 
families with sporadic cases. However, the O/E ratios of the separate malignant tumours were 
close to those of previous studies.6,12 
Chapter 1 
 
 
 42 
To assess the quality of the data concerning the occurrence of cancer among relatives, a 
positive and negative verification was performed by linking the questionnaire data of a similar 
study from our department on familial urothelial cell carcinoma to the population-based 
cancer registry. Three hundred thirty-nine relatives (case and control relatives) who lived in 
the catchment area of the Comprehensive Cancer Centre South (CCC South) were reported to 
have at least one malignancy diagnosed after 1975. This is the starting date of the cancer 
registry held by the CCC South. Three hundred one relatives could be linked to the cancer 
registry. In 77% of all tumours, the site registered by the CCC South and the site mentioned in 
the questionnaire were identical. For the 38 who could not be linked, additional information 
was obtained (through the proband or family). Fifteen relatives appeared to have been 
diagnosed and/or treated in hospitals outside the catchment area of the CCC South. Thus, the 
definitive positive linkage percentage was 93% (301 of 324). The remaining 23 relatives may 
not have been linked for several reasons, such as an inaccurate date of birth on the 
questionnaire, patient death within a few days after diagnosis (no pathology report), or the 
diagnosis was made in a nursing home (also no pathology report). A negative verification was 
performed as well. The 1940 relatives whom the probands reported as not having any 
malignancy were born before 1955 and lived in the catchment area of the CCC South. These 
relatives were also linked to the cancer registry, yielding a positive linkage percentage of 
2.8% for relatives who were reported to have no malignancy. It is possible that some of these 
patients were not informed that they had cancer (e.g., pTa bladder cancer) or that the involved 
relatives did not mention their diagnosis to their family. In that study, we also evaluated the 
reasons for no response. The reasons for not returning or not completing the questionnaire 
were stated to be no contact with relatives, too much effort, too emotional, too complicated to 
retrieve all data on relatives, and no permission of relatives to give any information. However, 
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it appeared that the percentage of a positive family history of urothelial cell carcinoma was 
8% in both responders and nonresponders, indicating an absence of response bias.16 
In the present study, we were able to demonstrate the familial aggregation of TC in 7 of 379 
families. The relative risk for first-degree relatives of patients diagnosed with TC was 3.3. 
Assuming a lifetime risk in the general population of 0.33 for TC,13 the lifetime risk for first 
relatives was approximately 1.1%. Brothers of patients with TC were noted to have the 
highest risk of developing TC. This corresponded with a 3 to 12-fold increased risk in 
previous studies. The actual proportion of FTC of 1.8% is consistent with other studies, which 
reported first-degree FTC in 1.0% to 2.8% of cases.3-7  
In two of our FTC families, lung cancer was diagnosed in a mother and a brother. In one 
family, the father developed prostate cancer at 84 years of age. In a fourth family, cancer of 
the digestive tract (brother) and breast cancer (mother) were found. Of interest, in all four 
families, the proband had a SGCT, but the numbers were too small to draw firm conclusions 
about the occurrence of nontesticular cancer in FTC families.  
In general, the clustering of cancer within a population may be the result of environmental 
and/or genetic factors. Various environmental factors such as prenatal exposure to estrogens 
and white collar or professional occupations have been associated with an increased risk of 
developing TC.2,17 However, study results have shown little consistency. Furthermore, the 
environmental risk factors would have to be very potent to induce familial clustering in 
absence of genetic susceptibility, and such a potent factor has not yet been identified in TC.18  
According to Knudson's two-hit theory, genetic susceptibility leads to an increased incidence 
of cancer at younger ages and bilateral involvement of paired organs.19 In a study by 
Nicholson and Harland,20 significantly lower ages at diagnosis among familial cases (29.1 
years) and bilateral cases (30.1 years) were observed compared with sporadic cases (35.7 
years). In the present series, the younger age among sporadic cases compared with familial 
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cases was due to a disproportionate number of NSGCTs among the sporadic cases. Analyzing 
the age differences stratified by histologic feature showed a slightly younger age at diagnosis 
among familial cases compared with nonfamilial cases within the group of patients with 
NSGCTs.  
Our findings of a greater proportion of bilateral tumours in FTC compared with sporadic TC 
is in agreement with published reports.4,5,20 We found a rate of bilateral involvement of 28.4% 
(2 of 7) in first-degree FTC.  
Higher rates of urogenital developmental anomalies have been associated with sporadic21 and 
familial TC.3 In a case-control study by Tollerud et al.,3 an increased risk of urogenital 
developmental anomalies was observed among familial cases compared with sporadic cases 
and controls (17% versus 2.7% and 5.3%, respectively). An undescended testis remains the 
most important risk factor, with a 2.5 to 11-fold greater risk of developing TC. Up to 10% of 
TCs are diagnosed in males with a history of an undescended testis. Possibly, the 
susceptibility to malignancy is determined by prenatal factors that cause both cryptorchidism 
and raise the risk of malignancy rather than by the position of the undescended testis.2 In our 
study, one of the FTC patients (14.3%) had an undescended testis compared with 10.5% of 
the sporadic cases.  
At present, the mode of inheritance in FTC is unknown. The observation that brothers were 
more affected than fathers favours a recessive mode of transmission. However, this finding is 
susceptible to bias as well. The introduction of cisplatin-based chemotherapy has dramatically 
improved the survival during the last generation.1 Before the introduction of cisplatin, there 
was essentially no effective treatment for metastatic TC. It is possible that only patients with 
late-onset disease were able to reproduce. In particular, the patients with NSGCT, which 
occurs 10 years earlier and has a worse prognosis than SGCT, may not have had a chance to 
reproduce. Consequently, more brother-brother pairs may be observed than father-son pairs.  
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In an effort to identify the susceptibility genes for TC, an International Testis Cancer Linkage 
Consortium has been formed to collect data on families with TC worldwide and to investigate 
candidate regions for a TC susceptibility gene. Candidate regions on chromosomes 3, 4, 5, 12, 
and 18 have been revealed, although the linkage was not strong.8,9 Recently, a genome-wide 
linkage search on X-suggestive families (no father-son transmission) showed a suspect region 
on chromosome Xq27, with a significantly increased presence of bilaterality and undescended 
testis among FTC. These results provide evidence of a germ cell susceptibility gene on 
chromosome Xq27 that may also predispose to an undescended testis.10   
In total, the families of patients with TC had a 1.2-fold increased risk of developing any 
cancer. As SGCTs and NSGCTs have different biologic and clinical aspects, it seems 
appropriate to analyze the cancer incidence among the relatives of patients with TC stratified 
by the histologic features. We did not find a difference between these groups. For 
nontesticular tumours, an increase in risk for first-degree relatives was found for respiratory 
tract cancers and female genital tract malignancies in sisters. In a study by Swerdlow et al.,22 
a nonsignificant increase in lung cancer incidence in both mothers and fathers of patients with 
TC was found. Heimdal and coworkers12 found a significant increased risk for mothers of 
patients with TC, but this was based on a few cases. In contrast to lung cancer, other smoking-
related cancers such as urinary tract and mouth and pharynx malignancies were observed less 
frequently than expected. A decreased risk was also found for other and unknown primary 
malignancies. The finding of an increased O/E ratio for lung cancer may have been because of 
the misclassification of metastases. Moreover, underreporting of superficial bladder cancer, 
which could be confused with benign papilloma, might have caused the low ratio for urinary 
tract malignancy.  
Our finding of no increase in hormonally related cancers in parents is in contrast to previous 
studies. In a study by Moss et al.,11 an increased incidence of breast cancer in the mothers of 
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patients with NSGCTs (odds ratio 4.4; P <0.05) was suggested. Heimdal and coworkers12 
reported an increase in endometrial cancer in mothers and a decreased incidence of prostate 
cancer in fathers. Although the increased risk of endometrial malignancies was not 
significant, they suggested that TC might be partially caused by a de-arrangement of the 
estrogen/androgen-related pathway. We found only a 2.8-fold increased risk of malignancies 
of the female genital system in 7 sisters, consisting mainly of uterine cancer (n = 3). 
 
Conclusion 
Brothers of patients with TC have an increased risk of developing TC. Among first-degree 
relatives of patients with TC, no strong clustering occurred with other cancers. Additional 
investigations in families with TC are recommended to map the candidate genes for TC. 
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Abstract 
Objective. To compare the relative survival in men younger and older than 50 years with a 
testicular germ cell tumour. 
Methods. Data on patients with testicular cancer diagnosed between 1973 and 1997 and 
registered by one of the nine population-based Surveillance, Epidemiology, and End Results 
(SEER) cancer registries in the United States were obtained from the National Cancer 
Institute public domain SEER*Stat 3.0 package. Survival rates adjusted for mortality owing to 
other causes (i.e., relative survival) were calculated for men within each category of the 
American Joint Committee on Cancer stage groupings. 
Results. Patients who developed a germ cell tumour before the age of 50 years had a better 
10-year relative survival (90.8%, 95% confidence interval [CI]: 90.6% to 91.0%) than those 
who developed one after the age of 50 years (84.0%, 95%CI: 81.9% to 86.1%).  
This difference remained after stratification by histologic type and stage, except for patients 
with localized seminomatous disease (97.9% versus 98.0% for men younger and older than 50 
years, respectively). The largest difference in 10-year relative survival was found in men with 
metastasized disease: seminomatous disease, 89.7% versus 69.6% and non-seminomatous 
disease, 76.9% versus 57.0% for men younger and older than 50 years, respectively.   
Conclusions. Lower stage and morphology-adjusted relative survival rate was observed 
among patients older than 50 years of age with testicular cancer. This difference was more 
evident in metastasised disease. Whether the worse prognosis in testicular cancer can be 
explained by a lower tolerance to chemotherapy and/or to sub-optimal treatment in the elderly 
has to be established.  
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Introduction 
Testicular germ cell cancer accounts for only 1% of all cancers in males.1 Once the leading 
cause of cancer deaths in men between 15 and 35 years of age, it has now proved to be a 
model of success with an overall 5-year survival rate exceeding 95%.2 This success is 
primarily attributed to the development of effective chemotherapy for advanced disease.  
Data from the population-based Cancer Registry in the Netherlands3 suggest that testicular 
cancer patients older than 50 years of age have a worse disease-specific survival. The 5-year 
relative survival rate was approximately 94% in men younger than 50 years versus 75% in 
men older than 50 years.3 This finding encouraged us to examine whether the same trend was 
present in a larger population.  
The aim of this study was to compare the relative survival rate in men younger and older than 
50 years with testicular germ cell cancer using the Surveillance, Epidemiology and End 
Results (SEER) Program of the National Cancer Institute in the United States. 
 
Material and methods 
Data on survival of patients with testicular cancer diagnosed in the United States were 
obtained from the public-domain computer package Surveillance, Epidemiology, and End 
Results (SEER) * Stat 3.0 (National Cancer Institute, 2000; see http://www-
seer.ims.nci.nih.gov/). This package contains data on the cancer incidence and survival of 
nine population-based cancer registries belonging to the SEER program. The SEER Program 
of the National Cancer Institute collects and publishes cancer incidence and survival data 
from population-based cancer registries covering approximately 10% of the U.S. population. 
The selected database was the August 1999 submission, with data on 2,440,153 patients 
diagnosed between 1973 and 1997. For this study, we selected 12,881 patients with testicular 
cancer. In subsequent analyses, tumours were classified according to morphology and only 
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the seminomatous (morphology codes 9061-9063) and non-seminomatous germ cell tumours 
(morphology codes 9060 and 9064-9102) were taken into account. For staging of the tumours 
the 4th edition of American Joint Committee on Cancer classification was used.4 Patients with 
regional or distant disease were classified as having metastasized disease. Unfortunately, 
complete data on treatment of testicular cancer patients were not available. 
In the public-domain database, no information is provided on the cause of death. Instead, 
observed survival can be adjusted for the expected probability of survival. The expected 
probability of survival was generated from age, race, and gender-specific population statistics 
from 1970, 1980, and 1990 from the U.S. Bureau of the Census. These data are also available 
in the SEER*Stat 3.0 package. Subsequently, the relative survival was calculated as the ratio 
between the crude and expected survival.5 All analysis were performed with the SEER*Stat 
3.0 package. 
 
Results 
The study population consisted of 12,811 patients with testicular cancer, of which 12561 had 
testicular germ cell cancer (Table I). Of these patients, 11,515 (91.7%) were younger than 50 
years of age. 5,890 (51.2%) of the tumours in the younger patients were non-seminomatous 
germ cell tumours (NSGCTs) and 5,625 (48.8%) were seminomatous germ cell tumours 
(SGCTs). The patients older than 50 years of age accounted for 8.3% of the study population, 
of whom 292 had a NSGCT (27.9%) and 754 a SGCT (72.1%). 
Patients who developed testicular cancer before the age of 50 years had a better 10-year 
relative survival than those who developed one after the age of 50: 90.8% (95% confidence 
interval [CI]: 90.6% to 91.0%) versus 84.0% (95%CI: 81.9% to 86.1%). The largest 
difference in relative survival between patients younger and older than 50 years was seen 
within the first year after diagnosis (96.9% and 92.5%, respectively). After stratification by 
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histologic type, this difference in relative survival remained. After stratification by stage, no 
difference was seen in 10-year relative survival rate between men younger and older than 50 
years in localized SGCT (97.9% versus 98.0%, respectively). By contrast, a significant 
difference was observed among men with localized NSGCT at 10 year after diagnosis (95.1% 
versus 88.9%). In patients with metastasized disease, the 10-year relative survival rate 
between both age categories was significantly different for both SGCT (89.7% versus 69.6%) 
and NSGCT (76.9% versus 57.0%). 
 
Table I Relative survival at distribution of stage and morphology by age 
Group (N) 1-year (%) 3-year (%)  5-year (%) 10-year (%) 
     
All testicular germ and non-
germ cell tumours (N=12,811) 
    96.5 92.5 91.6 90.1 
< 50 (N=11,686) 96.9 92.9 92.0 90.8 
≥ 50 (N=1,125) 92.5 88.0 86.6 84.0 
     
Seminoma     
< 50 (N=5,625) 99.0 97.6 97.3 96.0 
≥ 50 (N=754) 96.1 94.4 93.7 90.6 
     
Non-seminoma     
< 50 (N=5,890) 95.2 88.9 87.6 86.4 
≥ 50 (N=292) 88.5 78.5 76.4 74.3 
     
Seminoma, localized     
< 50 (N=4,312) 99.9 99.3 99.0 97.9 
≥ 50 (N=538) 99.5 98.7 98.6 98.0 
     
Seminoma, metastasized     
< 50 (N=1,185) 95.8 92.0 91.5 89.7 
≥ 50 (N=200) 87.5 83.3 81.3 69.6# 
     
Non-seminoma, localized     
< 50 (N=3,041) 99.1 96.8 95.8 95.1 
≥ 50 (N=154) 95.2 90.9 90.9 88.9# 
     
Non-seminoma, metastasized     
< 50 (N=2,679) 90.8 80.1 78.6 76.9 
≥ 50 (N=127) 80.9 65.0 59.5# 57.0# 
 
# Significant 
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Discussion  
In this study, we confirmed the observation of the Dutch Cancer Registry that elderly patients 
with testicular cancer have a worse disease-specific prognosis. To our best knowledge, 
published studies have not presented findings about age-related and survival differences in 
men with testicular germ cell tumours.  
The elderly represent a group of patients that is more difficult to treat because of alteration in 
organ function and presence of concomitant diseases.6-9 In cancer treatment, it has been 
reported that the elderly are more vulnerable to both surgery10 and chemotherapy11 compared 
with younger patients. In contrast, radiotherapy is equally well tolerated.12,13 The observed 
differences in relative survival in testicular germ cell cancer might be (in part) explained by 
the tolerability to different therapy modalities and/or by inadequate treatment.  
Firstly, patients with proven metastasized testicular disease receive chemotherapy (cisplatin, 
etoposide and bleomycin). All three chemotherapeutic drugs have shown to be associated with 
increased toxicity in the elderly.11 It is possible, that elderly patients have received dose 
reduction as result of toxicity,14 and/or that they have been under treated for fear of treatment-
related toxicity.7,8 The latter has resulted in a more than twofold increased death rate among 
elderly patients with breast and colorectal cancer.9 The evaluation of the effect of first-line 
chemotherapy in the older patient with testicular cancer is hampered because patients older 
than 50 years are sometimes excluded from participating in clinical trial on the basis of age.15 
Furthermore, the role of disease sensitivity to chemotherapy has to be taken into account. It is 
known that SGCTs are more sensitive to chemotherapy than NSGCTs. As a consequence, 
patients with SGCTs are subdivided into good or intermediate-risk groups, but NSGCTs 
contain also a poor-risk group.16 The difference in chemosensitivity might explain the overall 
difference in 10-year survival rate between metastasized SGCTs and NSGCTs. Among other 
diseases (acute myeloid leukemia, large cell non-Hodgkin’s lymphoma and coelomic 
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carcinoma of the ovaries), resistance to chemotherapy has been reported to intensify with 
increasing age of the patient.14 Although age was not an exclusion criterion for participation 
in studies on refractory testicular germ cell tumours (second-line treatment), no patient older 
than 50 years was included.17-20 Therefore, it is not possible to evaluate age as a prognostic 
factor for resistance to chemotherapy.  
Chemotherapy regimes have evolved considerably between 1973 and 1997.21 Patients treated 
before 1985 received different chemotherapy regimens (e.g., vincristine, actinomycin D, and 
bleomycin regimens, early vincristine and prednisone, single agents protocols, and cisplatin, 
vinblastine and bleomycin) than patients diagnosed thereafter. Since the mid-1980s, cisplatin, 
etoposide and bleomycin PEB has been used as first choice of first-line chemotherapy. It is 
possible that this somehow confounded our results. Therefore, we re-analyzed the data after 
stratification by calendar period of diagnosis. We assumed that only the patients with 
metastasized disease received full doses of chemotherapy and that if there a difference in 
relative survival was found, it would be most striking in those patients. As expected, the 
patients treated before 1985 had a poorer 5-year relative survival than those treated thereafter 
(Table II). In both periods, however, the difference between younger and older patients 
remained. Therefore, it may well be possible that the poorer prognosis among elderly 
testicular cancer patients is related to less than optimal treatment for the elderly. 
Second, in low-stage disease a difference was only observed among patients with NSGCT. 
One explanation might be that non-seminomatous disease is treated by surgery plus two 
courses of adjuvant chemotherapy in case of metastatic disease, and seminomatous disease is 
treated by radiotherapy. It has been stated that the elderly are more vulnerable to 
complications (cardiopulmonary conditions and sepsis) in the early postoperative period10,21 
and that the time to full recovery after surgery becomes more prolonged with advancing age.10 
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Table II 5 year-relative survival in patients with metastasized testicular disease in 
the period before and after the first of January 1985 in relation to the 
survival among patients diagnosed during the total period (1973-1997) 
Histology Age Period 5 year-
relative 
survival  
5 year-relative 
survival  
(1973-1997; table I) 
     
 Seminoma, metastasized <50 1973-1985 89.9 
91.5 
 <50 1985-1997 92.6 
 
  >50 1973-1985 75.4 
 >50 1985-1997 86.5 
81.3 
     
 Non-Seminoma, metastasized <50 1973-1985 69.9 
78.6 
 <50 1985-1997 86.9 
 
  >50 1973-1985 59.5 
 >50 1985-1997 60.4 
59.5 
     
 
 
It is unknown whether adjuvant chemotherapy in the elderly has influenced the prognosis. By 
contrast, radiotherapy schedules seem to be equally well tolerated, independent of patient 
age.12,13 However, if coexisting diseases are present in the radiation field (e.g., pulmonary and 
cardiac), these may deteriorate further and cause problems for continuing therapy. Patients 
with low-stage SGCT receive only radiation to a limited part of the retroperitoneum, and, 
incidental (1%) gastrointestinal tract toxicity results in treatment deviation.22 Consequently, 
the same relative survival among all patients may be explained in that they are treated equally 
well by radiotherapy. 
Some confounding by stage might have taken place. We were only able to stratify by 
localized and non-localized disease, and not by the extent of disease in combination with 
serum tumour markers, which are of prognostic significance.16 It is known that older patients 
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have a delay in diagnosis.9,23 Consequently, they might have presented with more advanced 
disease (poorer prognosis) than younger patients.  
The main issues concerning cancer management in the elderly are related to treatment strategy 
and tolerance. It is generally believed that tolerance to treatment might be compromised in 
older patients. Moreover, the true effect of age on tolerance is often obscured by the presence 
of comorbidities.24 As a consequence, the elderly might be under treated, although any 
scientific evidence for reduced treatment is lacking. To date, most of what we know about the 
diagnosis and treatment of cancer originates from studies in younger populations. Therefore 
priority must be given to define the optimal treatment strategy in elderly patients, perhaps 
with some selection criteria, that would discriminate between elderly patients who would 
benefit from 100% treatment and those who would be better treated less aggressively.  
 
 
Conclusions 
 
A lower stage and morphology-adjusted relative survival rate was observed in patients older 
than 50 years of age with testicular cancer. This difference was more evident in metastasized 
disease. Whether the worse prognosis in testicular cancer can be explained by a lower 
tolerance to chemotherapy and/or to reduced treatment in elderly has to be established.  
To define the optimal treatment regimen among the elderly, it will be necessary to include 
them into future clinical trials. 
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Abstract 
For patients with a clinical stage I nonseminomatous germ cell tumour of the testis cure rates 
should be close to 100%, whether surveillance, primary surgery, primary chemotherapy or a 
combination is chosen. The identification of patients with microscopic metastasis is difficult. 
Even with the best predictive factors currently available (vascular invasion and percentage 
embryonal cell carcinoma in the primary tumour), the identification of micro-metastases is no 
better than the flip of a coin. Several additional prognostic factors have been studied, but none 
is yet applicable in daily practice. 
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Introduction 
Since the application of cis-platinum-based chemotherapy, patients with testicular cancer are 
cured in the majority of cases, even in cases of disseminated disease. On the basis of histology 
(seminoma versus nonseminoma), the tumour stage according to the Royal Marsden Hospital 
staging system and the serum tumour markers, a risk group classification was defined at a 
consensus meeting of the International Germ Cell Cancer Collaborative Group in 1994.1 In 
the low-risk group 56% of patients with a nonseminoma are identified and 90% of those with 
a seminoma. In this risk group the 5 year tumour related survival is 92% and 86% 
respectively. In the intermediate risk group 28% of the nonseminoma patients are found (5 
year survival 80%), compared with 10% of the seminoma patients (5 year survival 73%). In 
the high-risk group, 16% of the nonseminoma patients are identified, with a 5 year survival of 
48%. Looking at these figures, it is obvious that in low- and intermediate-risk patients the 
survival is good to excellent. In this vast majority of patients, improving the efficacy of the 
therapy is not the main goal, but a reduction of therapy-related morbidity and/or 
individualization of the therapeutic schedule has become more and more important. A good 
example of this strategy is a recent European Organisation for Research and Treatment of 
Cancer, (Genitourinary) Group study number 30941, co-ordinated by de Wit. In that study 
three and four courses of BEP (bleomycin, etoposide and cis-platinum), administered for 2 or 
5 days, were compared in low- and intermediate-risk patients, with special attention to the 
quality of life. In high-risk patients, unfortunately, survival results are still to be improved. 
 
Clinical stage I nonseminomatous germ cell tumours 
The question of cure is even less relevant for patients with clinical stage I non-seminomas. In 
this patient group, 5 year survival should be close to 100%. After the initial clinical evaluation 
has excluded metastases, approximately 25-30% of these patients will develop metastases.
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The majority will develop metastasis in the retroperitoneal space, whereas only a small 
percentage will have lung metastasis.2 Without further discrimination between the real stage I 
patients and the microscopically stage IIa patients, 3 strategies are possible, each with their 
own advantages and disadvantages. 
 
  Surveillance. 
The advantage is that in the real stage I patients no unnecessary therapy is given.2-4 Although 
this advantage seems obvious, this is only possible on the basis of meticulous follow up. This 
not only includes regular CT scan’s, but most importantly, during the 1-2 years of follow up 
there is a constant psychological threat to the patient whether he is cured or not. 
Furthermore, meticulous follow up is only possible when the patient’s compliance 
(intelligence, travel distance) is guarantied. The disadvantage is that patients with microscopic 
disease, once they have been diagnosed with macroscopic disease, usually need a full course 
of chemotherapy, being three or four courses of BEP. In all, the cure rate is close to 100%. 
 
  Primary retroperitoneal lymph node dissection (RPLND) 
When patients are operated primarily, no microscopic metastasis will be found in 70%. In this 
group of patients, there remains a 5-10% risk of subsequent lung metastasis, which has to be 
treated with full-dose chemotherapy.2,4 All other patients are cured, unfortunately after 
unnecessary surgery. Although the short- and long-term morbidity could be limited with the 
use of laparoscopic RPLND, this seems restricted to experienced centres, and the long-term 
disease specific outcome remains unknown. 
The remaining 30% of patients have microscopic-positive lymph nodes. In that case two 
options are possible. In the case that no additional chemotherapy is given, approximately 70% 
of these patients will indeed be cured with surgery for microscopically metastasised disease.5
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On the other hand, however, 30% will still develop recurrent disease, although seldom in the 
retroperitoneum.2,5 These patients would still need full-dose chemotherapy, thereby wasting 
the potential advantage of surgery. With lymph node dissection and additional chemotherapy 
the cure rate is also (close to) 100%, whereas not all patients are cured with surgery and 
chemotherapy on indication. In the case of a negative RPLND or adjuvant chemotherapy after 
microscopic disease, retroperitoneal relapses are extremely rare.4  
 
  Primary chemotherapy 
Several reports have shown that primary chemotherapy again results in a high cure rate. 
Studer et al.,6 for example, found only 3.4% relapses in 59 high-risk (see risk factors in 
clinical stage I nonseminoma at page 68) stage I patients after two courses of chemotherapy. 
An interesting (partly) historical comparison between primary chemotherapy in high-risk 
patients and surveillance in stage I patients was presented at the 2001 EAU meeting in 
Geneva.7 In the historical series 83 patients were in a surveillance strategy. As expected 30 
(36%) relapsed and received chemotherapy. Of this group, one died of the disease, and one of 
heart failure. After 1985, this group used three primary chemotherapy protocols (one or two 
courses) in 123 high-risk patients. In this group, only five relapses were seen, of which two 
patients died of the disease. In the same period 124 low-risk patients, or those unwilling to 
receive chemotherapy, entered a surveillance protocol. In all, 33 relapses were seen (27%) 
and were treated with chemotherapy. Four patients died of the disease, and 1 of heart failure. 
Although four deaths out of 33 relapsing patients seems somewhat high, this study clearly 
illustrates that primary chemotherapy seems safe with regard to cure and long-term toxicity. 
However, even in high-risk stage I patients the rate of unnecessary chemotherapy is 
approximately 50%, and cure rates are, just as in the other two options in these patients, not 
100%. Moreover, the long-term toxicity of chemotherapy remains a potential problem 
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(fertility, coronary artery disease, neuro-toxicity, pulmonary fibrosis and secondary cancers). 
In case of teratoma, long-term follow-up and imaging of the retroperitoneum is mandatory to 
detect slowly growing teratoma recurrences. 
 
Risk factors in clinical stage I nonseminoma 
The problem in clinical stage I non-seminomas would be solved if we could identify those 
patients with (a high risk of subsequent) microscopic metastases. Well-established risk factors 
for metastatic disease are blood and lymph vessel involvement and the percentage of 
embryonal cell carcinoma (ECC) in the primary tumour.5,8 Additional histological factors are 
the absence of yolk sac tumour, a primary tumour greater than pT1 and less then 50% 
teratoma in the primary tumour. The presence of vascular invasion (VI) and ECC increases 
the risk of microscopic metastatic disease to 40-70% (i.e., high risk patient) whereas absence 
of these factors implies a risk of metastatic disease of around 10% (i.e., low risk patient).5,8  In 
our daily practice vascular invasion is used to advise a clinical stage I non-seminoma patient 
for wait and see or primary RPLND, with subsequent chemotherapy in case of positive nodes.  
Although many other factors have been studied for their prognostic value in testicular cancer 
patients, this has been predominantly for the reaction to chemotherapy or survival. Only a 
limited number of studies particularly looked at the potential prognostic factors in clinical 
stage I non-seminomatous patients. 
PET (positron emission tomography) has proven to be of use to identify vital tumour in 
residual masses after chemotherapy.9 Other imaging studies, such as CT scanning, rely on 
size, whereas in PET scanning tissue metabolism is taken into account. It has also been 
studied in stage I patients. Although with PET scanning normal sized nodes with abnormal 
metabolism (cancer!) can be detected, unfortunately the lower limit of detection is around 5 
mm, which is not significantly better as compared to modern CT scans. 
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The detection of circulating tumour cells with reverse transcriptase-polymerase chain reaction 
(RT-PCR) techniques seems to be related to survival in advanced disease, but again no 
additional value could be detected in stage I disease over the presence of ECC.10,11  
Heidenreich et al.8 found that p53, bcl-2, MIB-1, cathepsin D and E-cadherin expression did 
not have additional value over percentage ECC and VI in high-risk stage I patients. 
With the use of micro-satellite markers, the loss of heterozygosity at candidate regions for 
chromosomal loss have been studied. Apart from a better insight into the development of 
seminoma and non-seminomatous tumours from precursor cells, these techniques might also 
give more insight into which genes play a crucial role in the metastatic process of these 
tumours.12 So far, however, these techniques are not applicable in clinical practice. 
A new marker that has been studied is telomerase activity. The quantification of human 
telomerase messenger RNA expression in testicular germ cell tumours appeared to correlate 
inversely with tumour differentiation.13 This might give information with regard to the 
response to cis-platinum-based chemotherapy and the presence of mature teratoma 
components. 
 
Conclusion 
Except for high-risk nonseminomatous germ cell tumours, cure rates are excellent in patients 
with testicular tumours. Less treatment-related morbidity and a better quality of life, therefore 
are important goals in these patients. For patients with a clinical stage I non-seminomatous 
testicular tumour principally three approaches can be chosen: surveillance, primary surgery 
and primary chemotherapy. Even with the best prognostic factor available at present (vascular 
invasion and percentage ECC in the primary tumour) patient selection can be made with a 
50% change of microscopic disease. This means that a substantial percentage of these patients 
will always be under- or overtreated. The search for additional factors to predict the presence 
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or absence of microscopic metastasis is ongoing. PET scanning might give some additional 
information. The identification of circulating tumour cells or tumour markers is possible with 
RT-PCR techniques, but so far no correlation with clinical outcome has been found. Several 
other molecular markers have unfortunately not given the answer. 
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Abstract 
Objective. To compare retrospectively the treatment results of surveillance and primary 
retroperitoneal lymph node dissection (RPLND) of patients with clinical stage I non-
seminomatous germ cell tumours of the testis (NSGCT) in two institutions in The 
Netherlands. 
Material and Methods.  From 1982 to 1994, 90 consecutive patients with clinically stage I 
NSGCT were prospectively entered in a surveillance protocol in Amsterdam (group 1). In the 
same period, 101 patients with clinical stage I NSGCT underwent primary RPLND in 
Nijmegen (group 2). Both patient populations were comparable for patient age, presence of 
vascular invasion and embryonal cell components in the primary tumour. All patients in group 
1 with relapse, except for two, were treated with cisplatin-based chemotherapy. All patients in 
group 2 with vital tumour in the RPLND specimen were treated with two adjuvant courses of 
combined chemotherapy (cisplatin, etoposide, and bleomycin). 
Results. In group 1, at a median follow-up of 7.7 years, 23 patients (26%) relapsed. The 
median time to relapse was 12 months. Relapses were located retroperitoneally (n=18, 78%), 
in the lung (n=3, 13%), scrotum (n=1, 4%) and combined in the liver, lung and pleura (n=1, 
4%). After treatment of relapses (chemotherapy in 21 and/or surgery in 11) only one patient 
died of disseminated disease. The disease-specific survival rate was 98.5% at the median 
follow-up. The main toxicities consisted of short-lasting leucopenia, accompanied by 
infection (13%). Four patients reported cardiovascular and four neuropathy complaints. In 
group 2, the median follow-up was 6.9 years. In 31 patients (30.7%), vital tumour was found 
retroperitoneally. After two courses of combined chemotherapy, none of them had a relapse. 
Seven patients with pathological stage I disease (6.4%) had a pulmonary relapse within one 
year after surgery. No retroperitoneal relapses were found. After chemotherapy six patients 
with relapse were salvaged, and one died of disseminated disease. The disease specific 
  Surveillance vs RPLND in clinical stage I NSGCT 
 
 
 
 
 
75
survival in group 2 was 98% at the median follow-up. The most frequent surgical 
complications were abdominal pain (n=6), hydrocele (n=5) and lymfocele (n=3). The 
antegrade ejaculation rate was 94%. 
Conclusions. Excellent treatment results in terms of overall survival can be achieved in stage 
I NSGCT with both surveillance and primary RPLND. The choice of treatment should be 
based on balanced information and not on dogmatic principles.  
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Introduction 
Today, germ cell tumours are highly curable. Independent of initial treatment, the survival 
rate for patients with stage I nonseminomatous germ cell (NSGCT) patients is near 100%.1,2 
However, the proper treatment after orchiectomy remains controversial. Primarily, two 
strategies have been applied: watchful waiting with close surveillance and chemotherapy on 
relapse, or primary retroperitoneal lymphadenectomy (RPLND) with or without 
chemotherapy.2,3  
Today, treatment of clinical stage I disease can also be adapted to risk factors. 4-6 For patients 
at high-risk of metastases some investigators2 advocate RPLND with adjuvant chemotherapy 
for pathologic stage II disease and others recommend chemotherapy only.7,8 In contrast, 
patients at low-risk will enter a surveillance protocol. 
The purpose of our study was to compare the policy of surveillance in patients with clinical 
stage I NSGCT with that of primary RPLND in two different institutions in The Netherlands. 
 
Materials and Methods 
Retrospectively, we compared the treatment results of patients with clinical stage I NSGCT 
who entered a surveillance protocol at the Departments of Urology and Oncology of the 
Netherlands Cancer Institute Amsterdam/Antoni van Leeuwenhoek Hospital, Amsterdam 
(group 1) with those who underwent  RPLND at the Department of Urology of the University 
Medical Centre Nijmegen (group 2). Staging was done according to the criteria of the Royal 
Marsden Hospital.9 Clinical stage I NSGCT was defined as no radiologic evidence of 
metastatic disease and normalization of lactate dehydrogenase and the tumour markers, alpha-
fetoprotein ( FP) and beta-human chorionic gonadotropin ( HCG) according to their half-life 
kinetics after orchiectomy.  
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The following criteria were assessed: cancer-specific survival, relapse rate, treatment-related 
morbidity, complications, and prognostic factors indicating occult metastases. Complications 
were categorized as follows: minor complication requiring little if any additional treatments 
and no extended hospitalization beyond 2 days; major complication requiring additional 
treatment and at least 2 more days of hospitalization10; and long-term complications (more 
than 3 months after completion of treatment).  
Between 1982 and 1994, 90 consecutive patients with a median age at presentation of 30,1 
years (range: 16.9-60.0) entered group 1. In the same period 101 patients (median age at 
presentation 30,3 years; range 14.9-61.3) entered group 2 (Table I). The median follow-up for 
groups 1 and 2 was 7,7 years (range 1,0 – 14,9) and 6,9 years (range 1,0 – 15,1), respectively 
(follow-up until January 2000). The presence of vascular invasion (VI) and embryonal cell 
carcinoma (ECC) components in the primary tumour were comparable in both groups. 
Vascular invasion was defined as either venous or lymphatic invasion. 
The protocol of surveillance in group 1 included clinical examination, measurement of tumour 
markers and chest X-ray monthly in the first year, every second month in the second year and 
at 3-4 monthly intervals in the third year. In addition, abdominal CT was repeated every 2 to 3 
months in the first year, every four months in the second year, and biannually between the 
third and fifth year. After 5 years, the follow-up was at discretion of the clinician, but 
participants were encouraged to continue for at least 10 years. Most patients who relapsed 
were treated with platinum-based chemotherapy; residual masses were surgically removed. 
In group 2, all patients underwent standard RPLND as previously described.2 RPLND was 
performed unilaterally in 75 patients. The indication to perform a bilateral dissection was 
based on results of frozen section analysis during surgery. Bilateral dissection was done in 26 
patients. Since 1989, a nerve-sparing technique has been used to preserve ejaculatory function 
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(n=73). Patients with histologically proven lymph node metastases received two additional 
cycles of chemotherapy with cisplatin, etoposide and bleomycin.  
The follow-up procedure was comparable with that of the surveillance protocol; however, 
only one abdominal CT scan was performed in all patients 3 months after treatment 
completion. 
Kaplan-Meier survival analysis was performed for each group. The overall survival was 
defined as that from the date of histologic diagnosis of testicular cancer to date of death or last 
follow-up. Finally, in both groups, an independent analysis of the prognostic factors was 
performed by univariate analysis (two-tailed Student’s t-test; p<0.05).  
 
 
Results 
In group 1, disease relapse was recorded in 23 (26%) of the 90 patients; 16 (70%) were 
detected in the first year, four in the second year and the remaining 3 at 34 (n=2) and 44 
months (n=1). Relapses were located retroperitoneally (n=18, 78%), lung (n=3, 13%), 
scrotally (n=1, 4%) and combined in the liver, lung, pleura (n=1, 4%). Evidence of relapse 
was detected in 15 (65.2%) of 23 cases by both tumour markers and imaging studies. The 
median time to relapse was 12 months (range: 3 to 44). In the remaining cases (34.7%) only 
the imaging study were the first indication of relapse. Of the 23 patients with relapse, 21 
received combined chemotherapy. In 6 cases, RPLND for residual mass was performed (1 
embryonal cell, 2 mature teratoma, 2 fibrosis and 1 normal lymph node tissue). One patient 
underwent surgery for scrotal recurrence (mature teratoma). Two patients with a small 
retroperitoneal mass underwent surgical resection alone (mature teratoma, embryonal cell). 
Complete remission was obtained in 22 patients. The patient with the combined relapse died 
of organ confined disease within 6 years of follow-up. Initially, this patient was admitted for a 
testicular tumour 2 cm in diameter and slightly increased alpha-fetoprotein (10 ng/ml). 
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Histologic examination revealed mixed germ cell tumour containing seminoma, (im)mature 
teratoma and vascular invasion. At recurrence, the alpha-fetoprotein was increased (490 
ng/ml). In total, a disease-specific survival of 98.5% (95% confidence interval [CI]: 95.6-
100.0%) was achieved in group 1 at a median follow-up of 7,7 years (Table I). After 
treatment, 86% of the patients (n=77) completed the follow-up for at least 5 years. 
 
 
TABLE I. Characteristics of patients with clinical stage I disease. 
 Surveillance (%) RPLND (%) 
   
Patients (n) 90 101 
Mean age (yr) 30.1 30.3 
Median follow-up (yr) 7.7 6.9 
Medical History   
  Undescended testicle 7 (7.8) 15 (13.8) 
Raised initial tumour markers*   
  beta-HCG 22/86 (25.6) 35/88 (39.7) 
  alpha-FP 60/86 (69.8) 71/90 (78.9) 
  LDH 15/86 (17.4) 14/71 (19.7) 
Primary tumour side   
  right 50 (55.6) 57 (52.3) 
  left 40 (44.4) 52 (47.7) 
Primary tumour characteristics   
  Embryonal cell elements 73 (81.1) 85 (78.0) 
  Teratoma elements 65 (72.2) 68 (67.3) 
  Chorioncarcinoma elements 27 (30.0) 21 (19.3) 
  Yolk sac elements 25 (27.7) 14 (12.8) 
  Seminoma elements 28 (31.1) 26 (25.7) 
  Vascular invasion* 33/79 (41.8) 34/81 (41.9) 
Pathologic Stage IIa - 31 (30.7) 
Relapse 23 (25.6) 7 (6.9) 
Survival at median follow-up 98.5%; 95%CI:95.6-100.0% 98.0%; 95%CI:96.0-100.0% 
   
Key: RPLND:retroperitoneal lymph node dissection; beta-HCG: beta human chorionic gonadotrophin; alpha-FP: 
alpha-fetoprotein:; LDH: lactate dehydrogenase; CI: confidence interval. 
* when available 
     
 
 
Fifteen of the 23 patients had a chemotherapy-related complication (Table II). The main 
toxicities observed during chemotherapy consisted of short-lasting leucopenia, nausea, 
vomiting and temporary alopecia. Two patients were treated with intravenous antibiotics for 
pneumonia that developed during a period of leucopenia. One patient who received high-dose 
chemotherapy with autologous bone marrow transplantation was admitted twice with 
Staphylococcus epidermidis sepsis. After treatment, he had persistent polyneuropathy. Four 
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patients reported cardiovascular toxicity (Raynaud’s phenomenon and hypertension), and 
three had temporary tinnitus complaints. One patient was successfully treated with prednisone 
for osteomyelofibrosis and one with testosterone suppletion for 1.5 years. Two patients 
needed treatment for post-treatment depression.  
All patients who underwent a RPLND for residual mass experienced antegrade ejaculation. 
The average postoperative hospital stay was 7 days (range 5-10). One patient had a wound 
infection that was treated conservatively. One surgeon performed all procedures (mean 
operative time: 4 hours, range 3 to 6). 
In group 2, surgical staging confirmed that 69% of patients (n=70) with clinical stage I 
disease had pathologic stage I disease, and 31% (n=31) had positive nodes at operation (30 
patients with stage IIa and 1 patient with stage IIb). Frozen section histologic analysis was 
falsely negative in 5 cases. No false-positive findings occurred. All patients with pathologic 
stage II disease received two additional courses of combined chemotherapy and were 
salvaged. Pulmonary relapses were only found in patients with pathologic stage I disease 
(n=7, 10.0%) and all were identified within 12 months by chest x-ray. In three of them, rising 
tumour markers were also present. Treatment at relapse involved four courses of combined 
chemotherapy, without further intervention in 6 of these cases. One patient had a repeated 
relapse in the chest and died of disseminated disease at seven years of follow-up. Initially, this 
patient was admitted for a testicular tumour 5 cm in diameter and increased serum tumour 
markers (AFP: 3000 ng/ml and bHCG: 36 ng/ml). Histologic examination revealed mixed 
germ cell tumour containing (im)mature teratoma and vascular invasion. At both recurrences, 
the beta-human chorionic gonadotrophin level was increased (8.5 and 26 ng/ml). Two 
contralateral clinical stage I seminomatous germ cell tumours were detected at 22 and 70 
months of follow-up. The patients were treated successfully with orchiectomy and abdominal 
radiation. In total, the disease-specific survival rate is 98% (95%CI: 96-100.0%) at a median 
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follow-up of 6.9 years (Table I). After treatment, 87% of the patients (n=88) completed the 
follow-up for at least 5-years. 
The operative time ranged from 2 to 6 hours (mean 2, ). No intraoperative complications 
occurred, and the blood loss ranged from minimal bleeding to 1500 ml. The average 
postoperative hospital stay was 6 days (range 4-32). One surgeon performed 85% of the 
procedures. 
With respect to the ejaculatory function, 87 patients (86%) reported antegrade ejaculation. Of 
the 15 patients, reporting absence of ejaculatory function postoperatively, 6 underwent a full 
bilateral, 6 an unilateral and 3 a nerve-sparing bilateral dissection, respectively. One patient 
experienced a delay of 12 months before return of antegrade ejaculation after nerve-sparing 
bilateral dissection. Finally, 3 patients (1 unilateral and 2 bilateral) are able to have antegrade 
ejaculation with imipramine. 
After surgery, 6 major and 5 minor short-term complications occurred in 11 patients (Table 
II). Retroperitoneal lymphocele was the most frequent major complication postoperatively 
(n=3). It was treated by percutaneous drainage. One patient developed pulmonary embolism 
and was treated by heparinization. Three patients stayed longer at the hospital because of 
abdominal pain. In two of them, small bowel obstruction was diagnosed. All three patients 
were treated conservatively. In the long-term, 3 patients were readmitted for abdominal pain, 
caused by small bowel stenosis, necessitating resection of small bowel in one patient. The 
other two were treated conservatively, after which the pain disappeared. Five patients 
underwent hydrocele correction and 2 surgical reconstruction of a cicatricial hernia. In 3 
patients, scar tissue was removed for pain/traction (n=2) and cosmetic reasons (n=1). Two 
patients with, respectively, urinary bladder retention and urinary tract infection during the 
hospital stay developed recurrent urethral strictures in the long term, necessitating surgery. 
Moreover, five patients had chemotherapy-related toxicities: respectively, haematological 
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toxicity, ototoxicity, Raynaud’s phenomenon, neuropathy and a combination of haematologic 
and neuropathologic toxicity. 
 
Table II.
  
Complications of chemotherapy and retroperitoneal lymph node dissection 
Complications Minor (n) 
 
Major (n) 
 
Long-term (n) 
 
Surveillance at Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands 
    
After 4 cycles of chemotherapy (or high dose*)     
  Polyneuropathy    1* 
  Tinnitus   3 
  Raynaud   2 
  Hypertension   2 
  Leucopenia (pneumonia 
& sepsis) 
 2 &1* - 
  Osteomyelosclerosis   1 
  Low testosteron level   1 
  Post-treatment depression   2 
After secondary RPLND    
  Wound infection  1 
 
 
RPLND  at University Medical Centre, Nijmegen, the Netherlands 
After primary RPLND    
  Urinary tract infection 1   
  Urinary bladder retention 1   
  Gastro-enteritis 1   
  Ulcer of the heel 1   
  Lymfocele (symptomatic)  3  
  Pulmonary embolism  1  
  Abdominal pain          1 2 3 
  Hydrocele   5 
  Cicatrical hernia   2 
  Correction of scar tissue   3 
  Urethral stricture   2 
After 2 cycles of chemotherapy    
  Raynaud’s phenomenon   1 
  Hearing loss   1 
After 4 cycles of chemotherapy (or high dose*)     
Polyneuropathy   1+1* 
Raynaud   1 
Leucopenia 1+ 1*   
Osteomyelosclerosis   1* 
    
Key: RPLND: retroperitoneal lymph node dissection; *High-dose chemotherapy 
 
 
In group 1, the percentage of embryonal cell components and the presence of vascular 
invasion were significant risk factors associated with relapse. Vascular invasion was found in 
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33 of 79 primary tumour specimens (Table I). The relapse rate in 33 patients with vascular 
invasion was 51%, significantly greater than 11% in 46 patients without vascular involvement 
(P<0.0001). In 32 (84%) of the 38 patients with less than 50% embryonal cell components, no 
signs of recurrent disease were found, and in 17 (33%) of 52 patients with more than 50% 
embryonal cell components had a relapse (p<0.05). In group 2, only vascular invasion was 
associated with pathologic stage II disease. In 17 (50%) of 34 patients with vascular invasion, 
positive lymph nodes at RPLND were found, and in 35 (74%) of 47 patients without vascular 
invasion had pathologic stage I disease (p<0.05). 
 
Discussion  
This study compared routine management in two institutions in The Netherlands for clinical 
stage I NSGCT. In one institute this comprises surveillance and in the other RPLND. The two 
groups of patients were well balanced for clinical and pathologic parameters, enabling a 
comparison of the treatment results. 
Despite advances in diagnostic radiology (CT-scan11/PET-scan12) the controversy concerning 
the treatment of stage I NSGCT is mainly caused by the inaccuracy of clinical staging.5 In 
general, the rationale behind the surveillance strategy is that 60 to 70% of patients are cured 
by orchiectomy alone.1 In 30% to 40%, a potential delay in treatment there exists after clinical 
identification of metastases. RPLND allows careful pathological staging and offers a 
therapeutic benefit in about 30% of the patients with clinical stage I tumour. On the other 
hand, 60% to 70% will have undergone unnecessary surgery.13 Independent of both treatment 
options, the survival rate for patients with clinical stage I NSGCT is near to 100%.1,2  
In agreement with former studies, 26% of the patients on surveillance had a relapse and 31% 
of the patients who underwent a RPLND had metastatic disease. The pattern of relapse in the 
surveillance study was similar to that in published studies (local, retroperitoneal and 
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pulmonary relapses).1,14 In agreement with Donohue et al.,2 no relapses were seen among 
patients with pathologic stage II disease adjuvantly treated with chemotherapy. In our series, 
the survival rate at 5 years of follow-up was 100% for both groups. In both groups, 1 patient 
died of disseminated disease at 5.9 years (group 1) and 6.9 years (group 2) of follow-up. Both 
patients were at high risk for metastatic disease. In conclusion, high-risk patients stay at high 
risk even after RPLND. 
The pattern of relapse supports a policy of intensive follow-up for at least 2-years after 
orchiectomy, irrespective of the treatment policy. Tumour marker determination and imaging 
are necessary in both protocols. However, in the surveillance protocol a CT abdomen and 
chest x-ray are recommended; after RPLND a chest x-ray only is probably sufficient for 
follow-up, especially in patients with pathologic stage I disease.  
Finally, surveillance will only work if patients are compliant and if follow-up is done 
rigorously within a centre dedicated to surveillance.3 In a Canadian study, the compliance of 
76 patients with clinical stage I NSGCT was evaluated.15 Non-compliance was defined as 
missing more than one CT scan or two consecutive visits, including marker determination and 
radiographs. The compliance with clinical visits in the first and second year was 61% and 
35%, but for CT scanning, it was only 25% and 12%, respectively. The only two deaths were 
in non-compliant patients. Although the study was too small to draw firm conclusions on non-
compliance and survival, it is more likely that poor compliance results in detecting relapses at 
a more advanced disease stage. In our series, most patients completed the minimum required 
follow-up time of 5 years. The small travel distances within The Netherlands and the health 
insurance policy can explain this. Compliance to follow-up after RPLND is also mandatory. 
Although RPLND should eliminate retroperitoneal relapses, such relapses have been 
reported16, and, irrespective of RPLND, in 7 to 11% of patients with pathologic stage I 
disease, pulmonary relapses will occur.2,5  
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Because both treatment regimens have the same capability for cure, treatment-related 
morbidity is important. The morbidity of a surveillance policy is particularly related to 
chemotherapy for patients with relapse and possible additional treatment.17 In patients without 
progression, no treatment-related morbidity occurs. However, frequent follow-up visits are 
essential. Although they have been described as stressful,18 this was never prospectively 
assessed. In both groups, most complications were fully reversible. The main long-term 
complication of RPLND is loss of antegrade ejaculation, which is strongly related to the 
extent of the template and the surgical skills.19 The ejaculatory function can be preserved in 
most patients with stage I NSGCT, because the tumour load is limited and the dissection can 
be carried out unilaterally above the level of the inferior mesenteric artery. In accordance with 
published studies,19 the antegrade ejaculation in group 2 has been retained after almost all 
nerve-sparing procedures (97%). Moreover, approximately 15% (n=15) of the patients had 
complications that required secondary surgical treatment.  
Numerous studies have been reported identifying prognostic factors that predict metastatic 
disease in clinical stage I NSGCT.4,5 None of these studies has prospectively identified a 
cohort of patients with a significantly greater than 50% chance of recurrence on a surveillance 
regimen or metastasis to the retroperitoneum or chest when treated with RPLND. As of today, 
embryonal cell components and vascular invasion are still the best prognostic factors to 
identify patients with clinical stage I disease at low and high risk for metastasis. In group 1, a 
significant association was found between vascular invasion or the percentage of embryonal 
cell components and an increased risk of relapse. In group 2, only vascular invasion was 
associated with metastatic disease. In Nijmegen, the management has been changed since 
1994. Vascular invasion is used to select patients for RPLND and patients without adverse 
risk factors are put in a surveillance program. Between July 1, 1994 and December 31, 1998, 
46 patients with clinical stage I NSGCT were treated. Seventeen patients without vascular 
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invasion underwent surveillance. One patient experienced a retroperitoneal metastasis at 18 
months of follow-up. Two patients with vascular invasion preferred surveillance and 
developed a retroperitoneal or pulmonary relapse at 3 and 7 months of follow-up, 
respectively. Twelve of 27 patients with vascular invasion had pathologic stage II disease and 
were cured by two courses of combined chemotherapy. Two of the 15 negatively staged 
patients had a pulmonary relapse at 7 and 17 months. All patients with a relapse were 
successfully treated with four courses of combined chemotherapy. At last follow-up, all were 
free of disease (median follow-up 43 months, range 19-70). 
The role of primary chemotherapy has also been investigated. This strategy will work in 
approximately 50% of all patients at high risk of metastases and will prevent relapses that 
would require a higher dose of chemotherapy. In contrast, the remaining 50% will be treated 
needlessly, with the potential risk of toxicity. Therefore, primary chemotherapy would only be 
a realistic alternative treatment option if occult metastases could be identified. The objective 
in patients with clinical stage I disease is to reduce treatment toxicity and maintain high 
survival rates. Before that, any toxicity in patients without metastatic disease is significant.7,20 
 
Conclusions 
Surveillance and RPLND with adjuvant chemotherapy for stage I nonseminomatous germ cell 
tumours show comparable cancer-specific survival figures. The debate on the most 
appropriate management is still unsettled and awaits refinement of prognostic factors and/or 
more reliable imaging technique enabling detection of microscopic metastasis. Patients should 
be offered a choice, based on balanced information on treatment-related morbidity.  
Today, the choice of treatment will depend on the local expertise and treatment- and patient-
related factors. 
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Abstract 
Objective. To determine whether alpha-catenin expression pattern and DNA content have 
additional value over routine tumour histology, including information on vascular invasion 
and tunica albuginea invasion in detecting occult metastasis in patients with clinical stage I 
non-seminomatous germ cell tumours of the testis (NSGCT). 
Patients and Methods.  Fifty consecutive patients with clinical stage I NSGCT underwent 
retroperitoneal lymphadenectomy (RPLND) between 1986 and 1992. The orchidectomy 
specimens were histopathologically reviewed and immunohistochemically stained with mouse 
monoclonal anti-alpha-catenin antibody. The presence of an aberrant or negative staining in 
more than 10% of the malignant cells was defined as abnormal; in all other cases tumours 
were classified normal. Furthermore, intact nuclei were isolated from 50 μm thick paraffin 
sections of the primary tumour, Feulgen stained, and analysed with the Discovery image 
analysis system.  
Results. Of the 50 patients, 14 had positive retroperitoneal nodes (stage IIa, 28%), one 
pathologically staged I patient developed a lung metastasis (stage IV) within three months 
after RPLND. Univariate analysis revealed that presence of embryonal cell carcinoma, 
vascular invasion and tunica albuginea invasion were predictive for occult metastases. In 
multivariate logistic regression analysis only vascular invasion and tunica albuginea invasion 
were significant. All patients with no embryonal cell carcinoma in the primary tumour (n=11) 
were classified as having pathologic stage I disease. Also, the tumours which were DNA-
diploid (n=3) or DNA-polyploid (n=2) were pathologically stage I. In screening for occult 
metastases the DNA content and the alpha-catenin expression pattern did not have additional 
value. 
Conclusions. Vascular invasion and tunica albuginea invasion have prognostic value in 
identifying patients with clinical stage I NSGCT at high risk for occult retroperitoneal disease. 
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In contrast, the absence of embryonal cell carcinoma could predict all patients at low risk for 
metastasis. The DNA-ploidy also identified patients at low risk. Other DNA-analyses and the 
alpha-catenin expression pattern provided no additional information. Further studies are 
recommended to identify patients who are at low or high risk for metastasis. 
 
Chapter 5 
 
 
 92 
 
Introduction 
Testicular germ cell tumors are highly curable: independent of initial treatment, the survival 
rate for patients with stage I nonseminomatous germ cell (NSGCT) patients is near to 
100%.1,2 However, the proper treatment after orchiectomy remains controversial. Primarily, 
two strategies have been applied; watchful waiting with close surveillance and chemotherapy 
on relapse, or primary retroperitoneal lymphadenectomy (RPLND) with or without 
chemotherapy.2,3 Currently, the treatment of clinical stage I disease can also be adapted to risk 
factors.4-6 For patients at high risk for metastases some investigators2 advocate RPLND with 
adjuvant chemotherapy in pathological stage II disease, whereas others recommend 
chemotherapy only.7,8 In contrast, patients at low risk enter a surveillance protocol. 
The morbidity of a surveillance policy is low for those patients with no progression, but the 
frequent essential follow-up visits may be stressful. A surveillance policy in case of occult 
metastasis might result in a treatment delay, with the potential of a more extensive disease 
than would be identified by surgical exploration. However, about half of patients with clinical 
stage I disease at high risk for metastases who undergo RPLND have negative lymph nodes.9 
Although the morbidity of RPLND has significantly decreased through modifications in 
technique, efforts should be made to minimise over- or under-treatment.2,5 The role of primary 
chemotherapy has also been investigated. Again, this strategy will work in about half of all 
patients at high risk for metastases, but it prevents relapses that would require a higher dose of 
chemotherapy.7 In contrast, the remaining half will be treated needlessly, with the potential 
risk of toxicity. Primary chemotherapy would be a realistic alternative treatment option if 
occult metastases could be identified. Before that any toxicity in patients without metastatic 
disease is significant.7,9 
Currently, the objective in clinical stage I patients is to reduce treatment toxicity, while 
maintaining high survival rates and therefore a more rational approach to the treatment would 
   Prognostic factors in clinical stage I NSGCT 
 
 
 
 
 
  93
be possible if the likelihood of metastasis could be determined. Studies have been conducted 
to identify histopathological risk factors for occult retroperitoneal lymph node metastases. 
The presence of vascular invasion (VI) and both the presence and the percentage of 
embryonal cell carcinoma (ECC) in the primary tumour are of prognostic value.4,6,10-12 The 
combination of these parameters may have a predictive value of 86% for the presence of 
occult metastatic disease.4,12 However, because of contradictory results13 and the lack of 
sufficient specificity and sensitivity, the existing predictive markers need to be improved 
and/or new markers are needed in order to detect patients at low and high risk for metastases. 
The role of adhesion molecules (cadherin-catenin complex) has been examined in other types 
of cancer14-19 and in TGCT.20 Loss of those molecules results in an increase in the invasive 
ability of tumour cells. No studies of the loss of alpha-catenin expression in clinical stage I 
NSGCT have yet been conducted. Flow cytometric analysis of nuclear DNA content has 
important prognostic information for several genito-urinary tumours.21,22 In previous studies, 
relatively new variables like flow cytometry and single-cell cytophotometry have been used in 
CS I NSGCT23-30, but the findings were inconclusive. In the present study, we evaluated the 
additional prognostic value of the immunohistochemical expression of alpha-catenin and 
DNA image analysis cytometry over routine tumour histology. All results were composed in 
univariate and multivariate analysis.  
 
Patients and Methods  
Between 1986 and 1992, 50 consecutive patients with clinical stage I NSGCT underwent a 
nerve sparing RPLND. Clinical staging included measurements of serum tumour markers ( -
foetoprotein,  -human chorionic gonadotropin and lactic acid dehydrogenase) and CT of the 
abdomen and chest. All patients had undergone previous radical orchiectomy. Archival 
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material (formalin fixed, paraffin embedded tissue from the orchiectomy specimens) of all 
patients was obtained from the institution at which they had undergone orchiectomy. 
Pathological stage IIa patients were treated with two additional cycles of bleomycin, 
etoposide and cisplatin. The median follow-up time after last treatment was 6.3 years (range, 
2.3-11.1 years). Regular follow up data were available for all patients (physical examination, 
chest radiographs, abdominal CT and serum tumour markers). 
Paraffin embedded blocks (1-10, mean 2) of 50 patients were assessed; from each block a 5-
µm section, followed by a 50-µm section and finally a 5-µm section, were cut. The first and 
the last 5-µm sections were stained with hematoxylin and eosin (H&E), and used to ensue the 
presence of tumour tissue and for histopathological evaluation. Only blocks containing 
NSGCT were analysed: care was taken to avoid sampling necrosis, fibrosis and haemorrhage. 
All H&E slices were reviewed by one pathologist (H.E.S.), who was unaware of the clinical 
status of the patients. 
The presence of VI, tunica albuginea invasion (TI), ECC, choriocarcinoma, yolk sac tumour, 
(im)mature teratoma and seminoma was recorded. There was no formal quantitative 
assessment of each separate histologic cell type. VI was defined as either venous or lymphatic 
invasion and TI as tumour extension into the tunica albuginea. The tumours were staged 
according to the TNM 1997 pathologic staging system.31 
Immunohistochemistry for alpha-catenin was carried out on 5-µm tissue sections obtained 
from each of the tumour blocks present in a given case. The immunohistochemical staining 
protocol was conducted essentially as recently described [32]. Briefly, the monoclonal 
antibody clone HECD-1 (Takara, Berkeley, USA) at a dilution of 1:50 was applied at 40C, 
overnight. A Vectastain Elite kit (Vector laboratories, Burlingame, CA) was used for 
peroxidase visualization. 
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For alpha-catenin, non-malignant epithelium present in the tumour sections was used as an 
internal positive control: discrete staining should be present at cell-cell contacts only. Because 
the most malignant tumour cell population will ultimately determine the tumour’s biological 
behaviour, the presence of an aberrant or negative staining in more than 10% of the malignant 
cells was defined as abnormal.14 In all other cases, tumours were classified as normal. 
The preparation procedure for DNA image-analysis cytometry is described elsewhere in 
detail.33 In short, 50  m thick paraffin-embedded tissue sections were used to dissect 
selectively the areas in the section that contained tumour, using a preparation microscope. As 
a method for orientation and control of tissue composition, a 5- m thick, H&E-stained 
adjacently parallel tissue section was used. After deparaffinzation and rehydration, the 50- m 
thick microdissected tissue sections were placed in a centrifuge tube and incubated in 
phosphate-buffered saline (PBS, 137 mM NaCl, 13 mM Na2HPO4.2H2O, 3 mM KH2PO4, 
pH=7.4) with 0.1% protease (type XXVII (Nargarse), Sigma Chemical CO, St. Louis, USA) 
at 37º C for 5-30 min. Incubation was terminated by adding 4 to 5 ml cold (4º C) PBS, and 
putting the tubes on ice. The nuclei were washed twice with PBS using intermediate 
centrifugation steps. About 30,000 nuclei were counted with a Coulter Counter, centrifuged 
and 200  l fetal calf serum was added. Subsequently, the nuclear suspension was centrifuged 
to a glass slide using a cytocentrifuge for 10 min at 450 rpm, briefly air-dried, and fixed in a 
mixture of methanol, 37% formaldehyde, and acetic acid (85:10:5 by volume) for 60 min. 
Subsequently, the specimens were stained with Feulgen-pararosaniline.34 The Discovery 
image analysis system (Cellular Imaging Systems, Beckton and Dickinson, Leiden, The 
Netherlands) was used to measure the DNA content of tumour cells and the internal control 
cells (lymphocytes or neutrophylic granulocytes). The mean number of tumour cells per 
patient that was measured was 570 with a range of 136-872 nuclei. All measurements were 
taken by the same experienced cytotechnician. The DNA content of nuclei of tumour cells 
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was expressed as the DNA index (DI), defined as the nuclear integrated optical density of a 
nucleus divided by the median integrated optical density of the control cells (lymphocytes or 
neutrophilic granulocytes).  
The DNA histograms were visually classified as DNA-diploid, DNA-polyploid or DNA-
aneuploid according to the definitions given elsewhere.35 In a diploid DNA histogram, a 
distinct G0/G1 peak was found in the diploid region (2C; DI=1.0 0.1) with a small proportion 
of tumour cells in S and G2/M phases. In a polyploid DNA histogram, distinct peaks were 
present in the diploid (2C; DI=1.0 0.1) and tetraploid (4C; DI=2.0 0.2) regions, or in the 
diploid, tetraploid and octaploid (8C; DI=4.0 0.4) regions. DNA histograms were considered 
to be aneuploid in all cases with scattered DI distributions, or uni-, bi- or multimodal 
distributions, that were not diploid or not polyploid. In this group, a separate entity was 
defined as a DNA-triploid pattern, which has a distinct G0/G1 peak in the triploid (3C; 
DI=1.5 0.15) region, and a small proportion of tumour cells in the S and G2/M phases (6C; 
DI=3.0 0.3). In addition, the 2.5c exceeding rate (DI>1.25), 3.5c exceeding rate (DI>1.75), 
and 5c exceeding rate (DI>2.5) were calculated for each DNA histogram. One pathologist 
(P.C.deW.) who was unaware of the clinical status of the patients classified the DNA-
histograms.  
Univariate logistic regression model was used to determine whether the presence of 
histological variables, the expression pattern of alpha-catenin, the exceeding rates (2.5c, 3.5c 
and 5c), the DNA-ploidy and the DNA-index were each a significant risk factor associated 
with stage IIa disease.36 The univariate two-tailed Student-t-test and the Wilcoxon-test (for 
comparing square means) were calculated. If possible, the odds ratio with a 95% confidence 
interval was calculated to determine potential risk factors. All potential risk factors were 
considered in a multivariate logistic model to confirm the best set of risk factors. Differences 
between both groups were deemed statistically significant at a p< 0.05.  
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Results 
All 50 patients were clinical stage I NSGCTs: according to the RPLND specimen, 14 (28%) 
had histologically confirmed pathological lymph-node(s). These patients are finally staged as 
pathological stage IIa NSGCT. One pathological staged I patient developed a lung metastasis 
within three months after orchiectomy and was included for statistical analysis in the 
pathological stage II group. The histopathological parameters are listed in Table I. 
 
TABLE I The univariate analysis of variables predicting occult metastatic disease in 
50 patients clinical staged I NSGCT. 
  Pathological stage   
Variable No. of 
Patients 
35 stage I 
(%) 
15 stage IIa 
(%) 
p-value1 Odds ratio or mean 
(CI:95%) 
      
Histology, n (%)      
Embryonal cell  
carcinoma 
39 24 (69) 15 (100) 0.02 * 
Yolk sac tumour 18 14 (40) 4 (27) 0.52 0.55 (0.14-2.06) 
Mature teratoma 11 9 (26) 2 (13) 0.47 0.44 (0.084-2.36) 
Immature teratoma 9 8 (23) 1 (7) 0.25 0.24 (0.027-2.13) 
Seminoma 11 8 (23) 3 (20) 1.00 0.84 (0.19-3.75) 
Vascular invasion 18 7 (20) 11 (73) 0.001 11.0 (2.68-45.18) 
Tunica albuginea 
invasion 
18 7 (20) 11 (73) 0.001 11.0 (2.68-45.18) 
Abnormal alpha-
catenin expression2 
28 21 (62) 7 (47) 0.36 1.85 (0.54-6.30) 
      
Ploidy      
Diploid 3 3 (9) 0 0.55 * 
Polyploid 2 2 (6) 0 1.00 * 
Aneuploid 22 14 (40) 8 (53) 0.54 1.71 (0.51-5.80) 
Triploid 23 16 (46) 7 (47) 1.00 1.04 (0.31-3.50) 
      
Mean (SD)      
DNA index - 1.46±0.29 1.38±0.21 0.32 0.082 (-0.083 - 0.25) 
Exceeding Rate      
2.5c-exceeding rate - 47.94±23.28 42.86±18.15 0.46 5.09 (-8.51 – 18.68) 
3.5c-exceeding rate - 19.84±15.19 15.81±7.62 0.34 4.02 (-4.31 - 12.36) 
5c-exceeding rate - 8.87±8,85 7,07±5.98 0.48 1.81 (-3.23 – 6.85) 
 
*Not available, division by zero; 1 Student’s t-test for histology and ploidy, Wilcoxon test for DNA and 
exceeding rate; 2 49 specimen available for analysis. 
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Univariate logistic regression showed a statistically significant correlation between occult 
metastases and the presence of ECC, VI and TI. Interestingly, the absence of ECC identified a 
subgroup of patients (n=11) at extremely low risk for occult metastatic disease (negative 
predictive value of 100%). However, this negative predictive value precluded a multivariate 
analysis on EC (because a zero is present): thus for the analyses we assumed each of the stage 
I patients in turn with no ECC in the primary tumour was stage II. With this modification, VI 
or TI were the only significant parameters in multivariate analysis (p=0.001), with a 
sensitivity of 87.5% and specificity of 80.0% in predicting the final pathologic stage (Table 
II).  
 
TABLE II Predictive values of histological factors in identifying occult 
metastases in clinical stage I NSGCT (univariate analysis). 
 Embryonal cell 
carcinoma (%) 
Vascular invasion 
(%) 
Tunica albuginea 
invasion (%) 
    
Sensitivity 100 87.5 87.5 
Specificity 31.4 80.0 80.0 
Predictive value +ve 38.5 61.1 61.1 
Predictive value - ve  100 73.3 73.3 
    
 
 
On immunohistochemistry, in one of the 50 specimens the expression pattern of alpha-catenin 
was unclear: 49 specimens could thus be evaluated and in 28 there was an abnormal alpha-
catenin expression pattern with positive staining for benign testicular tissue (internal control; 
Figure 1). Seven of these had pathological stage IIa and 21 pathological stage I disease. A 
division between metastatic and nonmetastatic tumours was not possible from the alpha-
catenin staining results (Table I).  
On DNA image cytometry, of the 50 testicular tumours, 3 were uniformly DNA-diploid 
(6.3%), 2 DNA-polyploid (4.2%) and 45 DNA-aneuploid (89.6%). The DNA-aneuploid 
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tumours were subdivided into 22 DNA-aneuploid and 21 DNA-triploid. Of interest, the DNA-
diploid and DNA-polyploid tumours were all pathological stage I. Neither the ploidy 
parameters nor the DNA-index and the exceeding rate values were significantly correlated 
with stage IIa disease (Table I).  
 
 
 
 
 
 
 
 
 
Discussion  
The main problem in the treatment strategy for clinical stage I NSGCT is detecting occult 
retroperitoneal metastases. The 28% incidence of positive nodes found at RPLND in the 
present series of patients is in accordance with published results (30-35%).10,11 The 
identification of prognostic factors could be of great value for choosing the best therapeutic 
option. To date, the most important prognostic factors for occult retroperitoneal disease 
appear to be VI and the presence and/or percentage of ECC.4,6,10-13 VI in the primary tumour 
correlates with an increased risk of retroperitoneal lymph node metastases for clinically 
staged I NSGCT patients. Former studies show that 36-88% of these patients had metastases 
or recurrences, compared with 10-24% of patients with no VI.37 In a retrospective study of 92 
clinical stage I patients, Moul et al.12 found VI, with a sensitivity of 76.3% and a specificity of 
83.3%, to be the best prognostic factor for pathological stage II disease. In the present study, 
Figure 1. The immunoreactivity of 
α-catenin in nonseminomatous 
testicular cancer. Paraffin sections 
were stained with antibodies against 
α-catenin. Normal tissue on the 
luminal side of the rete testis (1) 
stained positively for α-catenin, 
whereas the tumorous part 
(embryonal call carcinoma, 2) had 
aberrant or negative staining for α-
catenin. (x200) 
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VI was, with TI, the best risk factor (87.5% sensitivity and 80.0% specificity). However, 
identifying VI is difficult: retraction artefacts in stroma may mimic lymphatic spaces and the 
stromal cells could be misinterpreted as lining endothelial cells.37 Artefacts due to knife 
implantation into vascular spaces can be misconstrued on histology, resembling 
pseudoinvasion.38 Therefore, some studies underline the importance of consulting experienced 
reference pathologists.11 
In contrast to VI, the results for ECC are contradictory: in the largest study of prognostic risk 
factor analysis for clinical stage I NSGCT (75 pathological stage I, 204 pathological stage II) 
ECC could not be confirmed as an important prognostic factor (p=0.08), whereas VI was 
shown to be a significant risk factor in uni- and multivariate analysis.13 Analysing the primary 
tumour for quantitative histopathology could increase the predictive value.4,6,12 Heidenreich et 
al.4 predicted in 85% of 48 selected clinical Stage I patients the correct pathological stage IIa, 
using an ECC threshold of  80%. A threshold of   45% ECC in the primary tumour of 77 
clinical stage I patients predicted pathological stage I with 88% accuracy. These predictive 
values were improved by combining the presence or absence of VI with ECC, respectively. 
However, prospective trials have failed to establish any specific level of ECC to be accurately 
predictive for metastasis.5,13 An explanation of these contradictory results might be that the 
pathological assessment of the percentage of ECC is subjective and depends on interpretation 
by the observer. As to quantitative histology, difficulties in recognising and distinguishing 
yolk sac tumour from ECC were reported.37,39 For instance, in mixed germ cell tumours the 
components are arranged diffusely, and pathological review requires an estimate of the 
percentage of each component on each slide. This easily causes inter- and intra-observer 
variation. Therefore, in the present study only the presence or absence of ECC was sought: all 
stage IIa patients (including the one with a lung metastasis) had ECC components. In contrast, 
all 11 clinical stage I patients with no ECC components in the primary tumour were correctly 
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classified as pathological stage I NSGCT. The absence of ECC independently improved the 
prediction of patients at extremely low risk for metastatic disease.  
The 1978 TNM classification, used in previous studies, revealed that the primary tumour 
stage (pT)   2 (meaning TI) was associated with a higher risk of metastases.10,11,13 Fung et 
al.40 reported, in 60 clinical stage I NSGCT patients, that 14 of the 20 pathological stage II 
patients had a pT of  2. In the present classification system (1997), TI has been lowered to a 
pT1 lesion, and VI has been added and classified as a pT2 lesion. The present results are 
comparable with former studies, as in all specimens TI coincided with VI. In 11 of the 15 
specimen TI was positively correlated with pathological stage II: in three invasion in the 
epididymis was also found. TI was, together with VI,  the best prognostic indicator in the 
present study. 
The cadherin-catenin complex is essential for the adhesion and detachment of cells. This 
complex, consisting of E-cadherin and  -,  - and  -catenins, is located in the cell membrane. 
Loss of those adhesive molecules results in an increase in the invasive ability of tumour cells. 
Cadherin expression is lost in advanced prostatic, breast, oesophageal, gastric, colonic, and 
testis carcinomas.14-20 In prostate cancer, E-cadherin probably uses  -catenin for anchorage to 
the cytoskeleton.14 Studies on oesophageal and gastric cancer suggested that aberrant  -
catenin expression might be a better indicator of tumour invasion and metastasis than E-
cadherin.17,18 Recently, Saito et al.20 reported aberrant E-cadherin expression in three of 16 
seminomas and in 10 of 16 NSGCT, which was not expressed on normal germ cells. An 
aberrant expression of  -catenin was detected in four of the NSGCT. They suggested that E-
cadherin-catenin complex might not be functional in testis tumours, as most E-cadherin-
positive testis cancers had no (or little)  -catenin expression. However, the functionality 
might be best tested by correlating the expression pattern with clinical and pathological 
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variables, e.g. the stage of disease and/or survival. In a retrospective study of 149 clinical 
stage I NSGCTs, 78 specimens could be evaluated for E-cadherin expression. Nineteen had a 
loss of E-cadherin expression, subdivided into 17 pathological stage II and 2 pathological 
stage I NSGCT (p<0.001).4 To our knowledge, the present study is the first to investigate the 
 -catenin expression in clinical stage I NSGCT:  -catenin was expressed in virtually all the 
specimens examined (98%). Unfortunately, we were unable to obtain any evidence that down-
regulation of the  -catenin expression was involved in the process of metastasis to 
retroperitoneal lymph nodes in clinical stage I NSGCT.  
New methods (e.g. DNA-analyses) have been developed to improve the assessment of risk 
factors in cancer.21 The hypothesis is that tumour cells have a higher amount of DNA than 
normal cells, which correlates to a more aggressive growth pattern, in terms of invasion and 
spread. To date, the results of these studies have been inconclusive.23-30 Consequently, DNA-
analyses have not yet been used routinely for staging clinical stage I NSGCT. Some 
investigators reported an abnormal DNA stem-line in NSGCT.23,24,27 Moul et al.24 suggested 
that if one sampled area of a NSGCT was DNA-diploid then other areas should be examined, 
and DNA-aneuploidy and DNA-multiploidy would be found. In contrast, in the present study, 
uniformly DNA-diploid and DNA-polyploid tumours were present only in pathological stage 
I patients. Moreover, all samples of pathological staged II patients were DNA-aneuploid: 
diploidy and polyploidy identified patients at low risk but a larger cohort is necessary to draw 
firm conclusions. In concordance with other studies, DNA-diploidy and the DNA-index had 
no predictive significance in detecting occult metastatic disease in NSGCT.23,24,27 
Image analysis can used to detect nuclei with a very high DNA content. Tumours with DNA-
hypertetraploid components are more likely to be pathologic stage II.25,29 In a retrospective 
study of 74 clinical staged I patients, 23 of the 33 staged II patients with a 5c-ER above 3.1% 
had metastatic disease.30 Unfortunately, this outcome is not useful a clinical setting 
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(sensitivity: 69.7%, i.e. 30.1% pathological stage IIa NSCGT were misclassified as stage I): 
the exceeding rates according to our study could not be used to predict the pathological stage 
of a tumour.  
 
Conclusion 
Although the primary goal of the present study was to evaluate the additional value of  -
catenin and DNA-markers over routine histology, we found VI and TI to be the most 
important predictors for occult metastatic disease. With a sensitivity of 87.5% and a 
specificity of 80%, VI and TI were useful for identifying clinical stage I NSGCT patients at 
high risk for retroperitoneal disease. In contrast, the absence of ECC in the primary tumour 
exactly predicted patients at low risk for metastasis. A DNA-diploid or DNA-polyploid 
primary tumour also identified patients at low risk. 
To differentiate patients at low and high risk for metastases, independent, reliable and 
reproducible prognostic factors are needed. Therefore, we suggest that an experienced 
pathologist, who is able to analyse tumour histology, should assess TI, VI and ECC. Further 
study is necessary to clarify the best set of prognostic factors for evaluating clinical stage I 
NSGCTs.  
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Abstract 
 
Objective. To investigate the role of 18fluoro-2-deoxyglucose positron emission tomography 
(18FDG-PET) in the initial staging of clinical stage I and II nonseminomatous germ cell 
tumours (NSGCTs) and in re-staging of (non)seminomatous GCTs after chemotherapy. 
Patients and methods. 18FDG-PET studies were undertaken in 50 patients. FDG uptake was 
interpreted visually and when possible the standardized uptake value was determined. A 
18FDG-PET scan was taken in 5 patients with clinical stage I and in 7 with stage II NSGCT. 
The scans were validated by histology. Stage I patients underwent a retroperitoneal lymph 
node dissection because of vascular invasion in the primary tumour.  
Thirty-eight scans were taken after the completion of chemotherapy (28 NSGCTs, 10 
seminomatous GCTs), and validated by histology or clinical follow-up.  
Results. In stage I NSGCT, 18FDG-PET staging was equivalent to computed tomography 
(CT) staging. One small lesion, consisting of mature teratoma, was missed by both 18FDG-
PET and CT scan. In stage II NSGCT, 18FDG-PET missed two lesions (mature teratoma and 
retroperitoneal mass with a small component of embryonal cell carcinoma) whereas CT 
correctly classified all.  
In 20 of 28 patients with NSGCT, histology was obtained after chemotherapy. In 1 of 3 
patients with viable tumourous residual mass the 18FDG-PET scan was clearly positive; in 4 
of 12 patients with mature teratoma and inflammation components retroperitoneally, the 
18FDG-PET was also positive. In contrast, 8 patients with solitary mature teratoma had a 
negative PET result. In 4 of 5 patients with necrosis after chemotherapy the PET result was 
correctly negative. All 8 patients on surveillance had a negative PET scan and are free of 
disease at median of 14 months (range 8-18). Interestingly, of the 12 patients with a correct 
negative PET result, 11 had no mature teratoma in their primary tumour. 
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Nine of 10 (90%) patients with seminomatous GCT (SGCT) were correctly staged. Two 
18FDG-PET studies showed increased uptake: in one, a viable seminomatous mass was found 
and in the other there was inflammation in the residual mass. In all other patients the 18FDG-
PET scan correctly predicted absence of viability in the residual mass.  
Conclusions. In primary staging, 18FDG-PET has no benefit over CT. In re-staging, a 
negative 18FDG-PET result predicts fibrotic residual mass in SGCT. Moreover, it could be 
useful to predict fibrotic residual mass in NSGCT in those patients with no teratoma 
component in their primary tumour.  
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Introduction 
 
As most testicular germ cell tumours (GCT) are curable, different therapeutic strategies have 
been evaluated to reduce the morbidity of treatment without affecting the survival rate. 
Currently, staging in GCT is used to determine the extent of disease and to facilitate the 
choice of treatment. However, clinical stage (CS) I nonseminomatous GCTs (NSGCT) are 
understaged in 30% of patients1, despite improvements of CT technology.2 Consequently, the 
optimal treatment after orchiectomy remains controversial. Primarily, two strategies have 
been applied, i.e. watchful waiting with close surveillance and chemotherapy on relapse, or 
primary retroperitoneal lymphadenectomy (RPLND) with or without chemotherapy.1,3,4 The 
morbidity of a surveillance policy is low for those patients without progression, but the 
frequent follow-up visits may be stressful. Moreover, a surveillance policy if there is occult 
metastasis might result in a treatment delay with the potential for more extensive disease. 
Conversely, approximately 70% of the patients who undergo RPLND have tumour-negative 
lymph nodes.1 Independent of initial treatment, the survival rate for stage I NSGCT patients is 
close to 100%.4 
At present, treatment can also be adapted to prognostic factors. The best predictors for 
metastatic disease (50%) are the presence of vascular and lymphatic invasion (VI) and 
embryonal cell carcinoma (ECC) components in the primary tumour.5 For patients at high risk 
for metastases some6 advocate RPLND with adjuvant chemotherapy in those with 
pathological stage II, whereas others recommend chemotherapy only.7 In contrast, patients at 
low risk will enter a surveillance protocol. The role of primary chemotherapy has yet to be 
defined, as half of the patients will be treated needlessly, with the potential risk of toxicity. In 
our centre RPLND is undertaken in CS I patients with vascular invasion in the primary 
tumour and those with no invasion are followed closely. However, the best choice of 
treatment is only possible if the presence of metastasis can be determined.  
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Another problem is the presence of indeterminate residual masses on CT after the completion 
of chemotherapy for disseminated GCTs. In general, the residual mass in NSGCT consist of 
viable tumour (10-20%), mature teratoma (30-40%) and necrosis or fibrosis (40-50%).8 Thus, 
half of the patients with residual mass undergo unnecessary surgical treatment. For 
seminomatous GCT (SGCT), two-thirds of the patients have a residual mass after 
chemotherapy and finally only 12-15% contain viable tumour.9 Some investigators have 
recommended resection of post-chemotherapy residual masses in SGCT10, others advocate 
surveillance.11 The response to therapy in SGCT can be assessed by the size of the residual 
mass.12 In our centre, patients with SGCT and a residual mass of < 3cm in maximal transverse 
diameter on CT will enter the surveillance protocol, and those with >3cm will have surgery. 
However, in both NSGCT and SGCT the optimal method for differentiating patients with a 
post-chemotherapy tumourous residual mass from those with necrosis/fibrosis has yet to be 
defined.  
A relatively new method of staging, 18fluoro-2-deoxyglucose positron emission tomography 
(18FDG-PET), might be useful to overcome the diagnostic problems in (re)staging GCTs. The 
glucose analogue FDG is a radiopharmaceutical that allows in vivo evaluation of glucose 
metabolism with PET. Most malignancies, including GCT, show increased glucose use.13 In 
this setting, functional imaging may provide a more accurate means of delineating malignant 
versus benign tissue. Moreover, in other malignancies 18FDG-PET seem to be more accurate 
in identifying metastatic disease in lymph nodes that are not enlarged.14 As 18FDG-PET can 
assess the metabolic activity of tissue it might be able to differentiate between different 
histological entities. We investigated the current applications and the added value of 18FDG-
PET over CT in patients with GCTs, reviewed our experience of 18FDG-PET in CS I and II 
NSGCT and evaluated post-chemotherapy residual masses in (non)seminomatous disease.  
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Patients and methods 
From November 1998 to July 2001, 50 men (mean age at diagnosis: 30 years, range 17-61), 
with CS I/IIa NSGCTs (n=12, Table I) or more disseminated GCTs (n=38, Table II) were 
studied. Patients were staged using abdominal and chest CT scan, determination of serum 
tumour markers and histopathological verification before the start of therapy. Primary staging 
was conducted according to Royal Marsden Hospital Classification. 
Five patients with CS I at high risk of metastases (vascular invasion in the primary tumour) 
and seven with CS IIA NSGCT underwent 18FDG-PET scan on the day before surgery. The 
results were compared with staging spiral CT. Solitary lymph nodes of < 1.0 cm in maximal 
transverse diameter were judged negative on CT. An experienced radiologist who was 
unaware of the disease status of the patient interpreted the CT images.  
Additionally, 38 patients with stage IIb-IV GCTs were included (28 NSGCT and 10 SGCT). 
All patients underwent CT and 18FDG-PET after the completion of first-line chemotherapy 
(cisplatin, etoposide and bleomycin). In all cases, FDG-PET imaging was taken within one 
month of CT. Histological verification of the residual tumour was obtained in 20 NSGCTs 
and 2 SGCTs. The median time from 18FDG-PET scans to surgery was 21 days (range 1-60). 
Verification of the nature of the residual tumours in the remaining patients was based on 
information from serum tumour markers, CT and the duration of the event-free follow-up 
after the FDG-PET study (median 12 months, range 2-18). The study was approved by the 
local ethical committee and informed consent was obtained from all patients.  
For the FDG-PET scan protocol, a  dedicated, rotating half-ring PET-scanner (ECAT-ART, 
Siemens/CTI, Knoxville, TN, USA) was used for data acquisition. Before injection with 
18FDG the patients fasted for at least 6 hours although sugar-free liquids were permitted. 
Immediately before the procedure the patients were hydrated with 500 ml of water. One hour 
after intravenous injection of 200-220 MBq 18FDG (Mallinckrodt Medical, Petten, The 
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Netherlands) and 20 mg furosemide, emission and transmission images of the area between 
proximal femora and the base of the skull were acquired (10 minutes per bedposition). The 
images were corrected for attenuation and reconstructed using the ordered-subsets expectation 
maximization algorithm. The reconstructed images were displayed in coronal, transverse and 
sagittal planes. All scans were interpreted by two nuclear medicine physicians (W.J.G.O., 
L.F.deG.O.) unaware of all clinical and pathological data. Tumour metabolism was evaluated 
using visual analysis and calculation of standardized uptake value (SUV). The visual scoring 
model was graded as suspect for carcinoma (++); increased uptake (+); negative (-). The SUV 
was calculated for the region of maximal FDG uptake.15 
 
 
Results 
Five patients with CS I and seven stage IIA underwent a FDG-PET scan before RPLND 
(Table I).  
 
Table I 18FDG-PET results in clinical staging non-seminoma testis stage I and IIa 
   Lymph node Stage   
Patient Primary 
Histology 
Tumour markers
(ng/ml)* 
CT (cm) 18FDG-PET 
(visual) 
SUV RPLND 
       
1 ECC, SEM N <1 - N.D. Negative 
2 ECC, SEM N <1 - N.D. Negative 
3 MT N <1 - N.D. Negative 
4 ECC N <1 - N.D. Negative 
5 MT, SEM N <1 - N.D. MT 
6 ECC, YST, MT N 2 ++ 14,8 ECC 
7 ECC, SEM N 2  
1.5 
++ 
++ 
5.5 
4.3 
Histiocytosis 
ECC 
8 ECC, MT, YST N 1,4 ++ 5 ECC 
9 ECC, YST, MT N 1,2 ++ 4,8 ECC 
10 MT, ECC N 1,3 ++ 3,8 ECC 
11 ECC N 1,2 - N.D. ECC1 
12 ECC, YST bHCG:6 1,5 - N.D. MT 
       
Key: *1 day before RPLND; ECC, embryonal cell carcinoma;  SEM, seminoma;  MT, mature teratoma; YST, 
yolk sac tumour; N.D, not done; ++clearly positive; - negative; N, normal; 1 microscopic disease (3 mm) 
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In CS I NSGCT, 18FDG-PET staging was equivalent to CT staging. One small lesion, 
consisting of mature teratoma (patient 5), was missed by both 18FDG-PET and CT. The 
remaining patients were correct negatively staged. In CS II NSGCT, the 18FDG-PET missed 
two lesions whereas CT was able to classify all correctly. One lesion seems to be necrotic 
tissue of 1.2 cm in which ECC (approximately 0.3 cm in diameter, patient 11) was found and 
the other lesion was a mature teratoma of 1.5 cm in transverse diameter (patient 12). The 
remaining patients were correctly positively staged (Figure 1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Thirty-eight patients were evaluated for residual mass after chemotherapy (Table II). Twenty-
eight patients with NSGCT were studied after chemotherapy; the surgical procedure was 
RPLND in 20, occasionally in combination with partial hepatectomy (patient 15) or 
thoracotomy (patient 16). The lesions detected by 18FDG-PET were classified as viable 
tumourous (n=3), teratomatous (n=12) or as residual necrotic mass (n=5) after chemotherapy.  
 
 
 
Figure 1. Sagittal and coronal PET scan with suspected retroperitoneal lymph 
node (arrow). The clinical diagnosis was stage IIa non seminoma testis. 
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Table II The characteristics of patients evaluated with FDG-PET after chemotherapy for advanced 
germ cell tumour 
 
  Initial Staging     After chemotherapy  
Patient Primary 
Histology 
Tumour 
stage 
Tumour 
markers1 
Region of interest CT (cm) FDG-PET 
(visual) 
SUV Histological 
diagnosis 
Follow-up 
(months) 
          
Surgery after chemotherapy for nonseminoma: viable cancerous disease      
13 MT, YST IID N Retroperitoneum 18 ++ 3..5 Teratocarcinoma 14 
14 
 
ECC, CHO IID 
IVL 
bHCG: 7 Retroperitoneum 
Lung 
8 
NP 
- 
+ 
NA. 
NA. 
ECC, CHO2, N/ F 
surveillance 
10 
15 
 
ECC, SEM IID 
IVH1 
N Retroperitoneum 
Liver 
5.2 
2x2 
+ 
- 
2.2 
ND 
ECC2, MT + His 
2X N/F 
17 
      
Surgery after chemotherapy for nonseminoma: mature teratoma      
16 MT, ECC IID 
IVL 
N 
 
Retroperitoneum 
Lung 
Paravesical 
1.5 
0.5 
0.4 
- 
- 
++ 
NA. 
NA. 
3.2 
MT 
MT 
NO. 
11 
17 
 
MT, ECC IID 
IIIn 
N 
 
Retroperitoneum 
Supraclaviculair 
3 ++ 
+ 
1.7 
2.4 
MT + His 
NO. 
12 
18 MT, ECC IID N Retroperitoneum 6 + 3.7 MT + His 13 
19 MT, YST, SEM IID N Retroperitoneum 6 + 1.8 MT + His 11 
20 MT, SEM IID N Retroperitoneum 9.5 + 1.9 MT + His 9 
21 MT, ECC, CHO IIB N Retroperitoneum 3 - ND. MT 13 
22 MT, ECC IIC N Retroperitoneum 7 - NA. MT 16 
23 MT, YST IIC N Retroperitoneum 5 - N.D. MT 2 
24 MT, ECC IIC N Retroperitoneum 4 - ND. MT 14 
25 MT, SEM IIC N Retroperitoneum 3 - ND. MT 10 
26 MT, ECC, CHO IID N Retroperitoneum 6 - ND. MT 18 
27 
 
IMT, SEM IIB 
IV 
N 
 
Retroperitoneum 
Lung 
4 
NP  
- 
- 
ND. 
ND. 
MT 
NO. 
9 
      
Surgery after chemotherapy for  nonseminoma: necrosis/fibrosis      
28 YST, SEM IID N Retroperitoneum 8 + 4.2 N/F+ Gran. tissue  17 
29 
 
EC,C CHO, 
SEM 
IID 
IV 
bHCG: 3.6 Retroperitoneum 
Lung 
4 
NP 
+ 
- 
2.8 
ND. 
N/F + His 
NO. 
10 
30 
 
ECC, SEM IID 
IV 
N Retroperitoneum 
Lung 
7.5 
0.5 –2.5 
- 
++ 
NA. 
NA. 
N/F 
NO. 
11 
31 EC, CHO, YST IIC N Retroperitoneum 2.5 - ND. N/F 13 
32 MT IIC N Retroperitoneum 3 - ND. N/F 12 
      
Follow-up after chemotherapy for nonseminoma      
33 CHO IIB N Retroperitoneum <1 - ND. surveillance 14 
34 ECC IIB N Retroperitoneum <1 - ND. surveillance 17 
35 ECC, SEM IIB N Retroperitoneum <1 - ND. surveillance 2 
36 ECC IIB N Retroperitoneum <1 - ND. surveillance 3 
37 
 
ECC, SEM IIB 
IIIn 
N Retroperitoneum 
Mediastinum 
<1 
<1 
- 
- 
ND. 
ND. 
surveillance 
surveillance 
9 
38 ECC IIB 
IIIn 
N 
 
Retroperitoneum 
Mediastinum 
<1 
NP 
- 
- 
ND. 
ND. 
surveillance 
surveillance 
3 
39 ECC IIB 
IV 
N Retroperitoneum 
Lung 
<1 
NP  
- 
- 
ND. 
ND. 
surveillance 
surveillance 
3 
40 ECC IIB 
IV 
N Retroperitoneum 
Lung 
<1 
NP  
- 
- 
ND. 
ND. 
surveillance 
surveillance 
3 
      
Surgery after chemotherapy for seminoma      
41 SEM IID N Retroperitoneum 4 ++ NA. SEM +N/F 15 
42 
 
SEM IID N Retroperitoneum 
 
5.5 ++ NA. N/F + 
inflammation 
11 
      
Follow-up after chemotherapy for seminoma      
43 
 
SEM IID N Retroperitoneum 
Retroperitoneum 
2.8  
2.0  
+ 02/2000 
-  03/2000 
2.6 
ND. 
surveillance 18 
44 SEM IID N Retroperitoneum 3 - ND. surveillance 17 
45 SEM IIC N Retroperitoneum 2 - ND. surveillance 12 
46 
 
SEM IID N Retroperitoneum 
 
2 - ND. surveillance 8 
47 SEM IIC N Retroperitoneum <1 - ND. surveillance 14 
48 SEM IID N Retroperitoneum <1 - ND. surveillance 14 
49 SEM IIB N Retroperitoneum <1 - ND. surveillance 10 
50  SEM IIC N Retroperitoneum <1 - ND. surveillance 14 
          
Key: abbreviations see Table 1; Cho, corioncarcinoma; His, histocytosis; NP, not present; N/F, necrosis,fibrosis; NA, not available; ND, not 
done; NO, not obtained, N, normal; 1, first response evaluation after chemotherapy;  2, microscopic disease 
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In 8 patients, the residual mass was evaluated as benign on the basis of an event-free follow-
up after chemotherapy.  
Three patients (13-15) had viable tumour in the residual mass. Patient 13 had a 
teratocarcinoma of 8 cm in the residual mass that showed intense 18FDG uptake (SUV 3.5, 
Figure 2). In patients 14 and 15, the tumourous part was not (clearly) detected by 18FDG-PET. 
In both, tumourous tissue was found in only one histological section, which is obviously 
below the detection limit of PET. In patient 14, small lesions in the lungs were also seen with 
moderate FDG uptake. However, CT of the chest showed no abnormalities and the patient has 
been followed up for 10 months with no evidence of disease. 
 
 
 
In most patients with NSGCT mature teratoma was found in the residual mass (16-27). In 5 of 
them (16-20) 18FDG uptake was found (SUV range: 1,7-3,7). On visual analysis, only patient 
16 and 17 had a suspect lesion at PET. However, the lesion in patient 16 was not surgically 
removed as it was not suspect for disease on CT and it was located outside the suspected 
residual area (paravesical). In contrast, the residual lesions in retroperitoneum and lungs seen 
on CT were suspect and therefore removed. Histology revealed teratomatous residual mass in 
Figure 2. PET image (coronal 
and axial) and CT (axial) of 
post-chemotherapy residual 
mass. PET scan reveals focus of 
FDG uptake (arrow). Pathologic 
examination revealed terato-
carcinoma. 
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both locations. In patient 17, 18FDG-PET showed increased retroperitoneal and 
supraclavicular uptake. Only histology of the retroperitoneal mass was obtained, which 
showed a teratomatous mass with an inflammatory component (histiocytosis). The 
supraclavicular lesion detected was probably caused by reactive tissue after the primary 
diagnostic puncture. After chemotherapy, this lesion was not suspect on CT nor on physical 
examination and therefore not explored. Currently, patient 17 is free of disease 12 months 
after treatment. 
Although patients 18-20 had increased SUVs, the lesions were not clearly suspect for 
metastatic disease on visual interpretation. All had 18FDG uptake in the rim of the residual 
mass and histology showed inflammatory reactive tissue consisting of macrophages 
(histiocytosis). The remaining 7 patients with histologically mature teratoma (21-27) had 
negative findings at PET (Figure 3). In three of five residual masses with necrosis/fibrosis 
(28-32) there was 18FDG uptake. The false-positive PET-scan (patient 28) was caused by 
benign granulomatous tissue. In patient 29, there was minor 18FDG uptake at the border of the 
residual mass, not suspect for malignancy. At histology, macrophages (histiocytosis) were 
found in the rim of this mass. Patient 30 had also pulmonary lesions on PET, which were in 
regression on CT and therefore not removed. The lung metastases disappeared after four 
months on PET and CT scan. The remaining two patients (31&32) had negative findings at 
18FDG-PET in the retroperitoneum, which were in agreement with histological findings. Of 
interest, 3 patients (29-31) with no teratomatous component in the primary tumour were 
correct negatively staged by PET. 
Eight patients (33-40) had no residual mass(es) after chemotherapy that were suspicious for 
malignancy and entered a surveillance protocol. Currently, all patients have no signs of 
disease at a median follow-up of 3 months (range 2-17). 
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Ten patients with SGCT received three or four cycles of cisplatin-based chemotherapy. Two 
patients (41 and 42) had a retroperitoneal residual mass of >3 cm. In both patients, the PET 
scan showed increased retroperitoneal uptake. At histology viable seminomatous tissue (no. 
41) and necrosis with inflammatory components (no. 42) was found. 
Eight patients (43-50) entered a surveillance protocol as the residual mass was <3 cm in 
transverse diameter on CT. Re-staging of patient 43 showed a residual mass of 2,5 cm on CT, 
which was positive at PET. 18FDG-PET 1 month later was negative and consequently the 
patient continued follow-up. Four patients (44, 47-49) had positive findings at 18FDG-PET 
outside the region of interest, probably caused by local activity at L5, bowel adenoma, 
oesophagitis and sarcoidosis, respectively. None of the patients with SGCT and on 
surveillance have relapsed during follow-up (median: 14 months; range 8-18 months).  
 
 
Discussion  
Currently, clinical staging of low-stage testicular GCTs is inaccurate; 30% of patients with CS 
I NSGCT are understaged.1 As CT predominantly relies on size criteria and is not specific for 
lymph nodes <1 cm in diameter, clinical staging has not been improved by the newest 
Figure 3. The PET scan 
shows no increased FDG 
uptake, whereas the CT-
scan shows a post-
chemotherapy residual mass 
(arrow). Histology revealed 
a mature teratoma. 
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generation of CT scanners.2 The new technique of 18FDG-PET has been useful in localising 
small volume metastatic disease in comparison with CT in various malignant tumours.17,18 
Another problem is evaluating residual mass after chemotherapy for disseminated 
(non)seminomatous disease. The visualization of the glucose metabolism by 18FDG-PET 
might identify (viable) tumourous tissue and distinguish it from benign tissue.19 Thus, we 
investigated the additional value of "whole-body" 18FDG-PET scan in both the clinical 
staging of high-risk CS I or IIA NSGCT and evaluated residual mass after chemotherapy in 
disseminated (N)SGCT. 
Albers et al.20 assessed 24 patients with NSGCT stage I to IIB who underwent 18FDG-PET for 
clinical staging. The 18FDG-PET scan detected six of the nine metastatic lesions. The three 
false-negative findings were found in two small metastatic lesions (<0.5 cm.) and in one 
retroperitoneal mature teratoma of 4.8 cm in transverse diameter. On CT only both small 
nodes were judged negative. In contrast, CT was false-positive in 4 of 9 patients with lymph 
nodes >1.0 cm, whereas FDG-PET was completely conclusive. These authors stated that 
18FDG-PET may not be helpful in primary staging of stage CS I NSGCT, but it might have 
additional value in CS IIA patients, by omitting false-positive findings on CT. A limitation of 
18FDG-PET and CT in initial staging of low-stage nonseminomatous disease is its inability to 
detect very small lesions.20 Perhaps malignant cells are already present in the lymph node 
before to nodal enlargement. Detecting even smaller lesions is an unending challenge since 
the detection of microscopic disease is probably impossible by any imaging technology. As 
18FDG-PET and CT miss microscopic disease, there may be no alternative but to submit high-
risk CS I patients for surgery. Moreover, it will be difficult to detect mature teratoma by 
18FDG-PET since it is a benign condition with a (near) normal metabolism. However, mature 
teratomas must be resected because of their potential for malignant transformation.21 In the 
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present series, 18FDG-PET had no additional value over CT in clinical staging of NSGCT I 
and IIa. 
As noted, it would be beneficial to have a predictive preoperative variable to eliminate 
unnecessary surgery after chemotherapy. In 30 patients with NSGCT and residual masses 
after chemotherapy, 11 had fibrosis, 15 a teratoma and 4 a viable tumour.22 The 18FDG-PET 
scan was able to differentiate viable tumour from residual necrosis/fibrosis or teratoma; 
unfortunately, it was unable to differentiate between necrosis/fibrosis and teratoma. In a 
similar study, Nuutinen et al.23 showed that 18FDG-PET scanning of residual mass could be 
hampered by false-positive findings. In three of nine positive scans inflammatory changes in 
benign tissue were found. Ganjoo et al.24 evaluated post-chemotherapy residual masses in 29 
patients with disseminated seminoma (19 first-line chemotherapy and 10 salvage 
chemotherapy). In only one patient the 18FDG-PET scan was positive for a posterior 
mediastinal mass, but the pathologic diagnosis showed necrotic tissue. They concluded that 
18FDG-PET had no benefit in evaluating seminomatous residual mass. As no patients have 
relapsed after first-line chemotherapy, it can also be concluded that a negative 18FDG-PET is 
useful for diagnostic surveillance. 
In the present study 28 patients with disseminated NSGCT and 10 with disseminated SGCT 
were evaluated by 18FDG-PET, to determine the ability to differentiate the histological 
content of residual masses after chemotherapy. In re-staging NSGCT after chemotherapy PET 
was hampered by false-positive lesions from inflammatory processes and by false-negative 
findings caused by mature teratoma residual masses after chemotherapy and microscopic 
viable lesions. However, 18FDG-PET has additional value in patients with no teratoma 
component in their primary tumour: three of these patients with a residual mass of >1cm and 
eight with a residual mass of <1cm were correct negatively staged. In contrast, most patients 
with a teratoma component in the primary tumour also had a teratoma component in their 
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residual mass, which was not (clearly) suspected on 18FDG-PET. As far as we aware this is 
the first study identifying a subgroup of patients with NSGCT in which 18FDG-PET might be 
a valuable adjunct in determining post-chemotherapy resection; the results must be confirmed 
in a larger trial. 
For SGCTs nine of ten patients were correctly staged; one false-positive result caused by an 
inflammatory process in the residual mass. In 8 patients the 18FDG-PET scan predicted the 
absence of viable residual mass. As seminomas do not contain teratomatous elements, a 
negative 18FDG-PET scan could be an argument for surveillance.  
Currently, 18FDG-PET scanning has been used in decision-making; one patient referred to our 
clinic had an undefined lesion in his right lung developed within 2 months after orchidectomy 
for SGCT. The CT scan of the thorax was inconclusive and all other parameters for metastatic 
disease were negative (clinical examination, serum tumour markers, abdominal CT-scan). He 
underwent PET, which was also negative and thus the presence of a metastasis could not be 
confirmed. This patient was staged as CS I SGCT and received radiotherapy on the 
retroperitoneum. Currently, he has  no signs of metastatic disease at 11 months of follow-up. 
 
 
 
Conclusions 
In the primary staging of low-stage NSGCTs, 18FDG-PET has no benefit over CT. In re-
staging, it can be used to predict fibrotic residual mass in SGCTs. Moreover, it could be 
useful to predict fibrotic residual mass in a subset of patients with NSGCT and no 
teratomatous components in their primary lesion. A significant limitation of 18FDG-PET 
FDG-PET is its inability to detect very small retroperitoneal lesions and mature teratoma 
components of any size. Moreover, there may be false-positive results caused by 
inflammatory processes. 
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CHAPTER 7 
 
 
The Role of 18fluoro-2-deoxyglucose positron emission tomography for monitoring 
chemotherapy response in patients with high stage testicular germ cell cancer  
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Abstract 
 
Objective. Positron emission tomography with 18F-fluorodeoxyglucose (18FDG-PET) reflects 
tissue and tumour viability. We investigated if sequential 18FDG-PET scans in patients with 
high stage testicular germ cell cancer provide early information on the efficacy of 
polychemotherapy.  
Methods: Serial 18FDG-PET studies were performed in 18 consecutive patients with 
advanced testicular cancer (14 non-seminoma and 4 seminoma), and who were subdivided 
into 15 and 3 patients with low and intermediate risk profile, respectively, according to the 
International Germ Cell Consensus Classification Group. The studies were performed before 
the start of chemotherapy, after the second chemotherapeutic cycle and 6 weeks after 
completion of chemotherapy. 18FDG-PET images were interpreted visually and compared to 
CT-scans made pre-and post-chemotherapy. PET and CT were validated either by histology 
(n=5) or by clinical follow-up. 
Results: Seventeen patients showed increased uptake before chemotherapy. The 18FDG 
uptake decreased in all 17 patients during therapy. In one patient serial-PET did not show any 
uptake at all. Overall, the clinical course of disease after first-line treatment was correctly 
predicted by serial 18FDG-PET in 71% of the patients (12/17) compared with 83% (15/18) by 
CT. PET was hampered by false-positive and negative findings caused by inflammatory 
processes and mature teratomatous tissue, respectively. 
Of 18 patients enrolled, 16 were free of disease at a median of 10.3 months. Two patients with 
an intermediate risk profile relapsed at three months after discontinuation of chemotherapy. 
Conclusion: This pilot study demonstrates that it is possible to monitor changes in 18FDG 
uptake in testicular germ cell tumours. However, a decrease in 18FDG uptake after start of 
therapy not necessarily predicts complete response in the further course of treatment. Serial 
PET-scanning in patients with low risk profile has no value over CT. Further studies in larger 
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series of patients are needed to estimate the additional value of serial-PET in patients with 
seminomatous germ cell tumours and in nonseminomatous patients with an increased risk 
profile. 
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Introduction 
Since the introduction of cisplatin based chemotherapy, the prognosis of testicular germ cell 
tumour (TGCT) has dramatically improved, resulting in a long-term survival of more than 
70%.1 Despite this success, it is known that some patients with advanced testicular germ cell 
tumours fail to respond to first-line chemotherapy, while others benefit from a reduced 
chemotherapy regimen without compromising survival.2,3 Thus, it is of great interest to have 
surrogate endpoints to distinguish responders from non-responders early after start of 
treatment.  
In TGCT, serum tumour markers and radiological changes in tumour size have been used to 
monitor response to chemotherapy. Unfortunately, not all TGCT produce tumour markers and 
radiological changes do not necessarily reflect pathological response. General restrictions to 
the radiological assessment of tumour size include delay between initiation of therapy and 
tumour shrinkage4 and the inability to differentiate malignant from non-malignant tissue in 
case of residual tissue after chemotherapy.5 Because it is still common practice to excise 
residual masses, some patients will be operated needlessly for non-malignant residual mass. 
As a result, it would be of obvious benefit to have a test that accurately predicts the response 
after treatment and thereby avoiding morbidity due to over-treatment.  
It has been demonstrated that malignant transformation of cells is frequently associated with 
increased metabolic activity and the use of glucose.6 By imaging the cellular glucose uptake, 
18FDG-PET can visualize tumour masses. This method seems to be promising for monitoring 
treatment response in solid tumours, like breast cancer, glioma and head and neck tumours.7,8 
In breast cancer patients, 18FDG-PET was able to differentiate responders from non-
responders early in the course of primary chemotherapy.7,9 Moreover, it has been stated that 
changes in metabolism often precede changes in tissue structure, which makes it possible to 
monitor the response to treatment earlier.10,11 
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The primary aim of this prospective pilot study was to evaluate the ability of 18FDG-PET to 
monitor the response to chemotherapy in patients with disseminated testicular germ cell 
cancer. In addition, PET was compared with radiological imaging, the tumour marker decline 
and the risk profile for disseminated germ cell cancer according to the International Germ 
Cell Classification Consensus Group.12 
 
Patients and methods 
Patients. Serial 18FDG-PET studies (n=54) were performed in 18 consecutive patients with 
disseminated TGCTs (at least stage IIB according to the Royal Marsden Hospital Staging 
system13). All patients were seen from January 2000 to December 2001. Details of the study 
were explained by a physician, and written informed consent was obtained from all patients. 
The study was approved by the ethics committee of the University Medical Centre Nijmegen.  
The chemotherapeutic regimen consisted of three courses of bleomycin 30mg (day 1-5, 8 and 
15), etoposide (day 1-5) and cisplatin (day 1-5) and a final course of etoposide (day 1-5) and 
cisplatin (day 1-5). In total, all patients received four courses of chemotherapy. Five patients 
underwent surgery for residual mass after chemotherapy. Patients’ characteristics are listed in 
Table I. 
Tumour response evaluation. Verification of histology of the primary tumour was performed 
at our pathology department. All patients were staged using abdominal and chest CT scan, 
and determination of serum tumour markers ( -human chorionic gonadotropin: HCG;  -
fetoprotein: AFP; lactate dehydrogenase: LDH). Baseline 18FDG-PET imaging was performed 
the day before start of treatment. All pre-treatment staging procedures were performed within 
5 days. Determination of tumour markers was repeated prior to each of the subsequent 
chemotherapy cycles. The second 18FDG-PET scan was performed the day before start of the 
third course of chemotherapy. Since there is no consensus for treatment monitoring 8,14 and an 
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increase in 18FDG-uptake has been reported after induction chemotherapy,15,16 we decided to 
perform the second scan at mid-treatment. All patients were completely re-staged by serum 
tumour markers, CT scan and whole body 18FDG-PET scan six weeks after completion of 
chemotherapy. 
 
Table I. Patients Characteristics (N=18) 
  
Median age (years) 
-range 
30.7 
23.1-50.0 
Primary histology  
-seminoma 
-non-seminoma 
4 
14 
Location of metastases  
-abdominal mass 
-nodes supra diaphragm 
-lungs 
-bone 
-liver 
17 
2 
3 
1 
1 
No. of patients with elevated tumour markers  
-HCG 
-AFP 
-LDH 
-None 
11 
10 
4 
4 
IGCCCG risk profile  
-low  
-intermediate  
15 
3 
Response to therapy  
-complete response (90-100% reduction in size) 
-partial response (<90% reduction in size) 
-stable disease 
13 
2 
3 
Histology of residual mass  
-mature teratoma 
-necrosis 
4 
1 
Course of disease after completion of therapy  
-no disease progression (for at least 6 months) 
-disease progression (within 6 months) 
16 
2 
Median disease free follow-up (months) 
-range 
9.6  
3.1-22.8 
  
HCG:  -human chorionic gonadotropin; AFP:  -fetoprotein; LDH: Lactate dehydrogenase 
 
CT scans were reviewed independently without knowledge of the clinical data. Response after 
chemotherapy was classified according to the modified WHO criteria.17 A decline of less than 
90% in transverse diameter was classified as a partial response whereas a complete response 
was defined as a more than 90% decline in diameter in combination with normalization of 
tumour markers.  
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Residual mass after chemotherapy was removed in all NSGCT and in SGCT in case the mass 
was larger than 3cm in transverse diameter.18 Surgery was planned within eight weeks after 
completion chemotherapy. 
All patients underwent monthly follow-up examinations including physical evaluation, 
evaluation of tumour markers levels, chest X-rays and a 3-monthly CT scan during the first 
year. 
18FDG-PET. A dedicated, rotating half-ring PET-scanner (ECAT-ART, Siemens/CTI, 
Knoxville, TN, USA) was used for data acquisition. Prior to 18FDG-injection, patients were 
fasting for at least 6 hours. Intake of sugar-free liquids was permitted. Immediately prior to 
the procedure, the patients were hydrated with 500 ml of water. One hour after intravenous 
injection of 200-220 MBq FDG (Mallinckrodt Medical, Petten, The Netherlands) and 20 mg 
furosemide, emission and transmission images of the area between proximal femora and the 
base of the skull were acquired (10 minutes per bedposition). The images were corrected for 
attenuation and reconstructed using the ordered-subsets expectation maximization (OSEM) 
algorithm.  
18FDG-PET image analysis. The reconstructed images were displayed in coronal, transverse 
and sagittal planes. All scans were interpreted by two nuclear medicine physicians [W.J.G.O., 
L.F.deG.O.], blinded to all clinical and pathology data. 
Tumour metabolism was evaluated using calculation of standardized uptake value (SUV) and 
visual analysis. In order to quantify 18FDG uptake, 3-dimensional regions of interest were 
drawn around the metastases. Standardized uptake values were calculated using the 
concentration of 18FDG in the metastases as measured by PET, divided by the injected dose 
and multiplied by body weight as a normalization factor. The visual scoring model was 
graded as suspect for carcinoma (++); increased uptake (+); or negative (-).  
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PET findings after chemotherapy were also correlated to histological findings of the resected 
residual mass. If no resection was performed, the clinical course of the patient was used. The 
absence of radiological tumour progression and negative serum tumour markers within 6 
months after completion of therapy were considered markers of complete remission.  
Statistical analysis. Because of the small number of patients available, we primarily used 
descriptive statistics in order to evaluate the value of PET. We evaluated the distribution 
differences of SUVs to differentiate between carcinomas with and without complete response 
after chemotherapy using the Receiver Operating Characteristic curve. We refrained from 
more elaborate analyses, especially the use of multivariable regression analyses to evaluate 
the independent value of PET, because of the limited power of the study. 
 
Results  
 
Eighteen patients receiving first-line treatment for testicular germ cell cancer were evaluated 
for treatment response by 18FDG-PET. Baseline characteristics of the patients are listed in 
Table I. In 5 patients histology of residual mass was available, while the remaining 13 patients 
were evaluated by the clinical course at a median follow-up of 9.0 months (range 5.0-23.2). 
Overall, 16 patients remained free of disease at a median of 10.3 months after treatment, 
while two patients relapsed, both at 3 months after treatment. 
 
Treatment response evaluation by 18FDG-PET 
Before the start of chemotherapy, 24 lesions in 18 patients could be identified by CT scan. 
Baseline PET prior to the start of chemotherapy was positive in all those lesions except in one 
patient (Table II, no.18). The retroperitoneal lesion of this patient could only be observed by 
CT-scan. After two cycles of BEP, only three patients had visible lesions and at completion of 
chemotherapy still two lesions could be detected by 18FDG-PET (Table II).  
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Overall, the clinical course of disease after first-line treatment was correctly predicted by 
18FDG-PET in 12 patients (P1-12; Table III). In 11 of them the on-treatment PET scan was 
already negative. In the remaining 6 patients the 18FDG-PET did not correlate accurately with 
clinical or pathology response (Table III). 
 
Table III. Prediction of response to chemotherapy in testicular germ cell cancer 
 
   Accurate outcome Inaccurate outcome 
  Response 
evaluation  
          total total False-
positive 
False-
negative 
False-postive 
or negative 
        
PET 17/18* 12/17 5/17 1/17  3/17 1/17  
    (15) (16-18) (14) 
CT 18/18 15/18 3/18 1/18  1/18  1/18  
    (7) (13) (14) 
 
STM 14/18 9/14 5/14  5/14  
      (13,14,16-18)  
        
  Complete Response         Incomplete Response 
IGCCCG       
-low risk  15/15     
 
-intermediate risk  1/3   2/3  
   
 
     
PET: positron emission tomography; CT: computed tomography; STM: serum tumour markers; IGCCCG: 
International Germ Cell Consensus Classification;* in 17 of 18 patients response evaluation by PET was 
possible; (..): refers to the patient number in Table II. 
 
Although the CT and PET scan suggested a complete response, patient 13 developed a 
retroperitoneal relapse at 3 months after chemotherapy combined with radiation therapy for 
bone metastasis. In two patients (P14 and P15), the follow-up PET did not normalise after 
therapy. It is difficult to determine if these scans are false negative or positive. Despite the 
fact that patient no. 14 was macroscopically free of tumour after surgery (see Figure 1), he 
relapsed at the crux of the diaphragm. Three months after surgery he died of chemotherapy 
refractory disease. Most likely 18FDG-PET detected histiocytosis (false-positive), but missed 
viable cells at the diaphragm (neither uptake found by PET nor suspect lesion seen on CT: 
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false-negative). In patient 15, the residual mass consisted of a combination of mature teratoma 
and histiocytosis. Because mature teratoma has a low metabolic rate, the detection of the 
residual mass by 18FDG-PET was most likely caused by the histiocytosis component. In three 
other patients (P16-18) postchemotherapy residual mature teratomatous mass was not 
detected. 
 
figure 1 
 
 
 
 
 
Coronal 18FDG-PET scan shows metastases of nonseminomatous testicular 
germ cell tumour in the retroperitoneum and in lungs with increased uptake of 
18FDG (arrow). The lesion in the retroperitoneum shows avital tissue 
(decreased uptake) in the center. The patient (no.14) showed partial 
radiological response during treatment: both decrease in 18FDG uptake and 
volume reduction on CT scan retroperitoneally, and disappearance of lung 
metastases. Surgery of residual retroperitoneal mass showed necrotic tissue in 
the centre and inflammatory tissue at the rim of the retroperitoneal mass. Three 
months after surgery, he relapsed at the crux of the diaphragm and finally died 
of disease. 
 
1) pre-chemotherapy 
2) before third course of chemotherapy 
3) six weeks after completion of chemotherapy 
 
 
Seventeen patients had visible lesions at baseline PET. The quantitative 18FDG uptake at 
baseline calculated by the standardised uptake value (SUV) is not predictive for complete or 
incomplete response after chemotherapy. The area under the Receiver Operating 
Characteristic curve is: 0.53 (95%CI: 0.21-0.84).  
 
  
   
1 2 3 
→ 
→ 
→ 
↓ 
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Comparison between 18FDG-PET and CT-scan in evaluation of treatment response. 
Posttherapy CT scan correctly predicted the outcome in 15 of the 18 patients. In patient 7, the 
CT scan showed a posttherapy residual mass of 3 cm, while the second 18FDG-PET scan 
showed a decreased intensity compared to the pre-treatment scan, and the third 18FDG-PET 
was true-negative. Similar to 18FDG-PET scanning, the CT scan of patient 13 suggested 
complete response and also showed no retroperitoneal mass at the crux of the diaphragm in 
patient 14. In contrast to 18FDG-PET, the residual masses containing mature teratoma (P15-
18) were clearly visualized by CT-scan.  
 
Comparison between 18FDG-PET and serum tumour markers in evaluation of treatment 
response. Since four patients (P10-12, P15) never had any elevated serum tumour markers, 
evaluation of the response was evaluated in 14 patients. In all patients, the serum tumour 
markers declined according to their half-life time to normal values posttreatment. In two 
patients (P13,14), although seemingly free of disease, the βHCG level started to rise 3 months 
after completion of treatment. In both patients a retroperitoneal relapse was found. On basis of 
the decline of serum markers it was not possible to differentiate mature teratoma (P16-18) 
from other histopathological entities. In total, the serum tumour markers correctly 
demonstrated complete response in 9 patients (P1-9).  
Although three patients (P10-12) showed no increased tumour markers before chemotherapy, 
serial PET was also able to monitor response correctly in these patients.  
 
Comparison between 18FDG-PET and International Germ Cell Consensus Classification 
System. According to the International Germ Cell Consensus Classification System 
(IGCCCG),12  three patients were classified as intermediate risk (P9,13,14) and the remaining 
15 as low risk. All patients in the low risk group showed a complete response for more than 
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six months. Two of the three patients in the intermediate risk group relapsed after treatment 
(P13 and P14).  
PET was correctly negative in eleven of fifteen patients and in one of three patients in the low 
and intermediate risk group, respectively. Consequently, the IGCCCG appeared to be more 
accurate to predict response than 18FDG-PET. 
 
 
Discussion 
Metastatic germ cell cancer is a very heterogeneous group of tumours with respect to 
prognosis under cisplatinum-based chemotherapy. The main determinants of complete 
response are not only the extent of the metastases but much more the biology of the 
underlying tumour which is represented by the location of the metastases and the level of 
serum tumour marker elevation. To date, patients can be categorized into different prognostic 
risk groups on basis of those determinants.12 This allows selection of patients for a risk-
adapted treatment in the good prognostic group and intensified therapy for the high-risk 
group. However, the observed clinical response to chemotherapy does not always correlate 
with the pathologic response, which is known to be of considerable prognostic importance.19 
Since not all patients will benefit equally from first-line chemotherapy, early insight into 
treatment response would be helpful in individualising treatment regimen. 
In other tumours, changes in 18FDG uptake have been correlated with response to anti-tumour 
therapy. The 18FDG signal appears to parallel the loss of tumour cells and to correlate with 
pathology.20 It has also prognostic value.9,21 To our knowledge, this is the first prospective 
study, which monitors first-line chemotherapy response in testicular germ cell tumours by 
serial PET. This study also compares 18FDG-PET results with established criteria for response 
assessment in patients with metastatic germ cell cancer. 
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Active testicular germ cell tumours and their metastases are known to have increased 18FDG 
uptake indicating high metabolic activity.22 It has been hypothesized that tumours with higher 
glycolytic rates may achieve a superior response to antineoplastic therapy.23 In that case, a 
single 18FDG-PET evaluation before therapy may be sufficient to predict the response to 
treatment. In other tumours an association was found between tumour grade and pre-treatment 
18FDG-uptake, but no correlation to pathologic response was found.24,25 In the present study, 
in all except one patient an increased 18FDG uptake was observed at baseline. In this single 
patient the sequential scans remained negative and the CT-scan did not show any clinical 
response. At surgery mature teratoma was found. It suggests that only teratomatous tissue was 
present pre-treatment, which is known to have a reduced to normal metabolism. It seems that 
this patient needlessly received chemotherapy. For such patients, PET scanning before 
chemotherapy might be useful. In the other patients, the pre-treatment 18FDG-uptake (visual 
score and SUV) was not associated with the level of serum tumour markers and the location 
of metastases at baseline, nor with response to treatment. We found a high degree of SUV 
overlap between patients with a complete and incomplete response to chemotherapy. As a 
result it was not possible to find a useful SUV cut-off value for predicting a complete 
response to treatment. 
Changes in 18FDG-uptake after start of treatment have been applied to assess tumour response 
and could be used to distinguish responders from non-responders.7,9,26 Because many factors 
play a role in the 18FDG uptake, the best protocol to monitor the response to chemotherapy 
has not been established yet.8,14 Wilson et al. studied the usefulness of serial 18FDG-PET 
scanning in five patients with TGCT.27 Although the timing of the on-treatment scan (2 to 4 
weeks after introduction of chemotherapy) and the administered first-line chemotherapy 
regimen varied, they found significant reduction of 18FDG uptake in responders compared to 
non-responders. On the other hand, it has been reported that the rate of 18FDG uptake 
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immediately after introduction of therapy may increase due to cellular repair processes.15,16 
Therefore, in this study it was decided to perform the mid-treatment scan halfway the 
treatment protocol. 
All patients with an initially increased 18FDG uptake showed a partial or complete remission 
on PET after two cycles of chemotherapy. In only 3 of 18 patients 18FDG uptake was 
observed after two cycles. Of interest, in one patient the 18FDG-uptake diminished to an 
undetectable level during therapy and on CT-scan the diameter of the seminomatous germ cell 
tumour shrunk from 7 to 3 cm post-treatment. Possibly, this tumour has an increased 
resistance to the antineoplastic effect of chemotherapy compared to those with negative mid-
treatment PET-scan and small residual tissue (<1 cm). However, residual seminomas, do not 
correlate well with viable residual disease. Most residual seminomatous masses do not grow, 
and will gradually regress over a period of months after treatment. Subsequently, surveillance 
by frequent marker and CT scan evaluation is an option.5,18,28 On the other hand, 10% of the 
residual masses do contain viable disease. 18FDG-PET seems to be useful in discriminating 
between tumorous and benign residual disease. Because there is no residual teratoma in pure 
seminoma, a negative postchemotherapy PET-scan of a residual mass of 3cm or more is 
highly predictive for non-malignant residual mass.29,30 To date, this patient is still free of 
disease at 6 months of follow-up. In two other patients with bulky retroperitoneal non-
seminomatous disease the metabolic activity remained increased on post-therapy evaluation. 
Histology of these residual masses, revealed inflammation combined with either necrosis or 
mature teratoma. It is known that macrophages, present in inflammatory processes, also 
accumulate 18FDG.31 This is assumed to take place mainly in the early phase of therapy.29 
However, in TGCT it has also been reported in residual masses after chemotherapy.32 The 
increased uptake of 18FDG is probably not caused by the teratomatous tissue of the patient. 
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This observation is further exemplified by three other patients with solitary teratomatous 
residual mass and a negative PET scan.  
In total, a negative mid-treatment PET-scan correctly predicted complete response in 11 
patients (61%). Posttherapy CT imaging showed a maximum volume decrease in those 
patients. In contrast, in patients without a large volumetric decrease on CT-scan, teratomatous 
residual disease was found. It is known that mature teratoma is not very sensitive to 
chemotherapy. Furthermore, it has to be regarded as a pre-malignant condition, because it 
might transform into malignancy or degenerate into non-germ cell cancers over time. In order 
to reduce false-negative PET findings, it might be useful to correlate the PET results with 
primary histology. It has been suggested that when a mature teratoma is present in the primary 
tumour it is also frequently found in the retroperitoneal mass.5 Subsequently, PET-scanning in 
those patients may not be reliable in detecting retroperitoneal teratomatous lesions.30,33 In our 
series, three patients with retroperitoneal teratomatous disease, also had a teratoma component 
in the primary tumour, suggesting some benefit of including primary histology.  
Irrespective of monitoring treatment response, the pre-treatment clinical findings, as used in 
the IGCCCG classification, seem to have the best prognostic value. All low risk patients 
remained free of disease after treatment, while two of three patients at intermediate risk 
relapsed at 3 months after therapy.  
This study population served as a model for the evaluation of the ability of PET to predict 
response to treatment already during the course of therapy. It shows that it is possible to 
monitor changes in 18FDG uptake in testicular germ cell tumours. However, 18FDG-PET has a 
limited role, if any, in the therapeutic monitoring of low risk testicular cancer and does not 
provide significant information to structural imaging and measurement of serum tumour 
markers. Although the results are discouraging due to the high response rates in this group of 
patients, it supports further study in targeting patients with increased risk profiles. 
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Furthermore, seminomatous germ cell cancer is worth for targeting because it does not 
contain teratomatous elements and consequently the outcome is less hampered by false-
negative results. 
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Abstract 
 
Objective. To define guidelines for the follow-up management of patients treated for 
testicular germ cell tumour this study assessed characteristics of patients with recurrent 
disease.  
Methods.  The charts of 505 patients with testicular cancer treated and followed-up at the 
University Medical Centre Nijmegen between 1982–2000 were reviewed retrospectively.  
Results. In 42 patients disease recurrence was found during routine follow-up. In a subset of 
patients no recurrences were seen after first-line treatment: (a) pathological stage IIa 
nonseminoma patients who were adjuvantly treated with chemotherapy and (b) histologically 
confirmed complete responders after primary chemotherapy. Furthermore, in low-stage 
disease no intra-abdominal recurrences were seen in (a) pathological stage I nonseminoma 
patients and (b) low-stage seminoma patients who received radiotherapy. 
Conclusions. The risk of recurrent testicular cancer depends on primary therapy and efficacy 
of it; these results indicate a limited role for follow-up in pathological stage II nonseminoma 
patients adjuvantly treated with chemotherapy and in histologically confirmed complete 
responders after chemotherapy. Abdominal computed tomography does not appear necessary 
in routine follow-up of patients treated for low-stage testicular cancer.  
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Introduction 
After treatment of testicular germ cell cancer patients are followed up by regular outpatient 
visits, during which physical examination, serum tumour marker studies, and radiological 
examinations are performed. Testicular germ cell tumour (TGCT) is somewhat unique among 
urological malignancies in that recurrence is highly treatable, especially when detected early. 
1,2 Optimal follow-up is therefore critical to the care of TGCT patients. No prospective studies 
have yet been performed to justify particular follow-up schedules.3 Most commonly used 
schedules call for patients to visit a medical specialist up to 30 times over a period of 
10 years. Some advocate even life-long follow-up, as late relapses have been recorded.4 Since 
the vast majority of men are relatively young and show an excellent response to treatment, 
routine follow-up consumes considerable time and money. 
The purpose of this study was to assess the efficacy of routine follow-up of patients treated 
with curative intent for testicular cancer in a single institution in order to examine the 
recurrence patterns and if possible to determine an optimal follow-up policy for testicular 
cancer patients. 
 
Material and Methods 
 
A retrospective study was performed of the medical records of all 535 patients, primarily 
treated for testicular germ cell tumours at the Department of Urology of the University 
Medical Centre Nijmegen between January 1982 and January 2000. Patients were considered 
eligible for the study if they were in complete remission for at least 3 months after first-line 
treatment and were routinely followed-up at our Department; the period of 3 months was 
chosen to distinguish recurrent disease from refractory disease. Thirty patients were not 
eligible (22 progressive disease, 8 recurrence within 3 months after primary treatment), and 
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therefore 505 patients were finally eligible for the study. Table I presents patients’ 
characteristics. 
Table I Study population by histology (N=505) 
 
 Seminoma  Non-seminoma  
   
Number of patients 145 360 
   
Median age at diagnosis (range) 37.3 (14.7-79.6) 28.9 (14.9-77.6) 
   
Clinical Stage at diagnosis   
I 68 184* 
IIa 31 39 
IIb-IId 34 65 
III 6 8 
IV 6 64 
   
Initial increased markers at diagnosis **   
AFP 0 70% (177/252) 
bHCG 30% (32/108) 62% (147/237) 
LDH 24% (24/102) 24% (52/216) 
   
Primary treatment after orchiectomy   
surveillance 4 24 
radiotherapy 96  - 
RPLND - 93 
RPLND and chemotherapy - 106  
chemotherapy  34 56 
chemotherapy and surgery  10 82 
   
Median routine follow-up in 
months (range) 
60.0 
(4-165) 
64.7 
(4-175) 
   
Status at last follow-up    
Alive without disease 
-still in follow-up 
-completed follow-up 
-lost to follow-up 
140 
68 
57 
15 
346 
233 
94 
19 
Dead of disease 0 9 
Dead of other disease  5 5 
   
key: AFP: alpha-fetoprotein; bHCG: beta-choriongonadotropin; LDH: lactate dehydrogenase; RPLND: 
retroperitoneal lymph node dissection; *24 patients on surveillance and 160 patients underwent RPLND: 93 
pathological stage I; 67 pathological stage II; ** information on the value of serum tumour markers was not 
available in all files. 
   
 
 
 
All patients underwent treatment as described by the EAU guidelines.5 Briefly, all 
orchiectomized patients were screened for metastases by computed tomography and staged 
according to the Royal Marsden Hospital classification.6 The vast majority of patients with 
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low-stage (stage I or IIa) seminoma germ cell tumours (SGCT) were irradiated, but some 
patients were only followed up for clinical stage I SGCT. 
Between 1982 and April 1996 all low-stage SGCT were irradiated on the iliac and para-aortal 
lymph nodes with 26–30 Gy. Thereafter the extension of the radiation field was reduced to the 
para-aortal lymph nodes only (20 Gy). Patients with low-stage (stage I or IIa) 
nonseminomatous disease (NSGCT) were treated with nerve-sparing retroperitoneal lymph 
node dissection (RPLND). Since 1994 only patients at high risk for metastasis (vascular 
invasion in the primary tumour) have undergone RPLND. In the case of lymph node 
metastases (pathological stage II) patients were adjuvantly treated with two cycles of 
bleomycin, etoposide, and cisplatin chemotherapy. Patients at low risk for metastasis were 
followed-up. Patients with either SGCT or NSGCT of high stage (>IIa) received cisplatin-
based chemotherapy after inguinal orchiectomy. Residual mass after chemotherapy was 
removed in all NSGCT and in SGCT if the mass was larger than 3 cm in transverse diameter.7 
In the case of teratomatous tissue or viable tumour in residual mass patients were carefully 
followed up and were treated by chemotherapy at relapse. 
The follow-up schedule consisted of outpatient visits every month during the first year, every 
2 months in the second year, every 3 months in the third year, every 6 months in the fourth 
and fifth years, and thereafter once per year for at least 10 years of follow-up, after which the 
continuation of follow-up was at the discretion of the clinician and patient s wish (Table II). 
For this study the follow-up period was defined as the time elapsed between completion of 
treatment and 31 December 2001. Routine follow-up was stopped in the event of tumour 
recurrence, severe other diseases, death, end of follow-up protocol, end of study period, or on 
the patient s demand, and was calculated by the Kaplan-Meier method. The overall median 
follow-up period was 60.0 months (range 4–175). 
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Recurrence was defined as any clinically, radiographically, or histologically confirmed 
tumour relapse, contralaterally or distant. The contribution of each investigation to the initial 
identification of recurrence was examined. Recurrence was considered asymptomatic if the 
physician found it during regular follow-up examination in a patient with no relevant 
complaints. It was considered symptomatic if it was detected by the patient himself before the 
physicians’  examination. The time from orchiectomy to death or date of last observation was 
defined as the survival time. The survival curves were calculated by the Kaplan-Meier 
method. Survival differences between groups were evaluated by the log-rank test.  
 
Table II. 
 
Follow-up protocol for testicular germ cell tumours by stage and histology 
 
Histology and Stage 1st Year 
(monthly) 
2nd Year 
(2-monthly) 
3nd Year 
(3-monthly) 
4th and 5th Year 
(6-monthly) 
6th –10th Year 
(once) 
      
Low stage      
stage I NSGCT at 
surveillance 
CE, Lab, CXR 
and 
3 monthly CT  
CE, Lab, CXR 
and 
4 monthly CT  
CE, Lab, CXR 
and 
6 monthly CT  
CE, Lab, CXR 
and 
once a CT  
CE, Lab, CXR 
and 
once a CT  
      
stage I and IIa 
NSGCT: RPLND 
with or without CTH  
& SGCT:RT 
CE, Lab, CXR 
and 
6 monthly CT 
CE, Lab, CXR 
and 
6 monthly CT 
CE, Lab, CXR 
and 
once a CT 
CE, Lab, CXR CE, Lab, CXR 
      
High stage      
stage > IIa NSGCT & 
SGCT: CTH with or 
without RPLND* 
CE, Lab, CXR 
and 
3 monthly CT  
CE, Lab, CXR 
and 
4 monthly CT  
CE, Lab, CXR 
and 
6 monthly CT  
CE, Lab, CXR 
and 
once a CT  
CE, Lab, CXR 
and 
once a CT  
      
Key: NSGCT: non-seminoma germ cell tumour; SGCT: seminoma germ cell tumour; RPLND: primary 
retroperitoneal lymph node dissection; CTH : chemotherapy ; RT: radiotherapy; CT: computed tomography of 
abdomen and chest; CE: clinical examination; Lab: serum alfa-fetoprotein, beta-human chorionic 
gonadotrophin, lactate dehydrogenase; CXR: chest x-ray. 
 
*Residual masses of pure seminoma less than three cm in diameter post-chemotherapy are followed by CT 
scanning at 3 monthly intervals for the first year, unless regression occurs. Masses that do not regress over the 
first year are followed by further CT scans at 6 monthly intervals for 3 years after completion of chemotherapy. 
      
 
 
Results 
Recurrences. Forty-two patients developed recurrent disease during the routine follow-up 
period (recurrence percentage at 5 and at 10 years of follow-up: 8.2% and 10.1%). Seven 
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patients had a recurrence in the contralateral testis (Table III), and 35 experienced systemic 
recurrent disease (Table IV). The median period between completion of first-line treatment 
and contralateral recurrence was 48 months (range 15–85). Contralateral recurrence was 
detected by a programmed follow-up in three patients and by self-examination in four. In six 
patients the contralateral recurrence was the isolated site of relapse at the time of detection, 
and all were free of disease after treatment of relapse. In one patient metastasized disease was 
already present, for which he received chemotherapy. He withdrew from follow-up 12 months 
after completion of chemotherapy. Thirty months later he was readmitted for general malaise 
due to advanced pulmonary metastases and finally he died from disease.  
The median period between completion of first-line treatment and the detection of systemic 
recurrence was 6 months (range 4–89). Of the 35 systemic recurrences 31 were detected 
during the regular follow-up visits (i.e., asymptomatic). The four symptomatic recurrences 
were detected by self-examination of supraclavicular lymph nodes (n=3) or by visiting the 
hospital because of neurological signs (n=1). 
 
Table III Contralateral recurrence by primary stage and histology 
 
Initial 
Stage 
Primary 
histology 
First-line 
treatment after 
orchiectomy 
Interval 
to 
contrala- 
teral 
recur-
rence 
(months) 
Number of 
recurrences 
per number 
of similarly 
treated 
patients 
histology 
and stage of 
recurrence  
 
Primary 
detec- 
tion of 
recur- 
rence         
Treatment of 
recurrence 
after 
orchiectomy 
Disease free 
follow-up 
after first 
recurrence 
(months) 
Outco-
me at 
routine 
follow-
up  
          
I SGCT 
SGCT 
 
SGCT 
 
NSGCT 
radiotherapy 
radiotherapy 
 
surveillance 
 
RPLND 
44  
85  
 
49  
  
71  
2 of 64 
 
 
1of 4 
 
1 of 93 
SGCT I   
SCGT IIa-
IVlung   
SGCT I 
 
SGCT I   
SE 
SE 
 
SE   
 
CE 
surveillance 
chemotherapy 
 
radiotherapy 
 
radiotherapy 
48 
12 
 
70 
 
37 
FOD  
FOD* 
 
FOD 
 
FOD 
 
IIb-d 
 
SGCT 
 
NSGCT 
 
NSGCT 
 
chemotherapy 
 
chemotherapy + 
RPLND 
chemotherapy + 
RPLND 
 
15  
 
48  
 
35  
 
1 of 35 
 
2 of 82 
 
NSGCT I   
 
NSGCT I   
 
NSGCT I   
 
CE 
 
CE+ 
marker 
SE 
 
radiotherapy 
 
radiotherapy 
 
surveillance 
 
49 
 
75 
 
126 
 
FOD 
 
FOD 
 
FOD 
          
          
key: (N)SGCT: (non)-seminomatous germ cell tumour; CE: clinical examination; SE: self-examination; FOD: free of 
disease; DOD: dead of disease; other abbreviations as in table I. 
*Twelve months after completion of chemotherapy this patient withdrew from further follow-up. Thirty months later he 
was readmitted for general malaise, due to advanced pulmonary metastases, from which he finally died. 
        
Chapter 8 
 
 
 156
 
Table IV Detection of systemic recurrences adjusted for primary histology and stage 
 
Primary 
histology  
& stage 
First-line 
treatment  
(histology) 
Interval 
to recur-
rence  
(months) 
Stage of 
recurrence 
 
Primary 
detection 
recurrence 
Therapy of 
recurrence 
Follow-up 
after first 
recurrence 
(months) 
Outcome 
        
SGCT I surveillance 17  IIa CTabd RT 4 fod 
        
RT 4  IIIn CTth + marker CHT 66 dood SGCT IIa 
,, 9  IIIn marker CHT 44 fod 
        
CHT 4  IIb-IVH CTabd salvage CHT + RT 113 fod 
,, 7  IIIn-IVl SE salvage CHT + RT 38 fod 
SGCT 
IIb-d 
CHT+RPLND 
(vi) 
5  IIC CTabd+marker salvage CHT + RT 65 fod 
        
surveillance 4  IVl CXR CHT 31 fod 
,, 4  IIB CTabd +marker  CHT 32 fod 
,, 4  IIB CTabd +marker CHT 36 fod 
,, 4  IVl CXR CHT 46 fod 
,, 9  IVl CXR CHT 30 fod 
NSGCT I 
,, 17  IIB marker CHT + RPLND 25 fod 
 RPLND 4  IVl CXR + marker CHT + RPLND 31 fod 
 ,, 4  IVl CXR CHT 52 fod 
 ,, 4  IVl CXR CHT 61 fod 
 ,, 4  IVl CXR CHT 62 fod 
 ,, 6  IVl CXR CHT 21 fod 
 ,, 6  IVl CXR + marker CHT 44 fod 
 ,, 6  IVl CXR+ marker CHT 69 dod 
 ,, 8  IVl CXR  CHT 31 fod 
 ,, 8  IVl CXR  CHT 121 fod 
 ,, 18  IVl CXR CHT 60 fod 
        
CHT 4  IIa marker surgery + salvage CHT 118 fod 
,, 6  IVl CTth + marker salvage CHT 7 dod 
,, 36  IVl marker CHT 62 dod 
CHT+RPLND    
(mt) 
5  IIB-IVH Ctabd + marker salvage CHT + surgery 15 dod 
,,        
          (vi) 
5  IVL marker salvage CHT 46 dood 
,,      
          (vi) 
12  IVL marker salvage CHT+ surgery  24 dod 
,,   
          (mt) 
19  IIIn marker salvage CHT + surgery  6 dod 
,,    
          (mt) 
52  IIIn-IVL SE salvage CHT 55 fod 
NSGCT 
IIb-d 
,, 
  (mt) 
89  IIIn SE surgery + RT 48 fod 
        
CHT 13  IVB SE palliation 1 dod 
 CHT+RPLND  
(vi) 
5  IVL marker salvage CHT 12 dod 
,,        
 (mt) 
12  IVL marker salvage CHT 53 fod 
NSGCT 
IIn-IV 
,,   
  (mt) 
37  IVL marker salvage CHT 14 dod 
        
        
Key: RT = radiotherapy; PRPLND = primary retroperitoneal lymph node dissection; CHT = chemotherapy. 
Tumour stage was according to the Royal Marsden Hospital Staging classification: I, no metastases; IIa, 
retroperitoneal lymph nodes smaller than 2 cm; IIb-d, retroperitoneal lymph nodes at least larger than 2 cm; III 
lymph nodes above diafragm IIIn; IVL, lung metastases; IVH, liver metastases; IVB, brain metastases. (..): 
residual mass after chemotherapy: mt: mature teratoma; vi: viable disease; FOD = free of disease; DOD = dead 
of disease; DOOD = dead of other disease. 
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Recurrence and first-line treatment. Recurrences were also analyzed according to first-line 
treatment given to patients with a particular stage of disease and histology (Tables III,IV). 
There was no recurrence in the 106 patients with low-stage NSGCT (39+67; Table II) who 
were adjuvantly treated with two courses of bleomycin, etoposide, and cisplatin chemotherapy 
for retroperitoneal metastatic disease, (95% confidence interval, CI: 0.0–2.8%; median 
follow-up 71.5 months). In contrast, at 5-years of follow-up 10.8% of the patients (95% CI: 
4.5–17.1%) who were negatively staged for retroperitoneal metastatic disease by surgery 
developed a recurrence (ten pulmonary metastasis (Table IV) and one contralateral SGCT 
(Table III). All patients except one, who developed multiple recurrent pulmonary metastases, 
survived. Furthermore, 6 of the 24 patients (25.2%; 95% CI: 7.7–42.7%) who were enrolled 
into a surveillance program (no vascular invasion in primary tumour) developed a 
retroperitoneal (n=3) or pulmonary recurrence (n=3) within 2 years of follow-up. All are free 
of disease at a median of 31.5 months after treatment for recurrence (Table IV).  
In low-stage SGCT no metastatic disease was found retroperitoneally after radiation treatment 
in 95 patients (95% CI: 0.0%–3.1%, median follow-up 63.0 months). Recurrences were found 
outside the radiation field (contralateral, n=2, Table III; supraclavicular, n=2, Table IV). One 
of the four patients on surveillance after orchiectomy for stage I SGCT developed a 
retroperitoneal recurrence (Table III).  
In high-stage disease pathologically incomplete responders after chemotherapy have a higher 
risk of systemic recurrent disease than complete responders. None of the 35 NSGCT patients 
with necrotic residual disease have relapsed since surgery at a median of 70 months (range 
12–175; 95% CI: 0.0–8.6%; Table II), whereas 6 of 39 patients with residual teratomatous 
tissue (recurrence proportion 15.4%; 95% CI: 2.7–28.1% at 5 years of routine follow-up), and 
3 of 7 patients with viable tissue relapsed (43%; 95% CI: 5.5–79.5% at 1 year of routine 
follow-up). The same observation was seen in SGCT patients: all ten patients with necrotic 
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residual disease were free of recurrent disease (95%; 0.0–0.3%; median follow-up 
99 months), whereas one patient with viable disease relapsed retroperitoneally at 5 months 
after surgery (Table IV). 
 
Recurrence and serum tumour markers. The correlation of marker levels at the time of 
diagnosis and recurrence for each specific tumour marker is shown in Table V. An elevated 
-fetoprotein level at first recurrence was observed in 7 of 14 NSGCT patients (50%) with 
elevated levels at the time of diagnosis. Choriongonadotropin levels at recurrence were 
elevated in 8 of 14 NSGCT patients (45%) and in 2 of 3 SGCT patients with elevated levels at 
diagnosis. Serum lactate dehydrogenase was elevated at the time of recurrence in 1 of 6 
NSGCT patients (17%) and in 1 of 3 SGCT patients (33%) who had elevated levels at the 
time of diagnosis. A normal tumour marker at presentation was associated with a normal 
marker at first recurrence.  
 
Table V Correlation between specific tumour makers at diagnosis and systemic recurrence 
 
Seminomatous germ cell tumour Non-semonimatous germ cell tumour tumour 
maker 
at diagnosis 
tumour 
marker at 
first 
recurrence 
Low 
stage 
(n=3) 
High 
stage 
(n=3) 
Totaal 
(n=6; %) 
Low stage 
(n=11/16)* 
High stage 
(11/13)* 
 
Totaal 
(n=22; %) 
        
AFP + AFP + n.a. n.a. n.a. 4 3 7 (32) 
AFP - AFP -  n.a. n.a. n.a. 3 5 8 (36) 
AFP + AFP -  n.a. n.a. n.a. 4 3 7 (32) 
AFP - AFP + n.a. n.a. n.a. 0 0 0 
        
BHCG + BHCG + 1 1 2 (33) 2 6 8 (36) 
BHCG - BHCG - 1 2 3 (50) 6 2 8 (36)  
BHCG + BHCG - 1 0 1 (17) 3 3 6 (27) 
BHCG - BHCG + 0 0 0 0 0 0 
        
LDH + LDH + 1 0 1 (17) 0 1 1 (0.5) 
LDH - LDH - 1 2 3 (50) 11 5 16 (73) 
LDH + LDH - 1 1 2 (33) 0 5 5 (23) 
LDH - LDH + 0 0 0 0 0 0 
        
key: AFP: alpha-fetoprotein , BHCG: beta-choriongonadotropin, LDH: lactate dehydrogenase; n.a.: not 
available; - serum tumour marker within range of normal levels, + increased serum tumour marker level. 
*information on the value of serum tumour markers was not available in all files. 
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Survival data. The 5-year disease-specific survival for the entire population was 98.4% (95% 
CI: 97.2–99.6%). The only patients who died of testicular cancer during routine follow-up 
were those with systemic recurrence. The chance of dying was highest in patients with initial 
systemic NSGCT and subsequent systemic recurrence: 62% (8 of 13) died of disease at a 
median follow-up of 22.5 months after orchiectomy. There was a significant difference in 
survival between NSGCT patients with complete and those with incomplete histological 
response after chemotherapy (Fig. 1). There was no significant survival benefit in patients 
with teratomatous residual mass compared to those with a viable residual mass (P=0.15).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Detection of second primary non-testicular tumours. During follow-up, 8 new malignancies 
developed in the 505 patients (1.6%): gastrointestinal cancer (n=2), leukemia, prostate, renal 
cell carcinoma and cancer of lung and breast (median: 73.5 months; range: 38-119). 
 
MONTHS
1751501251007550250
D
is
ea
se
-S
pe
ci
fic
 S
ur
vi
va
l R
at
e
1.00
.90
.80
.70
.60
.50
.40
.30
.20
.10
0.00
complete response 
p=0.04
Incomplete response 
Figure 1.  Disease-specific survival for non-seminomatous germ cell 
patients with histologically confirmed response (necrosis) after 
chemotherapy compared to those with incomplete histological response 
(mature teratoma, viable cancer). 
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Discussion 
Although no randomized studies have been performed, routine follow-up of all patients is 
recommended after definitive treatment for testicular germ cell cancer. Specific programs of 
follow-up have been suggested by stage of disease and nature of treatment.5 We evaluated our 
follow-up protocol to identify subsets of patients at increased or decreased risk for relapse to 
determine a more optimal follow-up regimen for testicular cancer patients. In our patient 
series contralateral recurrence developed later in time and was more frequently detected by 
the patient himself than systemic recurrences. The overall risk of 2.6% of contralateral disease 
at 10 years of follow-up in the present study is in accord with earlier findings.8,9 All 
contralateral tumours were found by physical examination. Although one patient who 
withdrew from further follow-up died of systemic disease originating from a contralateral 
disease, most patients with bilateral disease have had a favourable outcome.8,9 Furthermore, 
four patients found a contralateral relapse by self-examination after completion of routine 
follow-up. The second tumour was found at a median of 120 months (range 100–140) after 
first diagnosis (3 seminomas stage I and one pathological stage I nonseminoma). All patients 
are free of disease at a median follow-up of 39 months after bilateral orchiectomy (range 7–
101). 
Carcinoma in situ has been reported to be an important predictor for contralateral disease, 
being present in 5% of contralateral testis and leading in 50% of cases to invasive cancer 
within 5 years  time if left untreated.10 However, our own and other researchers  data11 do not 
support the routine use of contralateral biopsy for the early detection of carcinoma in situ. In 
our series physical examination is sufficient for detecting contralateral tumours, and life-long 
use of testicular self-examination must therefore be recommended to each patient. 
Remarkably, contralateral recurrence (n=11) seems to occur more frequently in patients who 
had not been treated systemically with chemotherapy (n=7). The very low recurrence rate 
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after two courses of carboplatin in stage I SGCT support this finding of a decreased risk for 
contralateral recurrence after primary systemic treatment by chemotherapy.12,13 Today it is 
also feasible to perform a partial orchiectomy and adjuvant local irradiation in select patients, 
thereby minimizing the recurrence rate and maintaining a normal testosterone level in the 
majority of the patients.14 In low-stage testicular cancer there was a stage- and treatment-
dependent risk of developing recurrent disease. In agreement with the literature,15,16 none of 
the NSGCT patients who received two cycles of adjuvant chemotherapy for confirmed 
retroperitoneal disease experienced a relapse. In contrast, approximately 10% of pathological 
stage I patients developed a pulmonary relapse and another 1% a contralateral tumour. In 
agreement with other studies, the elimination of thoracic computed tomography would have 
not changed the detection of pulmonary recurrences.17,18 
Since 1994 we have performed only RPLND in patients at high risk for metastatic disease. 
Patients at low risk are put on surveillance. Of the 24 patients at low risk three have 
experienced a retroperitoneal and three a pulmonary relapse. Analysis of the data of patients 
with stage I NSGCT disease treated before and after 1994 suggest that the three patients with 
retroperitoneal relapse while on surveillance could have been free of disease if a primary 
lymph node dissection had been performed. In contrast, the remaining 18 patients still benefit 
from surveillance, being free of disease at a median of 32.5 months (range 12–56). 
Furthermore, the three patients who developed lung metastasis would not have profited from 
retroperitoneal surgery. 
A wide range of risk factors have now been determined to distinguish cases that are truly 
clinical stage I from those that appear on the basis of investigation to be clinical stage I but 
are actually pathological stage II or higher. In all studies performed today vascular invasion is 
the most reliable and reproducible prognosticator for predicting metastatic spread in 50% of 
the cases.19 For low-stage SGCT the same remarks can be made. None of the patients who 
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underwent radiotherapy experienced a retroperitoneal relapse. Although the 0% recurrence 
rate in stage I SGCT might result from overtreatment with regard to the extension of the both 
radiation field to the iliacal lymph nodes, no recurrences have been reported since the 
limitation of radiation of the para-aortic nodes only. A review of published reports revealed 
less than 1% infradiafragmatic recurrences after radiation treatment for low-stage SGCT.20 In 
contrast, review of postorchiectomy surveillance series reports that approximately 20% of the 
patients relapse, but most of them have been cured by radiation or chemotherapy.21 
In high-stage disease none of the patients with necrotic tissue in their retroperitoneal residual 
mass experienced a relapse, whereas those with residual teratomatous and viable disease had 
an increased risk of relapse. It is known that the key to success in managing residual masses is 
the absence of viable tissue and complete resection of the residual mass.22 Although surgical 
resection of necrotic tissue after chemotherapy has no therapeutic benefit and confers good 
prognosis without relapse on the short term, follow-up is still advised for the long-term. In 
fact all high-stage patients are advised to be followed-up by a combination of diagnostic 
follow-up modalities.5 According to our data, long-term results must be awaited to 
definitively resolve the necessity of follow-up in histological complete responders. In our 
series two patients relapsed retroperitoneally within 6 months after lymph node dissection for 
postchemotherapeutic viable tissue, suggesting incomplete resection. In the literature there is 
an ongoing debate as to whether two additional courses of chemotherapy for viable residual 
disease have a survival benefit over our policy of careful observation and deferred treatment 
in cases of relapse.23-25 Despite all therapeutic options only 20–30% of these patients with 
relapse will be free of disease at the long-term.26 
In accordance with others series, serum tumour markers have more diagnostic value in 
detecting recurrence in high-stage than low-stage disease,27 and the marker status at time of 
recurrence was poorly related to marker status at the time of initial diagnosis.20,27 Although 
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tumour markers are of incalculable value in detecting recurrent disease,28,29 we believe that 
radiological exploration is still needed during follow-up, as markers are only presumptive 
evidence of recurrence. 
Although it is generally accepted that routine follow-up needs to be more intense initially with 
gradually increasing periods between the appointments, there is no consensus over the optimal 
frequency.30 In low-stage disease comparison of survival rates between different protocols 
shows no substantial differences. However, it must be kept in mind that a difference between 
one or two dead patients might not seem significant in terms of survival rate, but it is 
clinically relevant in potentially curable disease. Also the length of follow-up is not clear. 
Generally the yield with respect to recurrences is low if continued for more than 2 years, 
which is in agreement with our results. However, some relapses 5 and second malignancies 
may occur over a longer period of time.31 Although some authors feel that 2 years of follow-
up in low-stage patients is sufficient,32 only long-term follow-up of those patients will 
ultimately resolve the problem of appropriate length of follow-up in low-stage disease. In 
high-stage disease it is more difficult to justify a particular follow-up protocol. Our results 
suggest a limited role of follow-up in histologically confirmed responders. However, both the 
small number of patients in this group and in the literature means that conclusions might be 
considered tentative. 
Table VI proposes a recommended follow-up protocol according to our results. This protocol 
is for the greater part in line with the EAU guidelines on testicular cancer and the protocol of 
the German Testicular Cancer Study Group,5,30 with the exception that our results suggest less 
radiological follow-up of low-stage testicular cancer patient posttreatment. 
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Table VI Proposed follow-up protocol with regard to stage and treatment performed 
 
Histology and 
Stage 
1st Year 
(2-monthly) 
2nd Year 
(3-monthly) 
3rd Year 
(4-monthly) 
4th and 5th Year 
(6-monthly) 
6th –10th Year 
(once) 
      
Low stage SGCT       
Surveillance 
(CS I) 
CE, Lab, CXR 
and 
3-monthly CT 
CE, Lab, CXR 
and 
4-monthly CT 
CE, Lab, 
CXR 
and 
6-monthly CT 
CE, Lab, CXR 
and 
once a CT 
CE, Lab, CXR 
 
      
Radiation (CS I 
& IIa) 
CE, Lab, CXR once 
CT after 3 months* 
CE, Lab, CXR CE, Lab, 
CXR 
CE, Lab, CXR CE, Lab, CXR 
      
Low stage NSGCT      
Surveillance 
(low risk) 
CE, Lab, CXR 
and 
3-monthly CT 
CE, Lab, CXR 
and 
4-monthly CT 
CE, Lab, 
CXR 
and 
6-monthly CT 
CE, Lab, CXR 
and 
once a CT 
CE, Lab, CXR 
 
      
RPLND only 
(PS I) 
CE, Lab, CXR once 
CT after 3 months* 
CE, Lab, CXR CE, Lab, 
CXR 
CE, Lab, CXR CE, Lab, CXR 
      
RPLND and 
adjvant CTH 
(PS II) 
CE, Lab, once CT 
after 3 months* 
CE, Lab CE, Lab CE, Lab CE, Lab 
      
High stage SGCT & NSGCT (> IIa) 
 
   
Primary CTH 
only 
CE, Lab, CXR 
and  
3-monthly CT 
CE, Lab, CXR 
and  
4-monthly CT  
CE, Lab, 
CXR 
and  
6-monthly CT 
CE, Lab, CXR 
and  
once a CT 
CE, Lab, CXR 
      
Primary CTH 
with secondary  
RPLND and 
     
- non malignant 
residual disease 
According to our results, a less intensified protocol might be possible, however more long-term 
data on this category of patients are needed to justify a particular protocol. Up till then, we 
propose the same protocol as for malignant residual disease. 
      
-malignant 
residual disease 
CE, Lab, CXR 
and  
3-monthly CT 
CE, Lab, CXR 
and  
4-monthly CT  
CE, Lab, 
CXR 
and  
6-monthly CT 
 
 
CE, Lab, CXR 
and  
once a CT 
 
CE, Lab, CXR 
key: (N)SGCT: (non)-seminomatous germ cell tumour; CS: clinical stage; PS: pathological stage; RPLND: 
retroperitoneal lymph node dissection; CHT: chemotherapy; CT: computed tomography; SE: self-examination; 
CXR: chest X-ray. 
* after RT and RPLND, a baseline CT scan is obtained and repeated if clinically indicated thereafter. 
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In conclusion, the risk of recurrent testicular cancer depends on primary therapy and response 
to it, and it subsequently influences the follow-up protocol. In routine follow-up of patients 
with low-stage testicular cancer adjuvantly treated at the retropritoneum abdominal computed 
tomography is not necessary and computed tomography of the chest can be replaced by chest 
radiography.  
Routine follow-up of pathological stage II patients adjuvantly treated with chemotherapy or of 
histological complete responders after primary chemotherapy has limited value, as no 
recurrences were found in these subgroups of patients. However, only randomized studies will 
determine the optimal follow-up protocol. Until these studies are carried out, follow-up must 
be based upon the known natural history of the malignancy and the physicians’  assessment 
of the relative costs and benefits involved. Regardless any modification in follow-up regimen, 
life-long self-examination should be advocated. 
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Abstract 
 
Objective. There is no universally accepted standard protocol for surveillance of patients with 
clinical stage I Non Seminomatous Germ Cell Tumours (CS I NSGCT). Prospective studies to 
compare different follow-up policies have not been performed, even though a great deal of 
time and resources is spent in surveillance. In this study, we constructed a Markov model to 
evaluate the impact of different follow-up strategies on disease-specific mortality (DSM) and 
life expectancy (LE) of patients with CS I NSGCT. 
Methods. A discrete time non-homogeneous semi-Markov model was used to simulate 
different follow-up strategies for a hypothetical population of CS I NSGCT patients. 
Estimates of the model parameters were based on the literature. Output parameters were DSM 
and LE. Three different strategies were compared: 1) the intensive The Netherlands Cancer 
Institute/Antoni van Leeuwenhoek hospital (NCI/AvL) protocol; 2) the European Association 
of Urology (EAU) protocol; and 3) a hypothetical minimal protocol (i.e. follow-up limited to 
the first two years). Furthermore, we evaluated the impact of abdominal CT scans and chest 
X-rays on DSM. 
Results. Comparing with the EAU protocol (DSM: 3.05%; LE: 53.3 years), the intensive 
NCI/AvL protocol leads to a 1.2% lower DSM and a 6 months higher LE (DSM: 1.81%; LE: 
53.9 years). The hypothetical follow-up scenario during the first two years shows a DSM of 
6.83% and an LE of 51.4 years. Abdominal CT scans of the retroperitoneal lymph nodes 
appear to be important, while chest X-rays have little impact on DSM.  
Conclusions. A follow-up policy limited to the first two years will result in an unacceptable 
high percentage of death from disease (6.83%). The benefit of an intensive follow-up protocol 
as proposed by the NCI/AvL, compared to that of the EAU, must be weighed against its 
economic and psychological costs. Our model suggests that CT-scanning is essential for a low 
DSM, whereas the large number of X-rays seem to have little additional effect. 
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Introduction 
Before the 1980s, patients with non-seminomatous germ cell tumour (NSGCT) without 
clinical evidence of metastatic disease (i.e., clinical stage I) were treated with either 
retroperitoneal lymph node dissection (RPLND) or external beam irradiation to the iliac and 
para-aortic nodes. Histopathology of these nodes shows that approximately 70% of patients 
have no retroperitoneal metastases.1 Furthermore, up to 10% of patients will develop relapses 
outside the retroperitoneum.2 Despite the overtreatment of the majority of patients, this policy 
was justified by the need to cure at first attempt because of the lack of alternative treatment 
options. The introduction of cisplatin-based polychemotherapy for disease relapse, together 
with improvements in clinical staging by computed tomography (CT) and serum markers, has 
prompted a reassessment of adjuvant treatment after orchiectomy.3 Surveillance was 
introduced as an alternative management option. Interestingly, in Europe surveillance is now 
generally favored, while in the United States RPLND remains the standard approach. 
Abdominal external beam irradiation has been abandoned almost entirely. Regardless of the 
initial choice of treatment the 5-year relative survival of this group of patients is over 98%.1,4  
The first line treatment of clinical stage I NSGCT is one of the most controversial topics in 
urological oncology today. Unfortunately, the debate is hampered by the lack of comparative 
empirical data. The main advantage of RPLND is proper pathology staging, while at the same 
time being therapeutic. Clearly, the advantage of surveillance is treatment of the recurrent 
disease only. It relies on the detection of recurrent disease at an early stage. In comparison 
with follow-up schedules after RPLND, surveillance protocols are more intensive, especially 
during the first two years after orchiectomy, when the risk of recurrence is highest. Inevitably, 
surveillance will result in treatment delay, as some patients will have more extensive disease 
than they would have had after immediate surgical exploration. Because treatment efficacy is 
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related to disease extent at time of recurrence, optimal follow-up is critical to the care of 
patients on surveillance.5 
There is no universally accepted standard protocol for surveillance of patients with stage 1 
NSGCT. Prospective studies to evaluate particular follow-up policies have not been 
performed,6 even though a great deal of time and resources is spent in surveillance.7 The 
optimal design to study the efficacy of different follow-up policies is a randomized trial. 
However, such a trial would require both physicians and patients to be compliant during a 
long period of follow-up while less intensive policies may be considered unethical without 
clear evidence that these are equally effective. Alternatively, mathematical decision models 
can mimic randomized trials in order to estimate the value of different follow-up strategies 
without being hampered by the practical disadvantages of those strategies.   
The purpose of this study was to develop a Markov model to evaluate the impact of different 
follow-up strategies on disease specific mortality (DSM) and life expectancy (LE) in patients 
on surveillance for clinical stage I NSGCT.  
 
Materials and Methods 
Decision analysis was used to simulate three different protocols (Table I): 1. the intensive 
follow-up protocol currently used by The Netherlands Cancer Institute/Antoni van 
Leeuwenhoek hospital (NCI/AvL8); 2. the protocol recommended by the European 
Association of Urology (EAU 20029); and 3. a hypothetical minimum follow-up policy (i.e. 
follow-up limited to the first two years after orchiectomy). For the analyses, we constructed a 
discrete-time non-homogeneous semi-Markov model. Calculations were carried out using 
MATLAB software [MathWorks Inc., Natick, Massachusetts, 1999].  
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Table I Follow-up schedules (times per year) for patients on surveillance for 
clinical stage I non-seminomatous germ cell tumours  
     
Year Follow-up modality NCI/AvL EAU MFP 
     
1 Physical examination 12 6 12 
 Tumour markers 12 6 12 
 Chest X-ray 12 6 12 
 Abdominal CT-scan 4 4 4 
     
2 Physical examination 6 6 6 
 Tumour markers 6 6 6 
 Chest X-ray 6 6 6 
 Abdominal CT-scan 3 2 3 
     
3 Physical examination 4 2 - 
 Tumour markers 4 2 - 
 Chest X-ray 4 2 - 
 Abdominal CT-scan 1 1 - 
     
4 Physical examination 3 2 - 
 Tumour markers 3 2 - 
 Chest X-ray 3 2 - 
 Abdominal CT-scan 1 1 - 
     
5 Physical examination 2 2 - 
 Tumour markers 2 2 - 
 Chest X-ray 2 2 - 
 Abdominal CT-scan 1 1 - 
     
6-10 Physical examination 2 1 - 
 Tumour markers 2 1 - 
 Chest X-ray 2 1 - 
 Abdominal CT-scan 1 - - 
 
 
NCI/AvL: Surveillance protocol used by The Netherlands Cancer 
Institute/Antoni van Leeuwenhoek hospital8 
EAU: Surveillance protocol recommended by the European Association of 
Urology, 20029 
              MFP:                             Minimal follow-up policy: follow-up limited to the first two years  
                                                        (identical to NCI/AvL).   
     
 
 
Structure of the Markov model 
Markov models can be used to characterize the progression of a disease as a finite sequence of 
discrete states of illness. The course of the disease develops at certain transition rates between 
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the different states in fixed intervals.10,11 At the end of each interval (i.e., at discrete time 
moments), the patient either has made a single transition from one state to another or has 
remained in the same state. The final state is an absorbing state, usually associated with death. 
According to the fundamental Markov property,10 the probability of transition from one state 
to another is independent of disease history and the transition rates are constant at all times 
(i.e., homogeneous Markov model). Since the holding times in each state are exponentially 
distributed, the transitions between states are independent of the time spent in a particular 
state. Clearly, this approach is unrealistic, since the longer an individual has spent in a state of 
illness, the higher the probability that the next transition is to the absorbing state of death. 
Therefore, we used a semi-Markov model, where arbitrary hold times for each state can be 
applied and the transitions may depend on holding times.12 Because we allow some transition 
rates to vary with time, the model becomes non-homogeneous. 
To describe the course of disease of patients on surveillance for clinical stage I NSGCT, we 
developed a model with five non-absorbing and two absorbing states (Figure 1). A 
hypothetical cohort of patients enters into the initial state of the model: no clinical signs of 
disease after orchiectomy. At the end of each 1-month interval a fraction of the cohort is 
partitioned among subsequent states according to the transition probabilities. In this way, 
patients may remain in the same state, develop abdominal or extra-abdominal (sub-) clinical 
recurrent disease, recover from recurrent disease, or die from testicular cancer or other 
unrelated causes. A simulation period of 100 years was chosen to assure that eventually all 
patients end up in the absorbing states of death. The transition probabilities were derived from 
data in the literature. If no direct estimates for these probabilities were available, rates were 
calculated based on specific assumptions (see Appendix).  
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Figure 1: Markov state-transition model of clinical stage I NSGCT on surveillance 
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Legend of figure 1: Transition rates used for the Markov model simulation 
 1 : Transition rate from ‘no clinical signs of disease’ to ‘subclinical systemic recurrence’’ 
 2 : Transition rate from ‘subclinical systemic recurrence’ to ‘detection of clinical systemic recurrence’  
 3 : Transition rate from ‘detection of clinical systemic recurrence’ to ’no clinical signs of disease’’ 
 4 : Transition rate from ‘subclinical systemic recurrence’ to ‘death from testicular cancer’’ 
 5 : Transition rate from ‘detection of clinical systemic recurrence’ to ‘death from testicular cancer’  
 1 : Transition rate from ‘no clinical signs of disease’ to ‘death from other causes’’ 
 2 : Transition rate from ‘subclinical systemic recurrence’ to ‘death from other causes’’ 
 3 : Transition rate from ‘detection of clinical systemic recurrence’ to ‘death from other causes’’ 
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Hypothetical cohort 
The hypothetical cohort of patients is assumed to be a representative sample from the 20-year 
old male population of The Netherlands, apart from being hemi-orchiectomized for NSGCT. 
At entry into the model, the patients are assumed to have no clinical signs of metastatic 
disease (i.e., clinical stage I disease) and to comply with the surveillance regimen.  
 
Disease Progression 
At the end of each 1-month interval, patients may have developed disease progression. Such 
disease progression is assumed to occur in a sequence of non-absorbing states of illness. The 
onset of disease progression is not detectable, because of insensitive diagnostics (i.e., 
subclinical disease). As disease progresses, the recurrence will be detected by the patient 
himself (i.e., symptomatic clinical disease) or by the physician during a regular follow-up 
examination (i.e., asymptomatic clinical disease). The percentage of patients in whom 
recurrent disease was diagnosed per unit of time depended on the frequency of follow-up 
examinations and the sensitivity of the follow-up modality used. We assumed that patients 
with recurrent disease are treated with chemotherapy. Ultimately, all patients will be absorbed 
by one of two states of death: either ‘death from testicular cancer’ or ‘death from other 
causes’ (Figure 1). 
 
Follow-up  
As mentioned before, we analyzed three different surveillance policies (Table I). The protocol 
proposed by NCI/AvL was considered as a ‘maximum’ schedule because it is the most 
intensive protocol used in current daily practice.8 A hypothetical policy of follow-up limited 
to the first two years only was considered to be the ‘minimum’ protocol. The policy 
recommended by the EAU was chosen as an ‘intermediate’ policy.9 
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Sensitivity analysis 
Sensitivity analyses were performed to assess the robustness of the model to changes in 
assumptions. For model parameters with uncertain values, different input values were used to 
estimate their impact on DSM and LE. Transition rates that were directly derived from the 
literature were not subjected to a sensitivity analysis. All other model parameters were varied 
one at a time. The effect of age at diagnosis on DSM and LE was analyzed over a wide range 
of ages (i.e., 20, 30, 40, and 50 years).  
For the NCI/AvL protocol, we also investigated the impact of the sensitivity of abdominal 
CT-scans and the number of chest X-rays on DSM.  
 
Results 
The effects of the three different follow-up strategies on diseases specific mortality (DSM) 
and life expectancy (LE) are presented in Table II. The more intensive follow-up regimen 
proposed by NCI/AvL compared to that of EAU results in a decrease of DSM from 3.05% to 
1.81% for a 20-year old man. The potential gain from follow-up strategies was found to 
depend largely on the detection of subclinical abdominal disease. From Table II, it is clear 
that a more intensive follow-up program leads to a higher LE. The absolute gain in life 
expectancy for a 20-year old man who undergoes the intensive follow-up policy (NCI/AvL) 
compared to the minimum follow-up policy (MFP) is 2.5 years (53.9-51.4). The potential 
benefit in LE from an intensive strategy is less for older men, while the benefit in DSM is 
almost the same across age groups.  
The analyses were repeated to assess the sensitivity of the model to changes in baseline 
parameters (Table III). Both the DSM and the LE estimates for the different protocols are 
quite stable for a variety of alternative parameter values. The changes in DSM and LE are 
most pronounced for the minimal follow-up protocol. For example, if the transition rate from 
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subclinical recurrence to symptomatic recurrence (lambda 2) is changed from 1% per month 
to 2% per month the LE increases with more than 1 year while the DSM decreases with more 
than 2%. In the NCI/AvL and EAU protocols, the corresponding LE increase is only 0.3 and 
0.5 years, respectively, while the decrease in DSM is 0.6% and 1%, respectively. In the latter 
protocols, both the DSM and the LE seem to depend mostly on the doubling time of the serum 
tumour marker alpha-fetoprotein (component of lambda 4). For all three protocols, the model 
is less robust for DSM than for LE. 
 
Table II Effect of different follow-up strategies on disease-specific mortality (%) 
and life expectancy (%) for different ages at onset of disease. 
 
 
AGE NCI/AvL EAU MFP 
 
-Subclinical abdominal recurrence 
-Clinical abdominal recurrence 
-Subclinical extra-abdominal recurrence 
-Clinical extra-abdominal recurrence 
Disease Specific Mortality 
 
Life expectancy 
 
 
20y 
 
 
 
 
 
55.5* 
 
 
1.71 
0.06 
0.03 
    0.02  + 
1.81 
 
53.9 
 
2.86 
0.06 
0.12 
    0.02  + 
3.05 
 
53.3 
 
5.95 
0.05 
0.82 
     0.01  + 
6.83 
 
51.4 
 
-Subclinical abdominal recurrence 
-Clinical abdominal recurrence 
-Subclinical extra-abdominal recurrence 
-Clinical extra-abdominal recurrence 
Disease Specific Mortality 
 
Life expectancy 
 
 
30y 
 
 
 
 
 
45.9* 
 
1.71 
0.06 
0.03 
    0.02  + 
1.81 
 
44.5 
 
2.86 
0.06 
0.12 
    0.02  + 
3.05 
 
44.0 
 
5.94 
0.05 
0.82 
    0.01  + 
6.82 
 
42.5 
 
-Subclinical abdominal recurrence 
-Clinical abdominal recurrence 
-Subclinical extra-abdominal recurrence 
-Clinical extra-abdominal recurrence 
Disease Specific Mortality 
 
Life expectancy 
 
 
40y 
 
 
 
 
 
36.2* 
 
1.70 
0.06 
0.03 
    0.02  + 
1.80 
 
35.1 
 
2.84 
0.05 
0.12 
    0.02  + 
3.03 
 
34.7 
 
5.90 
0.05 
0.81 
    0.01  + 
6.77 
 
33.6 
 
-Subclinical abdominal recurrence 
-Clinical abdominal recurrence 
-Subclinical extra-abdominal recurrence 
-Clinical extra-abdominal recurrence 
Disease Specific Mortality 
 
Life expectancy 
 
 
50y 
 
 
 
 
 
27.0* 
 
1.66 
0.06 
0.03 
    0.02  + 
1.76 
 
26.1 
 
2.77 
0.05 
0.11 
    0.02  + 
2.95 
 
25.8 
 
5.76 
0.05 
0.80 
    0.01  + 
6.62 
 
25.0 
 
Key : see Table 1 
* Statistics Netherlands, Life Tables 1998: Life expectancy of general male Dutch  population39 
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Table III Sensitivity analyses: impact of variation in baseline parameters on 
mortality and life expectancy for 20-year old men on surveillance for 
clinical stage I non-seminomatous germ cell cancer. 
 
Transition rate Baseline 
assump-
tion 
Alter- 
native 
values 
Disease Specific Mortality 
(%) 
Life Expectancy  
 (years) 
   NCI/ 
AvL 
 EAU MFP NCI/ 
AvL 
 EAU MFP 
 
Simulation results (Table II) 
 
 
  
1.81 
 
3.05 
 
6.83 
 
53.9 
 
53.3 
 
51.4 
 
 2, symptomatic  
 
0.01 
 
0.005 
 
2.20 
 
3.71 
 
8.34 
 
53.8 
 
53.0 
 
50.7 
  0.02 1.24 2.07 4.59 54.2 53.8 52.6 
 
 3, treatment time [days] 75 50 1.80 3.05 6.84 54.0 53.3 51.5 
  100 1.83 3.06 6.83 53.9 53.3 51.5 
 
 4, die from subclinical disease         
-AFP (t=o)  0.00001 0.00002 1.92 3.17 6.92 53.9 53.3 51.4 
  0.000005 1.71 2.94 6.74 54.0 53.4 51.5 
-Doubling time  of AFP [days] 40 50 1.15 2.40 6.20 54.3 53.8 51.8 
  30 2.88 4.29 7.54 53.4 52.7 51.1 
 
 5, die from clinical disease 0.001 0.002 1.89 3.12 6.89 53.9 53.3 51.5 
  0.0005 1.78 3.02 6.80 54.0 53.3 51.4 
         
Key: see Table I 
AFP: serum tumour marker alpha-fetoprotein 
 
 
In all models, a lymph node of 10 mm or more located in the primary landing zone was 
considered as a positive CT scan. We examined the impact of different criteria for a positive 
CT scan in the most intensive follow-up strategy (see Table IV). If the cut-off point of CT 
scanning is decreased, its sensitivity will increase (while its specificity will decrease) leading 
to a net beneficial effect. For example, if the cut-off is lowered from 10 mm to 8 mm, the 
DSM during the first 10 years of follow-up will drop from 1.81% to 0.95%. The number of 
chest X-rays during follow-up appears to be less critical (Table V). Lowering the total number 
of chest evaluations with 25% will result in an increase of only 0.06% in DSM (from 1.81% 
Chapter 9 
 
 
 180
to 1.87%). A reduction of the number of chest X-rays with 50% results in an increase in DSM 
of only 0.16%. 
Table IV The impact of improved abdominal staging on 
disease-specific mortality for 20-year old men on 
surveillance for clinical stage I non-seminomatous 
germ cell cancer. 
 
Lymph node size in the 
primary retroperitoneal  
landing zone as cut-off point 
for a positive CT scan# 
Sens 
CT# 
 
Spec 
CT# 
DSM 
(%) 
Percentage death from 
abdominal disease 
   total subclinical clinical 
      
≥ 10 mm 37% 100% 1.81 1.71 0.06 
≥ 8mm 47% 100% 0.95 0.85 0.06 
≥ 6mm 67% 83% 0.27 0.16 0.06 
≥ 4mm 97% 58% 0.12 0.01 0.06 
      
 
Key: Sens: sensitivity; Spec: specificity; DSM: Disease specific mortality 
# Quoted from Hilton et al.14 
 
 
 
 
Table V The impact of the number of chest X-rays on disease-specific 
mortality for 20-year old men on surveillance for clinical stage I 
non-seminomatous germ cell cancer. 
 
Protocol DSM Death from extra-retroperitoneal disease 
 Total (%) Subclinical (%) Clinical (%) 
 
NCI/AvL at 
baseline 
 
1.81 
 
0.03 
 
0.02 
NCI/AvL – (75%)1 1.87 0.08 0.02 
NCI/AvL – (50%)2 1.97 0.19 0.02 
    
 
Key: 1) 75% of the number of chest X-rays, used in the standard NCI/AvL model 
         2) half of the number of chest X-rays, used in the standard NCI/AvL model 
         DSM: Disease specific mortality 
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Discussion 
The efficacy of routine follow-up in cancer is debated for many tumour sites, especially 
because disease recurrence is frequently detected between follow-up visits and the prognosis 
of recurrences is usually poor. Clinical stage I NSGCT is probably one of the exceptions. 
Close patient monitoring might result in survival advantage because 1. approximately one-
third of patients harbor micrometastatic disease; 2. most recurrences are diagnosed during 
follow-up visits; and 3. these recurrences can be treated effectively with chemotherapy.13 
Although there is general agreement on the benefit of follow-up, there is no universally 
accepted protocol for surveillance in clinical stage I NSGCT. The purpose of the present study 
was to design a decision model to quantify the value of follow-up in terms of DSM and LE of 
the various protocols.  
The simulation results confirm that surveillance influences DSM in clinical stage I NSGCT. 
The differences in DSM between different protocols seem small at first sight. However, these 
small absolute differences should be interpreted in light of the excellent 98% 10-year survival 
of this group of patients.2,4,5,7 The importance of follow-up is further underlined by the 
outcome of the minimal (2-year) follow-up policy: 6.8% of the patients will die from disease 
while the overall life expectancy is 2.5 years shorter than with the intensive NCI/AvL policy.  
It is well known that surveillance compared to RPLND delays the recognition of occult 
metastases. The drawback of surveillance is that abdominal CT misses retroperitoneal 
metastases in approximately one-third of patients when using the conventional criterion for 
lymph node enlargement of 10 mm in the primary landing zone.14 Previous studies indicate 
that the use of a smaller size criterion in this group of patients decreases the proportion of 
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false-negatives, although the downside is an increased number of false-positives.14-16 Our 
model shows a strong effect of increased sensitivity of abdominal staging on DSM.  
By contrast the number of chest X-rays is questionable.17 Lowering the number of chest 
evaluations has little impact on DSM, whereas the number of these investigations has clear 
impact on financial costs and cumulative radiation dose to the patient. Nevertheless chest X-
rays are still important in detecting relapse in the mediastinum and lungs.7 
Munro and Warde used a Markov model to evaluate the cost-effectiveness of more than 20 
different surveillance schedules for clinical stage I NSCGT.18 Relevant differences in 2-year 
survival were not found, whereas the costs differed significantly especially because of the 
different number of abdominal CT scans. The authors suggested that a prospective trial would 
have to reveal the true value of CT-scanning during surveillance. However, the results from 
this study must be interpreted carefully because the patients were followed for two years only. 
Differences in policies may become apparent only after a longer time period.  
Of course, the results of our study should be interpreted carefully as well. For example, in the 
absence of clinical data, we had to assume the transition rates to death from disease. The 
probability to die from subclinical disease was assumed to be related with the level of the 
serum tumour marker alpha-fetoprotein (AFP). Therefore, we chose a semi-Markov model, 
which emphasizes a time dependent transition rate. In other words, the longer time the patient 
has spent in this particular state of illness (i.e., subclinical disease), the higher the level of 
AFP and the higher the probability of transition to the state of death from disease. By contrast, 
for sake of simplicity the chance to die during chemotherapy ( 5) was assumed to be constant 
over time. In fact, this chance would reach its maximum just before the start of therapy and 
will be lower as treatment progresses. In the sensitivity analysis, only a small impact of 
different  5 was seen on DSM, which justifies the assumption of time independence of this 
parameter.  
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The rates of other causes of death were assumed to be equal in all health states and similar to 
those in the Dutch population. As patients with symptomatic recurrences will receive systemic 
chemotherapy, their risk of dying from other causes may be higher than that of the general 
population. We did not correct for this because the treatment-related mortality for 
chemotherapy for germ cell tumours is very low, particularly for previously untreated 
patients.19,20 
The probability of detection of a recurrence by the patient himself will increase by a longer 
follow-up interval. In theory, this probability reaches its maximum value just prior to the next 
follow-up evaluation. Our simplifying assumption that this rate is constant between follow-up 
intervals somewhat biases the results in favour of the NCI/AvL model.  
Survival is one parameter of the net benefit of oncologic follow-up. Effects on cancer-anxiety 
and quality of life are also important.21 Reassurance of absent disease outweighs the negative 
impact of follow-up visits for most men. For others, the thought of a terrifying outcome or the 
repetitive character of follow-up visits, outweighs such reassurance, making them to 
discontinue visits. In our analysis, we assumed that all patients were compliant to follow-up. 
Hao et al. reported a compliance of 61% in the first year but only 35% in the second year.22 In 
general, in patients in whom surveillance therapy is elected, this should be considered an 
active form of treatment with careful follow-up being mandatory as neglecting follow-up will 
result in lower LE. In addition, because we intended to show the more objective results of 
different follow-up protocols, we calculated LE unadjusted for Quality of Life. 
The statistical significance of differences in LE and DSM could not be determined because 
our analyses did not yield measures of uncertainty (i.e., standard errors). As an alternative for 
the cohort simulation, a Monte Carlo simulation would have allowed the calculation of 
standard errors, making statistical comparisons possible.11 But even then, the transition rates 
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of individual patients may be highly variable making these models only general guides to 
decision making of a group of patients.  
Until prospective randomized trials have been performed to evaluate the efficacy of different 
protocols, our model may help physicians to understand the anticipated effects of different 
follow-up protocols on long-term survival of clinical stage I NSGCT patients on surveillance. 
 
Conclusions 
The logistical and economical benefits of a less intensive follow-up protocol as proposed by 
the EAU compared to that of the NCI/AvL must be balanced against the increase in disease 
specific mortality rate from 2 to 3%. Follow-up limited to the first two years only will result 
in an unacceptably high percentage of death from disease (7%). Because of the excellent 
prognosis of clinical stage I NSGCT, follow-up schedules have limited impact on life 
expectancy. Our model suggests that CT-scanning is essential to disease-specific survival, 
whereas the large number of chest X-rays seems to have little benefit. 
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Appendix: Transition rates  
 
The transition rates indicated with   and μ, along the arrows in Figure 1, were derived from 
the literature, or estimated by ‘educated guess’ if no direct figures were available. These rates 
describe the conditional rate of occurrence of events per unit of time. 
Transition rates (  and μ) may be converted to transition probabilities (p) taking the time 
interval (Δt) into account, according to the formula: p = 1 – e- Δt. The monthly transition rates 
( -monthly) were approximated from the annual rates ( -annual) using the formula:  -
monthly = 1/12 *  -annual.23 
 
LAMBDA 1 ( 1): entering subclinical disease state 
In the model  1 represents the rate at which patients develop a subclinical recurrence. The 
time course of this rate,  1(t), was estimated from the database of The Netherlands Cancer 
Institute/Antoni van Leeuwenhoek Hospital (NCI/AvL).8 From this data we estimated a 
Kaplan-Meier relapse-free survival function, Ŝ(t), and subsequently calculated an estimate of 
the cumulative hazard function: Ĥ(t) = - log Ŝ(t).24,25 Plotting log Ĥ(t) versus time showed a 
strong linear trend (especially for large t, whereas for small t the trend was curved), 
suggesting a Gompertz distribution.26 An almost perfect fit (r=0.98) was found by first fitting 
Ĥ(t) to a 3-parameter exponential association growth model and subsequently taking the 
derivative, yielding the hazard function:    1(t) = e + t.  
The values for   and   are constant: NCI/AvL data:  = -3.823;  = -0.069. In order to refine 
the model and bring it into accordance with the clinical situation, we divided the data of 
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NCI/AvL into abdominal ( 1 abd) and extra-abdominal subclinical disease ( 1 xabd). The time 
course of  1(t)abd and  1(t)xabd were estimated in the same way. The values for   abd and   abd 
are -4.06975 and -0.06354, and for   xabd and   xabd -5.18180 and -0.08308, respectively. 
 
LAMBDA 2 ( 2): transition to symptomatic disease state 
The  2 represents the rate to develop clinical disease. It consists of an asymptomatic,  2 asym, 
(detection by follow-up examination) and a symptomatic,  2 sym, (detection by the patient 
between consecutive follow-up moments) component. 
We assumed  2 asym to be dependent of the accuracy of the imaging modality at follow-up, and 
to be zero between consecutive follow-up moments. Using the commonly accepted criterion 
of 10 mm for metastatic disease, the abdominal CT-scan has a sensitivity of 37% and a 
specificity of 100%14 and the chest X-ray of 35% and 99%, respectively.27 In our model, the 
specificity of the different imaging modalities was set to be 100% and the transition 
probability, p, to be equal to the sensitivity of the imaging modality. Consequently, the 
following formula was applied to find the transition rate:  2 asym(t) = -log(1-σ)/Δt, where σ is 
the sensitivity of the imaging modality, and Δt is the 1-month Markov interval time. 
The chance to detect a symptomatic recurrence is believed to be a function dependent on the 
time in-between two successive follow-up moments and therefore it was modeled to be 
inversely proportional to the frequency of the regular follow-up visits. Because both the 
published literature reported only a small percentage of symptomatically detected recurrences 
among patients on surveillance (0-2%)8,28-35 and for sake of simplicity, we assumed  2 sym to 
be constant over time and equal to:  2 sym = 0.01. 
 
LAMBDA 3 ( 3): transition to cured state. 
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Lambda 3 ( 3) is related to the time needed to be cured after the ‘detection of clinical 
systemic recurrence’. It was assumed that all patients received combined chemotherapy (three 
cycles of cisplatin, etoposide, bleomycin and a last cycle of etoposide, bleomycin during a 5 
day regimen) and are regarded as cured after completion of therapy. In total, it would take 75 
days (time between detection and start of chemotherapy is 7 days together with 68 days of 
treatment time) before a patient can leave the state ‘detection of recurrence’ and re-enter the 
state of ‘no clinical signs of disease’. In this way the states “detection of clinical systemic 
recurrence” behave like a first-in-first-out queue with a fixed time spent in that state (i.e., 
sojourn time).10,11 During the course of treatment,  3 has a value of zero. Only patients having 
spent the total sojourn time are regarded to be cured, and  3 takes on such a value that only 
that fraction of all patients in treatment is released to the initial state. The following transition 
rate was applied:  3 = -log(1-N1/Ntotal)/Δt, where N1 is the number of patients leaving the 
treatment queue and Ntotal is all patients in the treatment queue. 
 
LAMBDA 4 and 5 ( 4, 5): failure rate 
The transition rates  4 and  5 express the rate at which patients are transferred from the states 
“subclinical recurrent disease” and “clinical recurrent disease” to the absorbing state of “death 
from testicular cancer”, respectively. In the literature, approximately 1% dies from testicular 
cancer at five years after diagnosis to 1-3% at 10 years of follow-up.2,5 Clinical data on “death 
from disease” in the literature were sparse. Therefore, we assumed that all four transition rates 
( 4abd,  4xabd,  5abd,  5xabd) have the same impact on ‘death from testicular cancer’ and that 
combining these rates results into the overall percentage of death from disease in patients with 
clinical stage I NSCGT. 
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Literature data to calculate  4 are not available. Alternatively, we used a tumour growth 
model to estimate the natural course of developing a metastatic testicular tumour and to die 
from this metastasis without therapeutic intervention. In testicular germ cell tumours the 
prognosis in terms of survival seems to be more related to the level of the tumour markers and 
to the presence of metastasis in liver, bone and brain than to the growth of the pulmonary and 
retroperitoneal metastasis.36 Because the vast majority of metastatic disease in clinical stage I 
disease is found in the retroperitoneum and in the lungs, we have focused on the growth 
pattern of the tumour markers. We used the tumour marker alpha-fetoprotein (AFP) as an 
example to calculate tumour growth.37 The mean doubling time for AFP was 28.5 days. 
Because only 60% of the non-seminoma tumours produce AFP38, we assumed the remaining 
tumours (40%) had a doubling time twice as long as the AFP-producing tumours (57 days). 
All together, the average doubling time in our model was 40 days (0.6*28.5 + 0.4*57). 
Furthermore, we assumed that the chance to be cured is zero with an AFP-value of 100,000 
ng/ml and that the baseline value of AFP was 1/100,000 ng/ml. In the literature, most tumour 
growth models have shown an exponential growth pattern during the observation period.39 
Subsequently, the natural course to die from recurrent metastatic testicular disease will take 
33.2 doubling steps (0.00001* 2n = 100,000 ng/ml). Thus, it will take approximately 44 
months (33.2 * 40 days) to die from untreated recurrent systemic testicular cancer.   
The hazard function  5 is the proportion of individuals alive and treated for recurrent testicular 
cancer who die from recurrent testicular germ cell cancer during treatment. We adopted a 
baseline rate for treatment-related mortality of 0.001 according to Munro et al.18 
  
MU 1 ( 1), MU 2 ( 2) and MU 3 ( 3): mortality rates 
Transition rates ( 1,  2,  3) that led to the state ‘Death from other causes’ were based on male 
mortality data acquired from Statistics Netherlands.40 The ‘age-specific mortality rate’ for the 
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years 1990-1994 was averaged into an ‘average age-specific mortality rate per year’ which is 
the probability to die within one year given survival until a specific age. Subsequently, the 
‘average age-specific mortality rate per year’ was converted to a ‘monthly average age-
specific mortality rate’.  
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Abstract 
Objectives. To assess the prevalence of (in)fertility in men before and after treatment for 
testicular cancer.  
Methods. Information about fertility was collected using postal questionnaires from 226 out 
of 305 patients, treated for testicular germ cell cancer at the Department of Urology of the 
University Medical Center Nijmegen from 1982 to June 1999. Fertility was defined as the 
ability of a sexually active non-contracepting couple to achieve pregnancy within one year. 
The results were compared to the lifetime prevalence of infertility in the general population 
(20-28%). 
Results. Before the cancer was diagnosed, 79 of 120 couples (66%) who attempted to 
conceive, succeeded within one year. After treatment 38 of 88 couples (43%) conceived 
within one year. Seven couples used cryopreserved sperm to conceive a child after treatment. 
The different treatment modalities did not significantly influence the outcome of patients’ 
wish for children. Congenital malformations were recorded in approximately 4% of the 
children born before or after treatment.  
Conclusions. Although the majority of the patients with testicular cancer have a fulfilled wish 
with regard to children, it seems to be more difficult to father a child after treatment compared 
with the case in the general population. Because it is not possible to predict which patient will 
have fertility problems after treatment, cryopreservation should be offered to every testicular 
cancer patient. An increased risk for congenital malformations was not observed.  
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Introduction 
Although germ cell tumours of the testis (TGCT) account for only 1 percent of all tumours in 
males, it is the most common malignancy in males between 15 and 35 years of age.1 The 
combination of surgery, radiotherapy and chemotherapy has made TGCT curable in 
approximately 90% of patients with newly diagnosed disease.2 Since the majority of cured 
patients are young and have not started or completed families, fertility and sexual function are 
important issues.  
For several reasons, subfertility is common in patients with TGCT. Firstly, three quarters of 
the patients have a decreased baseline spermatogenesis at the time of diagnosis.3,4 Potential 
causes include a pre-existing defect in spermatogenesis, a history of cryptorchidism, hormone 
production by the tumour, antisperm antibodies, possible contralateral or intraepithelial germ 
cell neoplasia, and generalized stress associated with illness.2,5 Among all, cryptorchidism has 
been proven to be associated with both testicular cancer (relative risk [RR]: 2.5-11; see 
Benson et al.6), and infertility (RR: 2-6; see Lee7). 
Second, deterioration of spermatogenesis has been observed after adjuvant radio- or 
chemotherapeutic treatment in a dose-dependent fashion.4,8 Approximately a quarter of the 
patients remain azoospermic after treatment.2 Finally, up to half the patients undergoing 
surgery may suffer from ejaculatory dysfunction after treatment.9,10 
Even though most studies in patients with TGCT have used sperm quality as indicator for 
fertility, it is not apparent from the published reports that paternity is compromised. Because 
fertility is defined as the ability of a sexually active non-contracepting couple to achieve 
pregnancy within one year11, attempting paternity is a better measure for fertility.3 
To put this study into perspective, it is important to note that up to one-third of the couples (in 
the general population of industrialized countries), attempting parenthood appear to be 
subfertile.12 
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The objective of this study is to assess the prevalence of fertility in patients curatively treated 
for TGCT and to evaluate fertility-related factors, the frequency of use of cryopreserved 
sperm, the health of offspring and patients’ satisfaction with the given information on fertility 
and sexual dysfunction. 
 
Patients and Methods 
The medical records of testicular cancer patients treated at the department of urology of the 
University Medical Center Nijmegen between June 1982 and June 1999 were reviewed. 
Medical information was obtained from the patients’ records.  
Staging (Royal Marsden Hospital Staging; see Peckham13) and first-line treatment principles 
have been reported previously.14 In short, all orchidectomised patients were screened for 
metastases using abdominal and thoracic computed tomography scanning at the time of the 
initial diagnosis. Of those in whom no metastases were found, patients with seminomas were 
irradiated on the iliac and para-aortal lymph nodes with 26 to 30 Gy. Of patients with no or 
only small (<2 cm) positive retroperitoneal lymph nodes on computed tomography scan 
(Stage IIa), those with nonseminoma germ cell tumour (NSGCT) were treated with 
retroperitoneal lymph node dissection (RPLND).  
Since 1994, the decision to perform RPLND in patients with Stage I NSGCT was also 
dependent on the presence of vascular invasion in the primary tumour. RPLND was done in 
case of vascular invasion and was followed by two cycles of bleomycin, etoposide, and 
cisplatin chemotherapy in patients with lymph node metastases.  
When metastases were present and the tumour was minimally Stage IIb, patients with either 
seminoma or NSGCT received three to four cycles of cisplatin based chemotherapy after 
inguinal orchiectomy. Residual mass after chemotherapy was removed in all 
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nonseminomatous germ cell tumours and in seminomatous germ cell tumours in case the mass 
was larger than 3cm in transverse diameter. 
A questionnaire was sent to 305 patients who were assumed to live at the address given by the 
post office, did not relapse after first-line treatment and had been followed-up for more than 
18 months. Because no validated questionnaire was available, we designed it ourselves in 
collaboration with the Departments of Epidemiology and Gynecology at our institution.  
The questionnaire mainly consists of questions about pre- and post-treatment attempt for 
paternity, length of unprotected intercourse to conception or period of infertility, paternal and 
maternal age at attempts, health including (previous) testicular or gynecological disorder, 
patient lifestyle factors (duration and amount of using tobacco and alcohol), patient contact 
with chemical or other occupational hazards, health of offspring and the use of cryopreserved 
semen. Moreover, we asked if the patients were satisfied with the available information about 
fertility and sexual function after treatment.  
According to the ethics committee for biomedical trials of the University Medical Centre St. 
Radboud, it was not necessary to approve this study, as long as only a questionnaire was used. 
We have defined fertility as the ability of a sexually active noncontracepting couple to 
achieve pregnancy within one year.11 The prevalence of fertility before and after treatment 
was calculated among those who stated that they had attempted fathering a child (population 
at risk).  
The prevalence was expressed as percentages with corresponding 95% confidence intervals. 
Where applicable, differences in percentages were tested for statistical significance with 
Fisher's exact test and differences in continuous variables (e.g. age) was tested with T-tests. 
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Results 
Patient characteristics. In total, 74% (226/305) of the questionnaires were returned. Of the 
remaining 79 patients, 10 patients refused to take part, 5 patients had moved to an unknown 
address, and 64 did not return their questionnaires for unknown reasons. 
Fifty-four patients (24%) had been treated for seminomatous germ cell tumours and 172 
(76%) for non-seminomatous germ cell tumours. The median age at initial diagnosis was 31.7 
years (range 17.4 to 70.0 years). The median period between diagnosis and returning the 
questionnaire was 89 months (range 19-224 months). 
The influence of patient characteristics on the probability of fathering a live-born child was 
investigated (Table I). There was no significant effect of histological type, prior 
cryptorchidism or other genital condition on success at conception before treatment. Also 
lifestyle factors (history of or currently smoking and/or drinking) and occupation (history of 
or currently exposure to chemicals) failed to show a significant difference (data not shown). 
 
Fertility status before treatment. Before testicular cancer was diagnosed, 120 of 226 (53.1%) 
patients attempted to father a child. Ninety-tree patients (77.5%; 95%CI: 69.9-85.1) had 
fathered 194 live-born children. The majority of them succeeded in conceiving within 1 year 
(84.9%; 79/93). Six of 79 couples had initially experienced a miscarriage, but managed 
successful pregnancy within one year after their first attempt.  
Of the 14 couples who did not conceive within one year, one couple needed assisted 
conception treatment, and in one couple, the partner had been treated successfully for 
hormonal dysbalance. The remaining 12 succeeded spontaneously after attempting for more 
than one year. The median age of father and mother, respectively, at first attempt pre-
orchiectomy was 27.9 years (range: 20.0-36.0) and 24.8 years (range: 19.1-36.0). 
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Twenty-seven couples (22.5%), who attempted for more than one year, remained childless 
pre-treatment. Among them, 3 experienced a miscarriage after attempting for more than one 
year. Five couples sought specialized help: three patients appeared to have hypospermia, one 
woman had hormonal dysbalance and in one couple there was no explanation for 
childlessness. The median age of father and mother, respectively, at first unsuccessful attempt 
was 26.3 years (range: 19.1-35.0 years) and 23.4 years (range: 18.9-31.5 years). 
 
 
Table I Clinical characteristics and paternity in patients at diagnosis of testicular cancer 
 Fatherhood before 
treatment 
(n=93) 
Unfulfilled wish after 
attempting > 1 year 
(n=27) 
No attempt to 
father a child 
(n=106) 
    
Patients’ history before disease     
 -cryptorchidism 14 8 27 
 -inguinal hernia 10 5 11 
 -varicocele 1 - 2 
 -orchitis 3 1 4 
    
Paternity status before diagnosis    
Time to conceive 
  <0.5 year 
  0.5-1 year 
  >1 year  
 
68 
11 
14 
 
- 
 
- 
Median age father (years) 
 -range 
27.9 (at birth) 
20.0-36.0 
26.3 (at first attempt) 
19.1-35.0 
- 
Median age mother (years) 
 -range 
24.8 (at birth) 
19.1-36.0 
23.4 (at first attempt) 
18.9-31.5 
- 
    
At diagnosis    
Median age at diagnosis (years) 
  -range 
36.0 
26.4-70.0 
32.1 
22.1-58.7 
25.9 
17.4-62.6 
NSGCT/SGCT* 60/33 20/7 92/14 
Stage† 
  -I 
  -II 
  -III 
  -IV 
 
37 
38 
- 
13 
 
13 
12 
1 
1 
 
35 
39 
1 
21 
 
 
   
Key: *(N)SGCT: (non)-seminomatous germ cell tumour 
         †according to Royal Marsden Hospital Staging system13 
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Fertility status after treatment. After treatment, 88 patients attempted to have a child. Fifty-
four of them (62.5%; 95%CI: 52.5-72.5) had fathered a child (Table II), and of those 46 
patients had fathered by natural intercourse (median time after diagnosis: 44 months, range 12 
– 134 months) and 8 patients, by assisted reproduction (including two couples who used 
donor insemination). At the time of the questionnaire, one spouse was pregnant for 6 months 
after assisted help (see Table II). 
The median ages of the father and the mother, respectively, at first attempt after completion of 
treatment were 32.0 (range: 22.1-41.0 years) and 29.1 years (range: 21.3-39.0 years). In total, 
81 children were born post-treatment at a median of 46 months (range 12-143 months). 
Thirty-eight of the 88 couples (43%) succeeded in conceiving within one year. Although in 7 
of them a miscarriage occurred, 4 couples managed to conceive a successful pregnancy within 
one year after their first attempt.  
Although not significant, the percentage of patients who fathered after chemotherapy and 
surgery was higher than those receiving chemotherapy or surgery alone (Table II). No 
pregnancies occurred during any cancer treatment.   
Thirty-two of 33 patients attempted conception for more than one year at a median of 104 
months (range 18-216 months) after completion of treatment (Table II). The median age of 
father and mother, respectively, at first attempt (unsuccessful) after treatment was 33.3 years 
(range: 22.1-41.0 years) and 30.2 years (range: 22.9-39.5 years).  
Nine of the 138 patients, who did not attempt to father a child after treatment, reported a wish 
for children in the future. 
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Table II Patient characteristics and paternity after treatment 
 All 
patients 
SV 
 
RT 
 
PRPLND 
 
PRPLND 
and CT 
CT 
 
CT and 
SRPLND 
        
Fatherhood 54 3 8 9 17  7 11 
Time to conceive 
<0.5 year 
0.5-1 year 
>1 year 
pregnant at time of 
questionnaire 
 
28 
7 
19 
1 
 
1 
1 
1 
- 
 
5 
- 
3 
- 
 
5 
3 
1 
- 
 
10 
1 
5 
1 
 
4 
- 
3 
- 
 
3 
2 
6 
- 
        
No Fatherhood* 
(attempting > 1 year) 
33 
 
3 
 
2 
 
9 
 
7 
 
7 
 
4 
(and 1†) 
        
No attempt 138 14 26 26 18 30 24 
 
Key: SV, surveillance; RT, radiotherapy; PRPLND, primary retroperitoneal lymph node dissection; 
SRPLND, secondary retroperitoneal lymph node dissection; CT, chemotherapy. 
* Including 3 patients, who experienced a miscarriage within one year after attempt, but did not deliver a 
child at all. 
† at time of questionnaire attempting  0.5-1 year 
 
Association between fathering a child before and after treatment. Most of the patients who 
fathered a child before treatment did not attempt to do so after treatment (70/93; Table III). 
After having fathered a child before treatment, 23 patients also attempted to father a child 
after treatment. Sixteen of them succeeded. 
Six of the 27 patients who did not succeed in fathering a child before treatment did succeed 
afterwards. Two of those 6 couples experienced a miscarriage before treatment, and in one, 
the spouse had had a hormonal dysbalance that was corrected after completion of testicular 
cancer treatment.  
More than a quarter (60/226) of the patients did not attempt at all. 
 
Table III                        Association between fathering a child before and after treatment 
              After treatment        
 
Before Treatment 
Fatherhood No Fatherhood No attempt Total 
      
 Fatherhood 16 7 70 93 
 No fatherhood 6 13 8 27 
 No attempt 33 13 60 106 
 Total 55 33 138 226 
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Assisted reproduction after treatment. Between orchiectomy and adjuvant treatment, sperm 
cryopreservation was offered to 121 patients. Ninety-nine patients had accepted preservation, 
and in 78 patients, the quality of the semen was viable enough to preserve15 (Table IV). 
According to Table IV, the percentage of patients who attempted preservation after request 
was significantly higher among patients who were unsuccessful in reproduction before disease 
(100%) than in those who were successful before disease (50%). The sperm quality revealed 
no significant differences between those who fathered a child or being childless both before 
and after treatment (Table IV and V). 
After treatment 13 of 78 patients (17%) attempted artificial insemination with cryopreserved 
semen (Table VI). Seven of them had been successful (including a pregnancy of 6 months in 
one couple). Two azoospermic couples managed to have a child by donor insemination. 
 
Table IV Cryopreservation before adjuvant treatment in orchiectomized patients* for 
testicular cancer. 
 Fatherhood Unfulfilled wish No attempt Total 
     
offered 32 20 69 121 
attempted 16 20 63 99 
preservation† 15 11 52 78 
     
normospermic‡ 7 4 11 22 
hypospermic 5 7 31 43 
azoospermic 1 3 6 10 
 
* one patient cryopreserved his sperm before orchiectomy of his single testicle (see also table VI). 
† according to WHO guidelines (1999) 
‡ at least 20x106/ml; 40x106; 50% motility 
 
Table V Distribution of pre-treatment sperm-analysis and wish for children after 
adjuvant treatment for testicular cancer. 
              After treatment        
 
Before treatment 
Fatherhood No Fatherhood No attempt Total 
      
 normospermic* 12 2 8 22 
 hypospermic 17 8 18 43 
 azoospermic 3** 6 2 10 
      
  
*see Table IV 
**2 patients used donor insemination 
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 Table VI. Outcome of artificial insemination after treatment. 
 Histology and 
stage 
Treatment* Fertility problems Assisted 
reproduction 
Preg-
nancy 
Birth 
      
Non-seminoma IIa  PRPLND and CT dry ejaculation IVF  Yes Yes (3 children) 
Non-seminoma IIc CT and SRPLND dry ejaculation IVF  Yes Yes (1 child) 
Non-seminoma IIc CT and SRPLND dry ejaculation IVF  Yes Yes (1 child) 
Non-seminoma IId CT and SRPLND dry ejaculation ICSI  Yes Not yet,  
(6-months pregnancy) 
Non-seminoma IIa  PRPLND and CT dry ejaculation  & azoospermic DI  Yes Yes (2 children) 
Non-seminoma IIc  CT and SRPLND anejaculation after therapy ICSI  No No 
Non-seminoma I  SV attempting > 1 year 
 (irregular cycle of the partner) 
IVF  Yes Yes  (1 child) 
 
Non-seminoma I  PRPLND Attempting > 1 year 
 
IVF  Yes Yes (twin) 
Non-seminoma IV  CT attempting> 1 year 
 
IVF  No No 
Non-seminoma I  
 
PRPLND attempting> 1 year 
 
IVF  No No 
Non-seminoma IIa  PRPLND and CT attempting> 1 year 
 
IVF  No No 
Non-seminoma IIa  PRPLND and CT Attempting > 1 year: 
(azoospermic) 
DI  Yes Yes (twin) 
Seminoma I  RT bilateral orchidectomy† ICSI  Yes Yes (2 children) 
      
Note: IVF: In-vitro fertilization; ICSI: intracytoplasmic sperm injection; DI: donor insemination. 
Quality cryoperserved sperm: 1: normospermic; 2: hypospermic; 3:azoospermic 
* See Table 2 
†First orchiectomy for small cryptorche testicle 
 
 
 
Ejaculatory function after treatment. Thirty-three patients were found to have ejaculatory 
problems after treatment (radiotherapy: 2; chemotherapy: 4; surgery: 9; combination surgery 
and chemotherapy 18). This dysfunction recovered spontaneously within one year in six 
patients and in one by using sympathomimetic drugs. Seventeen patients with an (history of) 
ejaculatory dysfunction after treatment reported a wish for children. Four patients managed to 
father a child by natural intercourse after spontaneous recovery, and 6 patients used assisted 
reproduction (Table VI). 
 
Offspring. Two hundred seventy five children were born out of 320 pregnancies. One hundred 
ninety-four children and 81 children were born before and after fathers' diagnosis of TGCT, 
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respectively. The median time between discontinuation of treatment and birth of first child 
was 46 months (range 12-143 months).  
A congenital defect was identified in 8 children born before the diagnosis (defect: schisis, 2; 
poly-dactyly, 1; bifid spine, 1; heart disease, 1; undescended testicle, 2; Werdnig-Hoffman 
disease,1) and in 3 who were born after the diagnosis (poly-dactyly, 1; heart disease, 1; 
Zellweger Syndrome, 1). No relation was found between the type of treatment of father and 
the congenital defect of the child. Also, no relation was found between the period after 
completion of treatment and the birth of child with congenital defect.  
All except three children (Werdnig-Hoffman disease, Zellweger Syndrome and leukemia) 
have been reported to develop normally up to a median age of 181 months (range 1-582 
months). 
 
Evaluation of information on fertility and sexual function given before adjuvant treatment. 
Most of the patients (63%) reported that the information given at our department was 
sufficient. In contrast, 27% considered the information poorly sufficient to insufficient, and 
10% reported they were given no information on fertility and sexual function at all.  
Most patients said that they were poorly or not informed about possible treatment-related 
and/or disease-related poor sperm quality. Consequently, three patients would have tried 
assisted reproduction when they had preserved sperm before therapy. In contrast, almost all 
patients where informed about possible ejaculatory dysfunction after surgery.  
No correlation was observed between patients’ content about the given information and their 
(un)fulfilled childwish (data not shown). 
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Discussion 
The majority of studies that suggest a direct association between subfertility and TGCT, have 
used sperm analyses instead of paternity as a parameter for fertility.3 These studies do not 
control for the contribution of the female factor in infertility and use sperm analyses as an 
algorithm for fertility. 
In our series, several hypospermic patients were able to father a child, and even two patients 
who were diagnosed as azoospermic at time of diagnosis had fathered a child before or after 
treatment, respectively. Therefore, time to conception and rate of conception per unit time are 
more valid measures of fertility.5 We evaluated the prevalence of fertility in 226 patients 
before and after treatment for TGCT and used paternity and time to conceive as indicators.   
In accordance with Fossa et al.16, 78% of the patients (93/120) with newly diagnosed 
testicular cancer had been successful in their attempts to father a child before orchiectomy. In 
the majority of the cases (66%) the partner conceived within one year (and thus were 
considered fertile). It has been stated that approximately one third of all patients seek 
paternity after treatment for TGCT and more than half of them finally succeeds.4,8 This is in 
accordance with our figures: 88 of the 226 couples (39%) attempted to reproduce, and 55 
couples succeeded. In total, 43% of the couples (38/88) conceived within one year after 
discontinuation of treatment. Compared with the prevalence figures of infertility in the 
general population (20-28%; Schimdt et al.12), it seems that patients who have been treated 
for testicular cancer have a higher risk of infertility.  
However, it is also important to take into account that maternal age17, and post-treatment 
gonadal and ejaculatory (dys)function may affect pregnancy-rate.10 First, it is well known that 
the age of the spouse is an important determinant of the man’s ability to initiate pregnancy 
because the length of time required to establish pregnancy increases with advancing maternal 
age. The decline in fertility starts in the mid-thirties.18 In our series, the median ages of the 
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females who did not achieve pregnancy before and/or after their partners’ treatment is 23.4 
and 30.2, respectively. There was no significant difference in female age between the couples 
who conceived and who did not. Although some data might be not completely accurate due to 
recollection bias (the maternal and paternal age at successful attempt is easier to recollect than 
the age at first unsuccessful attempt), the contribution of maternal age to fertility related 
problems seems to be negligible in our series.  
Second, it is well known that spermatogenesis is sensitive to the effects of chemotherapy and 
radiotherapy in a dose-dependent fashion. More than four cycles of cisplatin-based 
chemotherapy4, and radiation doses of >30 Gy will result in long-term impaired 
spermatogenesis.8 In our series, none of the patients received a dose that exceeded the above-
mentioned doses because only those patients who were included were cured after first-line 
treatment.  
Furthermore, ejaculatory dysfunction may result from retroperitoneal surgery, radiotherapy 
and/or chemotherapy. Whereas surgery may damage the postganglionic fibers of the lumbal 
sympathetic nerves, radiotherapy and chemotherapy may affect the vascular and nervous 
systems of the retroperitoneal area.19 Since the introduction of nerve-sparing surgery, the 
incidence of ejaculatory dysfunction has reduced, without compromising the staging and 
therapeutic benefit.3 Moreover, some patients may benefit from taking sympathicomimetic 
drugs. In our series, one in seven patients reported ejaculatory dysfunction. In some, assisted 
reproduction was the only option the overcome this dysfunction.  
Today, the most effective way to preserve fertility in patients with TGCT is cryopreservation 
of sperm. Even extremely poor quality semen is worthwhile to cryopreserve with the 
availability of intracytoplasmic sperm injection techniques.20 In accordance with Fossa et  
al.15, the minority (17%) of the patients opting for sperm cryopreservation later makes use of 
the option. Moreover, most patients seem to discontinue sperm banking after treatment.21 At 
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first sight, sperm-banking seems to be less effective; however, as it is not possible to predict 
the fertility status for the individual patient after treatment22, it should be recommended to 
each patient who is adjuvantly treated after orchiectomy. 
Less is known about the risk of congenital defects among offspring of male cancer survivors. 
So far, no study has reported an increased risk among the offspring of testicular cancer 
patients.10,23,24 However, it must be kept in mind that most studies (including ours) are 
hampered by low power and lacking long-term results. In our series, the percentage of 
malformations was similar before and after fathers' treatment (4%). To put this into 
perspective, congenital defects were reported among 2.2% of live-born children in general 
population.25 This difference is best explained by selection bias.  
In addition, it is suggested that sperm should not be banked during chemotherapy and 
contraceptive intercourse is advised for at least 3 to 6 months after completion of 
chemotherapy.26,27 Besides the teratogenic effect, we also advise use of contraception during 
the first year after completion of treatment for psychological reasons, because the risk of 
recurrent disease is highest during this period.14
 
 
In retrospect, 37% of the patients found the pre-treatment information on possible fertility 
problems, especially on the possibility of cryopreserving sperm insufficient. In our series, 
preservation was offered to approximately half of all patients. Moreover, three patients who 
are unfulfilled childless were very upset about not having had any information on preserving 
sperm before therapy. Today, we extensively inform every patient, and the majority opts for 
preservation.  
According to the available evidence, it was impossible to predict the fertility outcome in 
patients with testicular cancer, but in general, they seem to have more difficulty fathering a 
child after treatment compared with the case in the general population. Despite fertility 
problems, a couple of patients fathered a child after using assisted-reproductive methods. In 
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accordance with results of previous studies, an increased risk for congenital abnormalities 
among the offspring of testicular cancer patients was not observed when starting to father a 
child one year after completion therapy.  
Thus, before any treatment is offered, information must be given about possible fertility 
problems, and sperm banking should be strongly recommended for each patient, as it may 
represent an extra chance of fathering a child. 
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Abstract 
Objective. While  (partial) recovery of spermatogenesis has been observed in most of the 
testicular cancer patients after chemotherapy (ciplastin), sperm genomic integrity and its 
implication for the patient’s fertility is poorly understood.  
Methods. Semen and serum from 22 patients treated for testicular cancer were analysed pre- 
and post-chemotherapy. Besides routine semen analysis, sperm samples were evaluated by 
computerized-karyometric-image-analysis (CKIA), chromomycin-A3 assay (CMA3, 
chromatin condensation) and TdT-mediated dUTP nick-end labelling assay (TUNEL, DNA-
damage). 
Results. External sperm characteristics (CKIA morphometry) and counts did not deteriorate 
after chemotherapy. An improvement in DNA condensation was assessed after chemotherapy 
(37% vs. 50% and 47.5% vs. 63.7% for CMA3 and CKIA respectively; P<0.005) but still a 
high percentage of TUNEL positive sperm was found in the samples (21% vs. 25% for pre- 
and post-chemotherapy samples respectively). Serum FSH and LH (IU/ml) increased after 
chemotherapy compared with pre-treatment levels (8.1 vs. 16.7 and 4.5 vs 6.8; P<0.05, 
respectively).  
Conclusion. In spite of the improvement in sperm chromatin packaging after chemotherapy, 
still an abnormal percentage of DNA-damaged sperm was found in these samples.  As sperm 
quality does not reach normal levels after treatment, it remains difficult to outline the best 
strategy and guidance concerning fertility potential of testicular cancer patients.   
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Introduction 
The introduction of cisplatin-based chemotherapy has greatly improved the cure rate for 
testicular germ cell tumours.1 Because the majority of men are in the prime of their 
reproductive lives, the long-term side effects become increasingly important.2  
Gonadal dysfunction is one of the most common side effects of chemotherapy. Both the 
endocrine and exocrine compartments of the testis are affected by chemotherapy. The serum 
follicle stimulating hormone (FSH) levels seem to rise immediately after initiation of 
chemotherapy, indicating a dysfunction of the germinal epithelium.3-7 Although the Leydig 
cells of the testes are more resistant to cytotoxic damage than germinal epithelium, the 
increased luteinizing hormone (LH) levels in men suggests an endocrine dysfunction.3-7 This 
probably represents a compensatory mechanism resulting from reduced negative feedback by 
testosterone at the hypothalamopituitary level, thereby reflecting a degree of impairment of 
testosterone production by the Leydig cells. The increased levels of LH and FSH are 
suggested to maintain normal testosterone levels and support sperm production as well.3-7  
Testicular exocrine function is even more affected by chemotherapy. The differentiating 
spermatogonia appear to be most vulnerable to the cytotoxic effects of chemotherapy.2,7 
Previous studies have shown that the majority of patients with testicular germ cell tumours 
have reduced sperm counts at diagnosis and this will further deteriorate during treatment.4-16 
The duration and severity of the spermatogenic depression depends upon the dose and 
duration of chemotherapy and the baseline testis function prior to therapy.7,13 Despite an early 
depression in spermatogenesis, a reasonable number of patients show recovery within one to 
two years after treatment with variable sperm counts in their ejaculates.3,6,9-11 On this point  
knowledge about the spermatogenesis and sperm integrity pre- and post chemotherapy is 
lacking. In the first place, it is not clear whether the cancer itself is also capable of inducing 
changes in the genomic integrity of the spermatozoon. Sperm DNA-breaks induced during 
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spermiogenesis or uncompleted maturated sperm with abnormal condensed chromatin may 
contribute to high rates of damaged sperm in the ejaculate. In the second place, it is doubtful 
whether classical semen analysis (WHO criteria17,18) gives the right information about the 
status of semen from men with testis carcinoma.  
The present study was set up to obtain more information about these problems. We used both 
conventional and new methods to determine the changes in the quality of ejaculated 
spermatozoa and applied them in samples obtained before and after exposure to cisplatin-
based chemotherapy. Sperm genetic integrity, defined as normal condensed, undamaged 
DNA, was measured using three techniques: computerized karyometric image analysis 
(CKIA), proved to be an objective method to study the morphometry, DNA density and 
chromatin texture of sperm samples and individual spermatozoa.19 Chromomycin A3 (CMA3) 
and the TdT-mediated dUTP nick-end labelling assay (TUNEL) were used to assess the DNA 
condensation (packaging) and damage rate (DNA breaks) respectively.20-23  
 
Materials and Methods 
Patients and controls. The subjects of this study were patients who had  hemi-ochiectomy and 
chemotherapy in the past as a result of testicular cancer. Of these patients, frozen sperm 
samples and serum were available, both obtained between hemi-orchiectomy and subsequent 
chemotherapy. All included subjects received bleomycin, etoposide and cisplatin on a 5-day 
regimen for advanced stage of disease. All patients gave written informed consent before 
inclusion in the study. This research was reviewed and approved by the institutional ethics 
committee.  
Semen samples of anonymous normospermic donors (controls, n=13) were used as control for 
CKIA, CMA3 and TUNEL assays. 
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Collection and work-up of samples. Semen and blood samples were stored before the start of 
chemotherapy treatment. For this study, a new blood sample (20 ml in EDTA) was taken and  
stored at –400C until assayed. Also a new semen sample was collected and cryopreserved in 
liquid N2 to avoid cryopreservation bias in the assessments. The paired (before and after 
treatment) semen and blood samples were analysed at the same time except for the routine 
semen analysis parameters (determined in the fresh samples). Cryopreserved control samples 
were treated similarly as for patients. 
 
Assessment of semen parameters. Semen analysis was performed in fresh samples as 
described before.18 Shortly, concentration and motility were measured using a Makler 
counting chamber. For morphology assessment, semen was mixed on a slide  with methylene 
blue/eosin, smeared and flame-fixed. Only vital cells (eosin negative) were evaluated for 
morphology using WHO criteria (1992 for samples previous and 1999 for post chemotherapy 
samples)(WHO 1999). Furthermore, we used the computerized karyometric image analysis 
(CKIA) for the quantification nuclear sperm characteristics in the frozen samples. For a 
detailed description see Ramos et al.19 The karyometric parameters were grouped into three 
categories: 1) morphometric parameters, which describe size, form and shape of the nuclei; 2) 
densitometric parameters, related to staining intensity of DNA content; 3) chromatin texture 
parameters, related to the stain distribution pattern.  
 
Assessment DNA damage and chromatin condensation. Sperm DNA damage was evaluated 
by the TdT-mediated dUTP nick-end labelling assay (TUNEL) to evaluate the percentage of 
cells with DNA fragmentation in the total sample. The TUNEL reaction detects single and 
double DNA-strand breaks. Defects in chromatin condensation that increase the accessibility 
of the DNA to fluorochromes were detected by using chromomycin A3 (CMA3).  The more 
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positive cells for CMA3 the more poorly condensed sperm DNA was present (i.e., abnormal 
or immature cells). The results in this study are given as the percentage (and range) of normal 
condensed sperm (CMA3 negative cells) in the samples. At least 200 cells were evaluated per 
sample for the TUNEL and CMA3 staining. Our methods have been described in detail 
before. 22,23  
 
Assessment of testicular function. Testicular function was evaluated by measuring luteinizing 
hormone (LH), follicular stimulating hormone (FSH) and testosterone in serum. FSH and LH 
were determined with the fluorescence Immuno Enzymatic Assay (Abbott, USA) using the 
Random Access Analyser type AxSYM. Testosterone was measured after extraction using the 
direct Radioimmuno assay.24  
 
Statistics. The paired t test was used if the differences in a paired set of data were normally 
distributed, if not normally distributed the Wilcoxon signed rank test was used. Correlations 
between continuous variables were estimated using Pearson product-moment correlation 
coefficients. 
 
Results 
Patients. From a total of 51 patients with stored sperm and serum obtained before the start of 
chemotherapy, 22 agreed to participate in the study. The relevant patient characteristics are 
summarized in Table I. 
 
Table I   Patient characteristics 
  
Number of patients 22 
Median age (range in years) 31.2 (22.2-41.6) 
Median time between end of treatment and 2nd 
semen preservation (range in months) 
48.2 (18.4-84.8) 
  
Histology  
-non-seminoma 19 
-seminoma 3 
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Routine semen analyses. The effect of chemotherapy on routine sperm parameters is shown in 
Table II.  
 
 
Table II Routine semen analyses before and after chemotherapy 
  Median before 
chemotherapy 
(range) 
Median after 
chemotherapy 
(range) 
p-value* 
    
Volume (ml) 3.1 
(0.8-7.2) 
2.1 
(0.5-7.0) 
0.02 
Sperm concentration (106/ml.) 24.5 
(0.5-160.0) 
30.0 
(0-200.0) 
0.33 
Total sperm count (106) 57 
(0.9-425.0) 
65 
(0.0-300.0) 
0.94 
% motile sperm 50.0 
(10.0-75.0) 
55.0 
(7.0-80.0) 
0.33 
% normal morphology 41 
(9.0-64.0) 
16 
(2.0-37.0) 
** 
    
 
% of patients with oligo-and 
azoospermia 
 
50% / 0% 
 
32% / 9% 
 
 
** 
% of patients with teratospermia 22% 47% 
 
** 
 
*   All calculated by the Wilcoxon signed rank test 
** Criteria for evaluation differed in time: 1992 and 1999 WHO criteria in samples before 
and after chemotherapy respectively 
 
 
The only statistical significant difference found was a lower ejaculate volume after 
chemotherapy. Because of the different criteria used in the evaluation of morphology (shift to 
a more strict evaluation criteria for the post chemotherapy samples), no statistical evaluation 
for the conventional morphology was performed. The decrease in the percentage cells with 
normal morphology after chemotherapy is probably not only due to a poorer spermatogenesis 
but also to technical changes. Using the cut-off values for teratospermia considered in our 
centre at the time of evaluation, 22% and 47% of the samples presented teratospermia before 
and after completion chemotherapy respectively. Two patients became azoospermic after 
chemotherapy treatment (9%). 
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Sperm DNA analyses. In Table III, the results obtained by CKIA, CMA3 and TUNEL are 
shown.  
 
Table III. Semen damage before and after chemotherapy 
 Median before 
chemotherapy 
(range in %) 
Median after 
chemotherapy 
(range in %) 
p-value* Control 
Group 
(N=13) 
 
CKIA 
    
normal morphometry 30.9 
(17.0-53.0) 
28.6 
(18.0-56.0) 
0.78 53.9 
(41.1-66.0) 
normal DNA condensation 47.5 
(28.0-85.0) 
63.7 
(24.0-94.0) 
0.005 81.3 
(73.5-89.9) 
normal chromatin texture 39.0 
(19.0-88.0) 
50.6 
(15.0-89.0) 
0.23 69.4 
(53.1-88.6) 
total normal cells 7.8 
(0.8-81.2) 
10.4 
(0.0-60.0) 
0.40 40.5 
(29.6-53.1) 
 
CMA3     
defect chromatin condensation 63.0 
(40.0-88.0) 
50.0 
(26.0-90.0) 
0.001 30.2  
(9.0-45.0) 
     
TUNEL     
Damaged cells 21.0 
(8.0-66.0) 
25.0 
(10.0-47.0) 
0.48 9.7 
(4.0-14.0) 
     
CKIA: Computerized karyometric image analysis; CMA3: chromomycin A3; TUNEL: TdT-mediated dUTP 
nick-end labeling assay. 
*All calculated by the Wilcoxon signed rank test 
 
The percentage of cells with normal morphometry by CKIA was equally distributed before 
and after treatment. Sperm DNA condensation improved significantly after chemotherapy 
according to CKIA and CMA3 assays (the percentage of CMA3 positive cells, i.e. abnormal 
condensed cells, was lower after chemotherapy). The number of DNA damaged cells 
(TUNEL positive) did not statistically change after chemotherapy treatment. Nevertheless, 
both percentages (chromatin condensation and DNA damaged cells) were significantly 
different (abnormal) for patients compared with controls. 
 
Hormone analyses. Elevated serum FSH and LH was measured after chemotherapy compared 
with pre-treatment levels (Table IV) without a significant change in the testosterone level. 
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There was a positive correlation between LH and FSH level both before (r = 0.99; P < 0.01) 
and after treatment (r = 0.87; P < 0.01). No correlation between testosterone and LH or FSH 
was found. 
 
Table IV. Hormone analyses before and after chemotherapy 
 Median before 
chemotherapy (range) 
Median after 
chemotherapy 
(range) 
p-value 
    
FSH (IU/L)1 8.1 
(0.2-49.3) 
16.7 
(3.5-62.1) 
0.003* 
LH (IU/L)2 4.5 
(0.2-27.0) 
6.8 
(1.3-32.5) 
0.04* 
Testosterone (nmol/L)3 18.7 
(1.7-44.0) 
15.8 
(6.7-26.0) 
0.15 
    
Reference range in our laboratory: 1) 1.5 – 7.5 IU/L; 2) 1.4 – 8.5 IU/L; 3) 11 – 45 nmol/l. 
*Calculated by the Wilcoxon signed rank test 
 
 
 
Discussion 
 
In this study, the effect of cisplatin-based chemotherapy (<400 mg/m2) was evaluated by 
using conventional semen parameters and DNA-integrity related tests in sperm samples of 
testicular cancer patients. It was found that treatment with cisplatin has no effect on sperm 
count and morphometric characteristics of spermatozoa. On the other hand, an improvement 
in sperm DNA condensation with elevated rates of DNA damage was observed after 
treatment, which was still abnormal compared to fertile semen samples.  
Recent literature is in agreement with our findings. After completion of chemotherapy, 
(partial) recovery of spermatogenesis occurs within two years and may continue thereafter. 2,5-
7,9-11,16 In our series, sperm concentration and total sperm count were not significantly affected 
after chemotherapy and approximately 50% of the patients still had at least 20*106 sperm 
cells/ml, with only 2 (9%) patients presenting azoospermia. These observations are all made 
after using mild chemotherapy (<400 mg/m2). In patients receiving more than 400 mg/m2 
total dose cisplatin a significant decrease in spermatogenesis has been described.13 
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Not only chemotherapy causes impairment of the spermatogenesis. In the literature has been 
described that 50-70% of the testicular cancer patients were subfertile or had impaired 
spermatogenesis before start of chemotherapy.8,9 This impaired spermatogenesis was neither 
related to stage of disease nor with the duration and severity of symptoms attributed to 
testicular cancer.4,9,10 This study confirms that a minority of patients who have been hemi-
orchiectomized for testicular cancer are normospermic at the time of diagnosis. Berthelsen 
and Skakkebaek showed that in 24% of their cases there were irreversible changes such as 
spermatogenic arrest (azoospermia) and in over half of the remaining patients there was a 
potentially reversible depression of spermatogenesis.25 
There are two major limitations of the routine semen analysis. In the first place there is a lack 
of standardisation and there is a significant observer bias.26-28  In the second place, the 
standard morphology analysis does not describe the integrity of the sperm DNA. To bypass  
the observer bias in the morphology analysis, we evaluated sperm morphology with computer 
qualitative measurements: CKIA. CKIA also gives information about sperm DNA 
condensation and chromatin texture. With this technique we found that although the external 
features in the morphometric parameters were equally distributed before and after 
chemotherapy, there were changes in internal characteristics (DNA stainability and 
condensation). Abnormal sperm DNA condensation is known to be adversely correlated to 
male fertility potential.21,29 In spite of the significant increase of cells with normal DNA 
condensation after chemotherapy, chromatin condensation as indicated by low CMA3 values 
(<60% negative) and CKIA is still poor if compared with normal donors. With respect to 
DNA damage, no adversely effect was measured as a result of chemotherapy. For this result 
also counts that the patient group scored significantly higher than the fertile donors. These 
observations support the study by O’Donovan who used propidium iodide for DNA 
condensation measurements.30 In our series none of the sperm samples had normal CMA3 
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values before start of chemotherapy, in contrast to 8 of 22 patients after chemotherapy. 
Available literature does not offer an obvious explanation for this observation. Based on 
animal studies, we hypothesize that spermatogonia with abnormal chromatin, as a 
consequence of the disease, might be more susceptible to chemotherapy, thus being 
eliminated by treatment.31 The remaining normal and more viable germ cells (spermatogonia) 
are responsible for the partial restoration of spermatogenesis after a recovery time. More 
research is necessary on this point, not in the last place to enable effective treatment: 
abnormalities in chromatin condensation may contribute to failures in sperm decondensation 
after penetration into the oocyte and subsequently result in fertilization failure.21 In the 
literature controversial results has been published on sperm DNA damage in testicular cancer 
patients. Stahl et al reported a significantly lower DNA damage among 16 patients compared 
with controls (healthy males) after completion of chemotherapy (7.3% vs. 11%; P = 0.028) by 
the use of the sperm chromatin structure assay.32 Gandini et al. reported a significant increase 
of DNA fragmentation in 30 testicular cancer patient postorchiectomy compared to healthy 
controls (11% vs 2.5%).33 Despite the fact that chromatin is better packed after treatment, no 
decrease in the percentage of sperm DNA damaged cells was observed and remained high 
compared with healthy controls. This is in accordance with the results obtained by 
O’Donovan with use of the Comet assay.30 Our results led us to postulate that there might be 
an intratesticular alteration in the apoptotic control system as reaction to neoplastic cell 
proliferation or that the chemotherapeutic treatment might affect removal of abnormal sperm 
by apoptosis. Consequently, damaged cells that should have been eliminated during 
spermatogenesis can be found in the ejaculates (abortive apoptosis).20,34  
Normal spermatogenesis also depends on normal endocrinologic balance. Testosterone, 
regulated by LH, is an absolute requirement for normal spermatogenesis. Our study 
demonstrated that standard doses of chemotherapy do not lead to a significant decrease of the 
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testosterone level. However, the LH values were significantly elevated, indicating a 
compensatory reaction to decreased Leydig cell function and resulting in the mentioned 
constant testosterone level. 3-7 In agreement with others we found biochemical evidence of 
germinal epithelial failure of the contra-lateral testis, indicated by increased FSH levels after 
treatment.3-7 The observed correlation between LH and FSH is not surprising given the 
relative susceptibility of Leydig cells and germinal epithelium to damage and suggests 
interaction between each other.3  
There is no doubt that testicular cancer and its treatment have serious impact on gonadal 
function in these young patients.35 Fertility is therefore a major concern, and health care 
providers are increasingly aware of the need to improve the quality of life of cancer patients 
by maintaining their reproductive capacity. In the past, recovery of high sperm counts were of 
main concern for effective treatment and this reduced the fatherhood chances of many 
patients.6,11 With the advent of assisted reproduction by ICSI it is now possible to offer a good 
chance of conception in all men with a low sperm count. Now a second problem arises: 
theoretically there is a possible risk of genetically transferred disease in the offspring as a 
result of the selection of spermatozoa with increased DNA damage.36  In animal models there 
is already evidence for this risk.37 In humans, an increase in the number of autosomal and sex 
chromosome aneuploidy was reported in sperm samples after chemotherapy, but genetic 
consequences to offspring are not yet known.38,39 In any case we have to conclude that the 
genetic effects of cancer and cancer treatment on sperm needs to be kept in perspective, 
meaning that we have to be careful in treatment and follow up of their offspring. 
In conclusion, sperm count and morphometry (CKIA) was not affected in the majority of 
patients treated with chemotherapy for testicular cancer. Although an improvement in the 
chromatin condensation was found in sperm, the percentage of DNA damaged cells did not 
decrease after chemotherapy. Sperm DNA integrity in general remained poor compared to 
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healthy controls. It should be elucidated whether the observed changes in sperm integrity 
represents a real post-chemotherapy removal of an abnormal germ cell subpopulation or 
whether the post-chemotherapy matured sperm presents other types of genomic damage not 
detectable by the current methods. Although our results call for further investigations, it 
seems prudent to evaluate semen from cancer patients not only by routine analysis as external 
characteristics of spermatozoa do not necessarily correlate with their DNA integrity. 
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The management of germ cell tumours of the testis (TGCT) has proved to be a model of 
success in terms of survival. The improved prospects of cure are attributed to the appropriate 
integration of a better understanding of the natural history of germ cell tumours, improved 
diagnostic and surgical techniques and last but not least effective platinum-based combination 
chemotherapy. Because the majority of patients are cured by first-line treatment, attention has 
turned to reduction of morbidity by altering therapeutic protocols in selected subsets of 
patients. This thesis focuses on refinements in the management of germ cell tumours in the 
platinum era. 
 
The first part of this thesis focuses on risk factors in the management of TGCT. Testicular 
cancer is most commonly diagnosed between the ages of 20 and 44 years and it is among this 
subgroup that the age-adjusted incidence has risen markedly in many Western populations 
over the past half-century.1 Lately, much research has focused on familial and hereditary 
factors in search for risk factors for developing testicular cancer. Chapter 1 presents the 
incidence of malignant tumours in first-degree relatives of patients with testicular cancer in 
the eastern part of the Netherlands. Brothers of testicular cancer patients seem to have a 5.9-
fold increased risk for developing testicular cancer. In contrast, first-degree relatives of 
testicular cancer patients do not seem to be prone to non-testicular cancer. We recommend 
further investigations in testicular cancer families to map candidate genes for testicular 
cancer. 
In contrast to the rise in incidence improved management has led to a markedly decline in age 
adjusted mortality rates. To date, the overall 5 year relative survival rate is in excess of 90%.2 
In chapter 2, we used the follow-up data from Surveillance, Epidemiology, and End Results 
cancer registries in the United States to examine whether testicular cancer patients older than 
50 years of age have a worse disease-specific survival than patients younger than 50 years of 
age, as observed in The Netherlands. In the United States, a lower stage- and morphology-
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adjusted relative survival rate was observed in patients older than 50 years of age with 
testicular cancer. This difference was more evident in metastasized disease. Whether the 
worse prognosis in testicular cancer can be explained by a lower tolerance to chemotherapy 
and/or to a reduced treatment in elderly has to be established. This study suggests that elderly 
patients might be undertreated one way or another, and therefore it justifies inclusion of 
elderly into future clinical trials and treatment in tertiary centres. 
 
The second part of this thesis provides three studies regarding a rational approach in the 
management of clinical stage I non-seminomatous germ cell cancer (NSGCT). To date, 
patients with clinical stage I nonseminomatous germ cell cancer can expect survival to 
approach 100%.3 The achievement of these excellent results has resulted into research for 
refinements in treatment without compromising the cure rates. In chapter 3 an update is 
presented of the current available treatment alternatives for low stage nonseminomatous germ 
cell tumours: surveillance, primary surgery, or primary chemotherapy. 
Today, there is an ongoing and increasing controversy regarding the management of these 
patients. Interestingly, the dichotomy of views toward the surgical versus the conservative 
approach has worldwide geographic trends. In the United States there is a strong urological 
surgical tradition, whereas in Europe the conservative approach is generally favoured. 
Unfortunately, this controversy about the optimal choice of management has been 
exacerbated by a lack of comparative data, mainly caused by geographic different choices in 
treatment. In the Netherlands, the University Medical Centre (UMC) in Nijmegen is the only 
hospital that performs primary retroperitoneal lymph node dissections in low stage NSGCT. 
In chapter 4, we compared the results of the two currently available treatment options in the 
Netherlands: primary surgery at the Department of Urology at the University Medical Centre 
Nijmegen or surveillance at the Departments of Urology and Oncology of the Netherlands 
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Cancer Institute/Antoni van Leeuwenhoek Hospital Amsterdam. Although this study was 
performed retrospectively, we believe that both groups were well balanced not only for 
clinical and pathological parameters but also for the period of follow-up. Furthermore, the 
strength of this study was that the choice of treatment is independent on health insurance 
policy and the travel distance to the hospital (important for compliance, especially in 
surveillance protocol). Both options provided excellent overall survival close to 100%. Given 
these comparable outcomes, selection of the most appropriate treatment regimen could not be 
guided by survival considerations. The choice of treatment seems to depend on regional 
factors related to the local expertise and treatment availability and the patient-related factors.  
In fact, the current controversy is driven by the performance characteristics of the presently 
available staging methods. About 20-30% of the patients with clinical stage I NSGCT are 
understaged by clinical staging and appear to have pathological stage II disease at lymph node 
dissection. The choice of treatment would be facilitated if the likelihood of presence of occult 
disease could be increased. In chapter 5, we evaluated prognostic risk factors in 50 
consecutive clinical stage I NSGCT patients to identify patients at high and low risk for occult 
metastatic disease. The prognostic value of histological factors, such as vascular invasion, 
tunica albuginea invasion, presence of embryonal cell carcinoma, alpha-catenin expression 
and the tumour DNA-content were evaluated. In 14 patients (28%) occult metastatic disease 
in the lymph node specimen was detected, and one patient developed a lung metastasis within 
3 months after diagnosis. In multivariable logistic regression analysis only vascular invasion 
and tunica albuginea invasion were predictive of occult disease. The absence of embryonal 
cell carcinoma (n=11), diploid (n=3) and polyploid (n=2) tumours correlated with 
pathological stage I disease. However, the numbers are small. Meticulous analysis of 
prognostic indicators, might individualize the management of stage I NSGCT. Nevertheless, 
for the group of low stage patients it is important to have independent, reliable and 
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reproducible prognostic markers. In the literature, vascular invasion is the best reproducible 
marker and is currently being used to stratify patients into low and high risk for occult 
disease.4-6 The presence of vascular invasion in the primary tumour increases the risk for 
occult disease to 50%, whereas its absence implies a risk of approximately 10%. To date, we 
(UMC Nijmegen, the Netherlands) advise high-risk patients to undergo a retroperitoneal 
lymph node dissection, and surveillance to low-risk patients. 
 
The third part of this thesis discusses the potential role of 18-Fluoro-Deoxy-Glucose 
Positron Emission Tomography (18FDG-PET) in different staging aspects of testicular germ 
cell tumours. To date, the diagnostic work-up of patients with testicular tumours remains a 
difficult clinical challenge. Not only in primary staging of low stage non-seminomatous 
disease (see part II), but also in re-staging after chemotherapy for advanced testicular cancer, 
it is of great interest to identify patients who require surgery and those who do not in order to 
optimise individual treatment. After the completion of chemotherapy, residual viable tumour 
lesions are found in up to 15% of patients with seminomas,7 to 20% of patients with NSGCT.8 
Furthermore, in 40% of the residual non-seminomatous masses, also mature teratoma is 
found.8 Because radiologic criteria derived from the conventional imaging methods have 
failed to differentiate reliably between the histologic entities, definitive differentiation is 
possible only with histological examination of the resected specimen. Improvement of non-
invasive methods would allow avoidance of unnecessary surgery. 
Positron Emission Tomography imaging using 18Fluoro-Deoxy-Glucose (18FDG-PET) is a 
new diagnostic technique that has the potential to distinguish viable cancerous tissue from 
non-viable (fibrosed or necrotic) tissue. In general terms, tumour cells are characterized by a 
higher glucolytic rate than normal tissue cells. PET exploits this difference by assessing the 
rate of 18Fluoro-Deoxy-Glucose uptake in the tumour. Because the metabolic activity alters in 
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cancer well before structural changes occur, 18FDG-PET has proven to be useful both in 
detecting small nodules in non-small-cell lung cancer,9 and monitoring the changes in 
treatment response before any changes become apparent with anatomy-based imaging 
modalities.10 
In chapter 6, we evaluated the value of 18FDG-PET in both primary staging of low stage 
NSGCT tumours and in re-staging of advanced germ cell tumours after chemotherapy. In 
primary staging of low stage non-seminomatous germ cell cancer 18FDG-PET has no 
additional value over abdominal computed tomography, because small pathologic nodes and 
mature teratomas of any size are not detected. In re-staging after chemotherapy, PET results 
are hampered by false-negative and false-positive findings; a negative PET may represent 
either necrosis, mature teratoma or very small (<5 mm) viable carcinoma, whereas a positive 
PET represents viable carcinoma or inflammatory processes. 
The main resource of false-negative findings in the residual mass was the presence of mature 
teratoma, probably caused by equal metabolism of the mature teratoma compared to normal 
tissue. In our series, the diagnostic efficacy of 18FDG-PET could be improved when patients 
with no mature teratoma in the primary tumour were excluded from analysis. Unfortunately, 
this finding could not be confirmed in a larger series.11 Because seminomatous germ cell 
tumours do not contain teratomatous elements, a negative PET-scan might have additional 
value in staging the residual mass after chemotherapy.12,13 Secondly, a limitation of 18FDG-
PET is its inability to detect very small tumorous lesions in primary staging and in re-staging 
after chemotherapy. 
Because 18FDG is not a tumour specific agent, also false-positive findings might occur.14 It is 
known that macrophages, present in inflammatory processes, also accumulate 18FDG. To 
reduce this phenomenon, the interval between completion of treatment and PET examination 
was required to be at least three weeks.15 However, in our series it even occurs after 6 weeks. 
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In conclusion, larger series have to elucidate the definitive clinical value of 18FDG-PET in re-
staging of residual seminomatous germ cell cancer. The first results are conflicting regarding 
a positive PET-scan, in contrast to a negative scan result which is suggestive for fibrotic 
residual mass.12,13 There seems to be no benefit of 18FDG-PET in any staging of non-
seminomatous germ cell cancers. 
Another utility of PET is monitoring response to treatment. Assessing the tumour response 
after the start of treatment might be a useful parameter to distinguish responders from non-
responders: successful therapy can be maintained and ineffective treatment can be suspended 
and other options considered. To date, 18FDG-PET has been applied to monitor response in 
other tumours such as lung, brain, breast and colorectal tumours, but has not yet been used in 
daily practice.10 In chapter 7, we evaluated the value of serial 18FDG-PET in monitoring the 
response of advanced testicular germ cell tumours to chemotherapy. This pilot study shows 
that 18FDG-PET has a limited, if any role, in the therapeutic monitoring of low risk testicular 
cancer and does not provide significant incremental information to structural imaging and 
measurement of serum tumour markers.  
 
The fourth part of this thesis embraces the different aspects of follow-up in management of 
patients with testicular cancer. For patients with testicular germ cell cancer, long-term, close 
surveillance has traditionally been the “sine qua non” of post-treatment care. In the past, these 
patients have usually been treated within the context of a clinical trial in which close follow-
up protocols were used to evaluate the results. With the introduction of cisplatin-based 
combination chemotherapy regimens, dramatic improvements in survival have been seen and 
established the “Bleomycin, Etoposide and cisPlatin” regimen as the new standard.16 
Although a lot of effort has been taken to optimise the chemotherapy regimen for the different 
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risk-group of patients,17-19 little attention has been paid to the role of follow-up in the 
management of testicular cancer.  
In chapter 8, we evaluated the value of routine follow-up for the detection of recurrent 
disease after curative treatment of testicular cancer. This study clearly shows that the risk for 
recurrent testicular cancer depends on primary therapy and the response to it, and indicates a 
response-to-treatment guided approach of the follow-up protocol. Abdominal and thoracic 
computed tomography provided no additional value in patients, treated at the retroperitoneum 
for low-stage disease and followed by chest X-ray. In this group of patients, two years of 
routine follow-up seems to be sufficient. Furthermore, there seems to be a limited role for 
follow-up in patients, adjuvantly treated with chemotherapy for pathological stage IIa 
nonseminmatous disease, and in patients who are histologically proven free of disease after 
chemotherapy. Although these data advocate a less intensified follow-up protocol, we believe 
prospective randomised trials or mathematical decision models are needed to justify response-
to-treatment guided follow-up schedules in testicular cancer. 
In chapter 9, we evaluated the efficacy of different follow-up regimens on disease-specific 
mortality (DSM) and life-expectancy (LE) of patients on surveillance for clinical stage I 
nonseminomatous disease. The optimal design to study this issue would be a randomised trial. 
However, such a trial would require both physicians and patients to be compliant during a 
long period of follow-up while less intensive policies may be considered unethical without 
clear evidence that these are equally effective. Alternatively, mathematical decision models 
can mimic randomised trials without being hampered by its’ practical disadvantages. We used 
a Markov model to compare the efficacy of the surveillance protocol of the European 
Association of Urology (EAU), the Netherlands Cancer Institute/Antoni van Leeuwenhoek 
hospital (NCI/AvL) and a hypothetical minimal protocol (i.e. follow-up limited to the first 
two years) with each other: comparing with the EAU protocol (DSM: 3.05%; LE: 53.3 years), 
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the more intensive NCI/AvL protocol leads to a 1.2% lower DSM and a 6 months higher LE 
(DSM: 1.81%; LE: 53.9 years). The hypothetical follow-up scenario during the first two years 
shows a DSM of 6.83% and a LE of 51.4 years. In conclusion, the logistical and economical 
benefits of a less intensive follow-up protocol as proposed by the EAU compared to that of 
the NCI/AvL must be balanced against the increase in disease specific mortality rate from 2 to 
3%. In view of the high survival rate in clinical stage I NSGCT, this difference is enormous. 
Follow-up limited to the first two years only will result in an unacceptably high percentage of 
death from disease.  
Until prospective randomized trials have been performed to evaluate the efficacy of different 
protocols, our model may help physicians to understand the anticipated effects of different 
follow-up protocols on long-term survival of patients on surveillance for clinical stage I 
nonseminomatous disease.  
 
The last part of this thesis deals with fertility aspects in the management of germ cell tumour 
of the testis. Because of the long-term survival of these young man, limiting disease- and 
treatment-related complications such as infertility becomes increasingly important. Prior to 
the discussion of the relation between testicular cancer and infertility, it is salient that most 
studies have used semen analysis and not necessarily the definition of infertility as the gold 
standard. Infertility is defined by the American Society of Andrology as the inability to 
conceive after one year of unprotected intercourse. In the general population, the prevalence 
of infertility varies between 20- and 28%.20 In chapter 10, we estimated the prevalence of 
infertility before and after treatment for testicular cancer. Infertility was reported by 34% of 
the patients before disease, whereas by 57% after treatment. Although it seems to be more 
difficult to father a child after treatment, none of the treatment modalities in particular 
influenced this outcome. Because it is not (yet) possible to predict which patient will have 
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fertility problems after treatment, cryopreservation should be offered to every testicular 
cancer patient before the start of treatment. In our series, 18% of the couples used 
cryopreserved semen to deliver a child after treatment. In accordance with other published 
series, no increased risk for congenital malformations was observed among the children 
before and/or after treatment for testicular cancer of their father. 
In the last chapter we evaluated the influence of cisplatin-based chemotherapy on the quality 
of ejaculated spermatozoa. Serum hormone levels, routine semen sample including qualitative 
measurements by computer analysis (CKIA) and sperm DNA integrity (sperm DNA damage 
and condensation) were compared before and after exposure to chemotherapy. 
Increased levels of LH are found after chemotherapy to maintain normal testosterone levels 
and the increased FSH suggests evidence of germinal epithelial failure of the contralateral 
testis. 
The sperm count and morphometry (CKIA) was not affected in the majority of patients 
treated with chemotherapy for testicular cancer. Although an improvement in the chromatin 
condensation was found in sperm, the percentage of DNA damaged cells did not change after 
chemotherapy. Overall, the Sperm DNA integrity remained poor compared to healthy 
controls. It should be elucidated whether the observed changes in sperm DNA represents a 
real post-chemotherapy removal of an abnormal germ cell subpopulation or whether the post-
chemotherapy matured sperm presents other types of genomic damage not detectable by the 
current methods. Although our results call for further investigations it seems prudent to 
evaluate semen not only by routine analysis in case of ICSI as external characteristics of 
spermatozoa do not necessarily hold the same internal structures post-chemotherapy. 
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Treatment results of testis cancer have improved dramatically over the last 25 years, with 
overall cure rates for individuals with low stage disease approaching 100% and more than 
80% for patients with advanced disease. The present cure rates illustrate that significant 
diagnostic, chemotherapeutic and surgical advances have transformed testicular cancer from a 
once fatal disease into an oncological success story. To date, the challenge is to pursue 
therapeutic methods that further increase the overall cure rates while decreasing the 
disadvantages associated with treatment.  
The current controversy in the treatment of testicular germ cell tumours is mainly driven by 
the performance characteristics of presently available clinical staging methods. Clinical 
staging is hampered by both the inability to detect micrometastatic disease and the inaccuracy 
to distinct residual malignant from non-malignant disease. 
Because 70% of patients with a clinical stage I non-seminomatous germ cell cancer have no 
metastatic disease, a central issue relates to the stratification into true stage I disease, which 
should be cured with orchiectomy alone versus true stage II disease requiring adjuvant 
treatment. In low stage non-seminomatous germ cell cancer, advances in technology are 
focused on lowering the false-negative rate of clinical staging. Because the sensitivity of 
conventional imaging studies is inversely proportional to tumour volume, other non-invasive 
staging methods have been developed to detect micrometastatic disease. The principle of 
18Fluor-Deoxy-Gluose Positron Emission Tomography has the potential to detect altered 
metabolic activity in cancer before structural changes occur. In low stage germ cell cancer, 
this technique did not have additional value over CT in the early detection of micrometastatic 
disease. To date, other 18F-labelled tracers have been developed, but have not yet been tested 
in clinical staging.1 
Another non-invasive staging method, that has been developed to detect micrometastatic 
disease but has not yet been implemented into testicular cancer research, is the combination of 
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magnetic resonance imaging with the intravenous injection of ultra-small super paramagnetic 
iron oxide particles. This technique has been shown to detect small metastatic lymph nodes in 
prostate- and urinary bladder cancer2 and should, therefore, be tested in the detection of 
lymphogenic micrometastases in germ cell tumours. 
To my opinion, the detection of even smaller lesions is an unending challenge, as detection of 
microscopic disease is probably not possible by any clinical imaging method. To date, 
retroperitoneal lymph node dissection still the most accurate staging method. In an effort to 
decrease the morbidity associated with open lymph node dissection, several centres have 
applied laparoscopic surgical techniques to assess the presence of micrometastatic disease.3-6 
Moreover, to locate the sentinel node more accurately during laparoscopy, 
lymphoscintigraphy using intratesticular radiocolloid administration might be feasible.7,8 
Although laparoscopy might replace open surgery as a staging tool, it has not yet proven its 
therapeutic capability. In all studies 3-6 chemotherapy had been administered at detection of 
stage II disease. Since deferred treatment of patients with pathologic stage II disease is 
usually successful, as employed in surveillance series, what would be the benefit of 
laparoscopy? In other words, if the intent is to treat retroperitoneal-only disease with 
chemotherapy, why not enter the patient into surveillance protocol and treat him with 
chemotherapy not before clinical relapse? The future will reveal the definitive place of the 
laparoscopy in management of low stage non-seminomatous disease. 
Despite research in clinical staging, in 30% of the cases microscopic disease is still missed. 
Several studies have evaluated predictive variables in the primary tumour to predict the 
presence or absence of metastatic disease. The presence of embryonal cell carcinoma and 
vascular invasion in the primary tumour are established risk factors for micrometastatic 
disease. However, many of these studies have limitations, in that the populations studied were 
selected and the parameters used to predict metastasis may suffer from interobserver 
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variability. To define a paradigm that is more useful in the prediction of pathologic stage, 
prospective studies comparing consecutive, unselected patients managed by retoperitoneal 
lymphadenectomy versus surveillance is needed. Furthermore, it is unclear whether or not 
patients with such risk factors necessarily have poor outcome if they are managed 
aggressively at diagnosis (surgery or primary chemotherapy) as compared with their outcome 
if they are managed by surveillance.  
As long as we are not able to identify patients with or without (increased risk of) microscopic 
metastasis, controversy in the management of low stage disease will persist. Consequently, 
the ultimate method to evaluate the best choice of treatment at the moment would be a 
randomised trial comparing surveillance, lymphadenectomy and primary chemotherapy by 
using proper long-term survival analysis as well as cost, toxicity, fertility, work-performance, 
and quality of life parameters.  
 
The diagnostic work-up of patients with residual mass after chemotherapy remains another 
clinical challenge. Because it is not possible to discriminate between malignant and non-
malignant residual disease on radiologic imaging, there is no alternative but to submit all 
these patients for surgery. It would be of utmost benefit, if we could distinguish responders 
from non-responders after chemotherapy. In this thesis, 18FDG-PET has been applied to 
monitor response during and after chemotherapy for disseminated germ cell tumours. 
Although PET has the ability to monitor treatment response in low risk non-seminomatous 
germ cell tumours, it does not provide significant additional value to structural imaging. 
Further studies targeting patients with intermediate to high-risk profiles might have additional 
value, as the a priori likelihood of response is less favourable. Although the future 
applications of PET in cancer management seem to be promising, the additional value of 
18FDG-PET in testicular cancer is limited. Because FDG is not a tumour specific and sensitive 
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marker in testicular cancer, results were hampered by false-positive observations 
(inflammatory processes) and false-negative observations (mature teratoma, and 
micrometasis). Hopefully, new 18F-ligands will improve the accuracy of PET in the 
management of testicular germ cell tumours.1  
 
In general, follow-up after treatment for cancer is assumed to be beneficial. With the 
improved treatment possibilities in patients with testicular cancer, it is time to focus on the 
real value of follow-up in the management of these patients. In this thesis we have identified a 
subgroup of patients who might benefit from less extensive follow-up schemes. Furthermore, 
we have developed a computer model to evaluate the impact of follow-up on the overall 
survival rate of patients on surveillance for low stage non-seminomatous disease. This thesis 
provides data to evaluate the value of follow-up in low stage disease and in patients with 
complete response after chemotherapy in a prospective randomised trial. In addition, it is 
worth looking at psychological stress, as it is assumed to be related to follow-up, but this has 
never really been assessed prospectively.  
 
There is no doubt that testicular germ cell cancer and the treatment of this disease both have 
serious impact on the gonadal function in these young patients. Further research is needed to 
elucidate the best objective parameter for semen quality. Our present knowledge should force 
us to counsel these men about fertility-aspects and the possibilities for cryopreservation.  
With the increased possibilities of assisted reproduction, a multi-disciplinary approach is 
recommended for the testis cancer patient with fertility problems instead of treatment for 
cancer at the urology department and treatment for fertility at the departments of fertility and 
gynaecology.  
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Furthermore, the issue of a theoretical risk of inborn errors in children fathered by these 
patients after treatment has not yet been clarified. Clinical investigations do not indicate such 
a risk, but the present studies have been small and careful registration of sufficient numbers of 
cases and sufficient follow-up of children is needed to determine the real risk of inborn errors. 
 
Finally, in the more distant future improved understanding of the biology and genetics of 
germ cell tumours will lead to new therapeutic targets and approaches. By discovering the 
genetic alternations involved in testicular cancer development, gene therapy and new 
molecular markers may become a reality. Hopefully, genetic-based therapy may lead to less 
toxicity while maintaining the same efficacy.  
 
In the last three decades great strides have been made in treating germ cell tumours, but it is 
likely that future advances will occur in smaller steps that aim to fine tune the management of 
germ cell tumours of the testis. Despite the fact that a small percentage of the male population 
will develop germ cell cancer of the testis and the majority will survive today, we should 
continue research to further optimize the management of testicular cancer. In this way testis 
cancer could be a therapeutic milestone in treatment of other cancers. We encourage financial 
support to future trials. 
The seeds of death have become the seeds of concern and will return the seeds of ……live? 
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Deze samenvatting geeft een overzicht van de inhoud van dit proefschrift zodanig dat niet-
medici een overzichtelijk en begrijpelijk beeld krijgen van zaadbalkanker. 
 
Zaadbalkanker neemt slechts 1% van alle maligne aandoeningen bij de man voor haar 
rekening. Jaarlijks wordt in ons land bij ongeveer 500 mannen zaadbalkanker vastgesteld. In 
de leeftijdscategorie van 20 tot 35 jaar komt zaadbalkanker het meest voor. 
 
De meeste mannen bij wie zaadbalkanker wordt vastgesteld, hebben zelf een verandering aan 
een zaadbal geconstateerd. Deze verandering bestaat uit een vergroting van de zaadbal en/of 
een verharding in de zaadbal, waardoor deze anders aanvoelt. Bij verdenking op 
zaadbalkanker dient zowel echografie van de zaadbal als bloedanalyse naar tumormakers 
(bèta-humaan choriogonadotrofine; alfa-foetoproteïne en lactaatdehydrogenase) te worden 
verricht. Als de uitkomsten van de echografie en het bloedonderzoek op zaadbalkanker 
wijzen, dient de zaadbal via het lieskanaal te worden verwijderd. 
 
Het wegnemen van de zaadbal is het begin van de behandeling. Nader onderzoek wijst uit om 
wat voor type zaadbalkanker het gaat: een seminoom, een nonseminoom of een combinatie 
van beide. Daarnaast wordt de uitgebreidheid van de ziekte, met behulp van een CT-scan, 
vastgelegd in het zogenaamde stadium: 
 
Stadium I: De ziekte zit alleen in de zaadbal. 
Stadium II: De ziekte zit in de zaadbal en in de lymfklieren onder het middenrif. 
Stadium III: De ziekte zit in de zaadbal en in de lymfklieren onder en boven het middenrif. 
Stadium IV: De ziekte zit in de zaadbal en heeft zich uitgezaaid naar andere organen. 
Grootte van de uitzaaiing: a: <2cm; b: 2 – 5cm; c > 5cm. 
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De combinatie van het type en het stadium van de kanker bepaalt de soort behandeling. Bij 
een seminoom in de stadia I en IIa wordt standaard radiotherapie gegeven. In de stadia groter 
dan IIa wordt standaard chemotherapie gegeven. Chemotherapie kan in sommige gevallen 
worden gevolgd door een verwijdering van het restant aan tumorweefsel. Bij een 
nonseminoom in stadium I bestaat de behandeling vaak uit ‘wait and see’ of preventieve 
verwijdering van de lymfklieren onder het middenrif. In geval van ‘wait and see’ wordt de 
patiënt geruime tijd zeer regelmatig gecontroleerd. Bij een nonseminoom in de stadia II, III en 
IV wordt vrijwel altijd chemotherapie gegeven en wanneer er dan nog restweefsel resteert, 
wordt dit operatief verwijderd. 
 
De geneeskans bij zaadbalkanker hangt af van het type zaadbalkanker en van het stadium 
waarin de ziekte wordt ontdekt. De kans dat een patiënt met zaadbalkanker geneest, is 
tegenwoordig groot. Negentig procent van alle patiënten kan worden genezen en heeft 
vervolgens een normale levensverwachting. Na afloop van de behandeling wordt jarenlang 
gecontroleerd of de ziekte niet terugkeert.  
 
Door de vaak jonge leeftijd van de patiënt en de goede prognose na behandeling heeft de 
kwaliteit van leven een steeds belangrijker plaats ingenomen in het management van deze 
ziekte. Met name de fertiliteit is een belangrijk aspect bij deze jonge mannen. Bij de 
behandeling met zowel radiotherapie, chemotherapie als operatieve verwijdering van 
tumorweefsel kan verminderde vruchtbaarheid optreden. Soms is dat blijvend. Patiënten die 
nog kinderen willen krijgen, kunnen het beste vóór het begin van de behandeling sperma laten 
invriezen.  
 
Sinds de intrede van platinum-bevattende chemotherapie in de tachtiger jaren is 
zaadbalkanker, wat daarvoor nog voor de meeste patiënten het doodvonnis betekende, één van 
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de best te behandelen kankersoorten geworden. Door verbeterde overleving is de nadruk in de 
behandeling van zaadbalkanker meer komen te liggen op vermindering van de bijwerkingen 
zonder de goede prognose aan te tasten. Dit proefschrift beschrijft de zoektocht naar 
verfijningen in het management van zaadbalkanker in het chemotherapie tijdperk.  
 
Het eerste gedeelte van dit proefschrift beschrijft een tweetal epidemiologische factoren in 
het management van zaadbalkanker. De incidentie van zaadbalkanker neemt toe in West-
Europa. In Nederland steeg de incidentie met 40 procent in de periode 1990-2000. Tot op 
heden is er geen duidelijke verklaring voor deze stijging gevonden. Wel is bekend dat er een 
verhoogde kans op zaadbalkanker aanwezig is bij mannen van wie de testikels niet op 
natuurlijke wijze in de balzak zijn ingedaald. Mogelijk is er ook sprake van erfelijke aanleg. 
Het eerste hoofdstuk beschrijft de incidentie van kwaadaardige aandoeningen onder 
eerstegraads familieleden van patiënten met zaadbalkanker in Oost-Nederland. Broers van 
patiënten met zaadbalkanker hebben een 5.9 maal verhoogd risico op het ontwikkelen van 
zaadbalkanker. Daarentegen is er geen verhoogd risico op het ontwikkelen van andere 
vormen van kwaadaardige aandoeningen onder eerstegraads familieleden. Om nader inzicht 
te krijgen in de rol van erfelijkheid bij het ontstaan van zaadbalkanker is bestudering van de 
overerving van genen in deze ‘zaadbalkanker’ families noodzakelijk.  
In diezelfde periode (1990-2000) is het aantal mannen dat aan zaadbalkanker overleed 
gedaald van 38 naar 25 per jaar. Uit gegevens van de Nederlandse Kankerregistratie blijkt dat 
patiënten met zaadbalkanker die ouder dan 50 jaar zijn een slechtere prognose hebben dan 
patiënten jonger dan 50 jaar. In hoofdstuk twee wordt gekeken of dit verschil ook aanwezig 
is in de grotere kankerregistratie database van de Verenigde Staten van Amerika 
(Surveillance, Epidemiology and End Results cancer registries). Ook hier werd een lagere 
overlevingskans (gecorrigeerd voor uitgebreidheid en type van zaadbalkanker) waargenomen 
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voor patiënten ouder dan 50 jaar. Met name oudere patiënten met uitzaaiingen bleken een 
slechtere prognose te hebben. Het is onduidelijk of dit het gevolg is van verminderde 
tolerantie voor chemotherapeutische behandeling of dat oudere patiënten een minder 
uitgebreide behandeling hebben ondergaan. In ieder geval worden oudere patiënten op een of 
andere manier onderbehandeld, wat mijns inziens pleit voor inclusie van oudere patiënten in 
toekomstig onderzoek.  
 
In het tweede gedeelte van dit proefschrift wordt een drietal studies gepresenteerd 
betreffende een rationele benadering van klinisch stadium I nonseminoom. Ter 
verduidelijking, klinisch stadium I nonseminoom wil zeggen dat hoewel er bij screening met 
CT-scan geen lymfklieruitzaaiingen zijn aangetoond er bij 30% van deze patiënten toch 
micro-uitzaaiingen in de lymfklier aanwezig zijn.  
Patiënten met klinisch stadium I nonseminoom hebben een te verwachte overlevingskans van 
bijna 100%, ongeacht keuze van behandeling. Hoofdstuk drie presenteert een uitgebreid 
overzicht van de drie huidige therapiekeuzes in klinisch stadium I nonseminoom: ‘wait and 
see’, lymfklierdissectie, of chemotherapie. De eerste twee behandelingmethodes zijn alom 
gerespecteerd. Chemotherapie wordt alleen nog in onderzoeksverband gebruikt. De 
tweedeling in therapiekeuze heeft een geografische verdeling. In de Verenigde Staten van 
Amerika wordt, als gevolg van de traditionele chirurgische benadering van ziekte, de 
operatieve benadering gepropageerd, terwijl in Europa met name conservatieve benadering 
(‘wait and see’) wordt nagestreefd. Door de geografische tweedeling is er een gebrek aan 
goede vergelijkende studies. In Nederland is het Universitair Medisch Centrum in Nijmegen 
het enige ziekenhuis dat lymfklierdissectie verricht in klinisch stadium I nonseminoom.  
In hoofdstuk vier worden de huidige twee behandelingsmethoden voor klinisch 
nonseminoom stadium I in Nederland met elkaar vergeleken: lymfklierdissectie verricht door 
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de afdeling urologie van het Universitair Medisch Centrum in Nijmegen of ‘wait and see’ 
geadviseerd door afdeling urologie en oncologie van het Nederlands Kanker Instituut/Antoni 
van Leeuwenhoek ziekenhuis te Amsterdam. Alhoewel het een retrospectieve studie betreft, 
zijn beide groepen vergelijkbaar qua grootte, klinische parameters en follow-up periode. 
Onafhankelijk van therapiekeuze is de overlevingskans ook in Nederland bijna 100%. De 
keuze van behandeling lijkt met name te worden bepaald door de voorkeur van de 
behandelend arts, de lokale mogelijkheden voor behandeling en patiënt gerelateerde factoren. 
In feite wordt de tweedeling in behandelingsvoorkeur veroorzaakt door de huidige 
stadiëringscapaciteit van de CT-scan. De keuze van behandeling wordt vereenvoudigd 
wanneer de kans op het waarnemen van aanwezigheid of afwezigheid van micro-uitzaaiingen 
kan worden vergroot. In hoofdstuk vijf wordt bij 50 patiënten met klinisch stadium I 
nonseminoom gezocht naar prognostische risicofactoren voor de aanwezigheid of afwezigheid 
van micro-uitzaaiingen in lymfklieren. In 14 patiënten (28%) werden micro-uitzaaiingen 
vastgesteld en 1 patiënt ontwikkelde binnen 3 maanden na zaadbalverwijdering een uitzaaiing 
in de long. Bij analyse (multivariate logistische regressie analyse) blijken vasculaire invasie 
en tunica albuginea invasie in de primaire tumor (d.w.z. de zaadbal) voorspellend te zijn voor 
micro-uitzaaiingen. De afwezigheid van enkele factoren (embryonaal cel carcinoom (n=11), 
diploïdy (n=3) en polyploïdy (n=2)) werd daarentegen geassocieerd met de afwezigheid van 
micro-uitzaaiingen.  
Uit literatuurgegevens blijkt, overeenkomstig onze studie, dat vasculaire invasie de meest 
betrouwbare en reproduceerbare prognostische marker is. Bij aanwezigheid van vasculaire 
invasie in de primaire tumor is er 50% kans op micro-uitzaaiingen in de lymfklieren, tegen 
maar 10% bij afwezigheid. Het huidige beleid in Nijmegen is gebaseerd op de aan- of 
afwezigheid van vasculaire invasie in de primaire tumor. Bij aanwezigheid adviseren we een 
lymfklierdissectie, maar bij afwezigheid wordt een “wait and see” beleid gevolgd. 
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In het derde gedeelte van dit proefschrift wordt de rol van 18-Fluoro-Deoxy-Glucose 
Positron Emissie Tomografie (18FDG-PET) in stadiëring van zaadbalkanker besproken. De 
stadiëring van zaadbalkanker is belangrijk aangezien dit de behandelingsstrategie bepaalt. 
Daarnaast vindt re-stadiëring na chemotherapie plaats, om het effect van chemotherapie te 
evalueren en te besluiten of er nog aanvullende chirurgie noodzakelijk is. Na chemotherapie 
wordt in 15% van de seminomen7 en 20% van de nonseminomen8 nog een restmassa met 
actieve tumorcellen gevonden. Nog eens 40% van de nonseminomen bevat bovendien matuur 
teratoom (premaligne aandoening).8 Met andere woorden, na chemotherapie is 85% van de 
seminomen en 40% van de nonseminomen vrij van (pre)maligne cellen. Aangezien de CT-
scan geen onderscheid kan maken tussen maligne en niet-maligne weefsel, wordt uit voorzorg 
restant weefsel na chemotherapie verwijderd. Een aantal patiënten wordt dus achteraf bekeken 
onnodig geopereerd. 
18FDG-PET is een nieuwe diagnostische techniek om actieve cellen (kankercellen) van niet-
actieve cellen te onderscheiden. De werking van 18FDG-PET is gebaseerd op glucoseverbruik 
van de cel. Cellen met een verhoogde stofwisselingsactiviteit, zoals kankercellen, zullen meer 
18FDG opnemen dan cellen met een lagere activiteit. Met behulp van een PET-scan kan de 
verhoogde activiteit worden waargenomen. Omdat uitzaaiingen in de lymfklier niet direct 
hoeven te leiden tot een kliervergroting, heeft visualisatie van het metabolisme een 
theoretische meerwaarde ten opzichte van een anatomische weergave, zoals bij de CT-scan.  
18FDG-PET heeft op deze manier een additioneel effect bij de stadiëring van kleincellig 
bronchuscarcinoom.9 Daarnaast blijkt dat het behandelingsresultaat eerder wordt 
waargenomen dan met de CT-scan.10 
In hoofdstuk zes wordt de waarde van 18FDG-PET geëvalueerd in zowel primaire stadiëring 
van stadium I en IIa nonseninomen als in re-stadiëring van (non)seminomen (stadium >IIa) na 
behandeling met chemotherapie. In primaire stadiëring heeft 18FDG-PET geen additionele 
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waarde aangezien noch kleine uitzaaiingen noch grotere uitzaaiingen met premaligne cellen 
(matuur teratoom) worden gedetecteerd. In re-stadiëring van nonseminomen na 
chemotherapie blijken de resultaten van 18FDG-PET negatief te worden beïnvloed door 
foutpositieve en foutnegatieve bevindingen: een negatieve PET-scan kan geen onderscheid 
maken tussen necrose (littekenweefsel), matuur teratoom (premaligne weefsel), en erg kleine 
tumorcellen(<5 mm); een positieve PET scan daarentegen kan indicatief zijn voor zowel een 
actieve tumor als een actief ontstekingsproces. 
De voornaamste oorzaak voor foutnegatieve bevindingen is de aanwezigheid van matuur 
teratoom. Matuur teratoom heeft een gelijke stofwisselingsactiviteit als normaal weefsel, en 
wordt daarom niet waargenomen. In onze serie kon de effectiviteit van 18FDG-PET worden 
verhoogd door die patiënten met matuur teratoom in de primaire tumor (zaadbal) uit te sluiten 
van analyse (matuur teratoom in primaire tumor geeft ook vaak matuur teratoom in de 
uitgezaaide lymfklier). Deze subanalyse kon helaas niet worden bevestigd in een grotere 
serie.11 Bij seminomen komt per definitie geen teratoom voor, en hier lijkt een rol weggelegd 
voor de PET-scan: een negatieve PET-scan bij restadiëring van seminoom na chemotherapie 
suggereert littekenweefsel.12,13  
Een tweede oorzaak voor een foutnegatief resultaat is dat de 18FDG-PET, net zoals de CT 
scan, niet in staat is om zeer kleine uitzaaiingen op te sporen. 
Omdat 18FDG niet tumorspecifiek is, kunnen ook foutpositieve waarnemingen plaatsvinden.14 
Het is bekend dat macrofagen, de zogenaamde afweersysteemcellen, ook 18FDG stapelen. 
Verhoogde macrofaag activiteit wordt met name gezien bij afbraakprocessen, zoals afbraak 
van dode cellen na chemotherapie bijvoorbeeld. Om kans op foutpositieve waarneming te 
verminderen wordt geadviseerd PET-scanning tenminste drie weken na beëindiging van 
chemotherapie te verrichten.15 In onze serie werd zelfs na 6 weken nog verhoogde afbraak 
waargenomen. Concluderend, grotere series zijn nodig om de definitieve rol van 18FDG-PET 
Samenvatting en Discussie 
 
 
 
 255
in stadiëring van zaadbalkanker (met name seminomen) te bepalen. Mijns inziens is er geen 
rol voor 18FDG-PET weggelegd in primaire stadiëring en herstadiëring van nonseminomen.   
Een ander aspect van PET scanning is de mogelijkheid van therapiemonitoring. Het meten 
van tumor respons na behandeling biedt de mogelijkheid om vroegtijdig een onderscheid te 
maken tussen responders en non-responders. In geval van respons wordt de behandeling 
voortgezet en bij een non-responder kan de ineffectieve behandeling worden gestaakt, waarna 
andere opties kunnen worden overwogen. In onderzoeksverband is therapiemonitoring met 
behulp van 18FDG-PET reeds verricht bij andere tumoren zoals die van long, borst, hersenen 
en darm.10  
In hoofdstuk zeven wordt de waarde van opeenvolgende 18FDG-PET scans in 
chemotherapiemonitoring voor uitgezaaide zaalbalkanker geëvalueerd. Deze pilot studie toont 
aan dat een tussentijdse 18FDG-PET scan nauwelijks van toegevoegde waarde is in het 
voorspellen van het therapieresultaat.  
 
Het vierde gedeelte van dit proefschrift behelst verschillende aspecten van follow-up na 
behandeling van zaadbalkanker. Follow-up is in het algemeen bedoeld om een recidief in een 
vroeg stadium vast te stellen, om zodoende de behandeling bij een zo laag mogelijk 
tumorvolume te kunnen starten. Het is de “sine qua non” van nazorgse behandeling. In het 
verleden werden de follow-up schema’s met name gebruikt om het resultaat (effectiviteit en 
bijwerkingen) van verschillende soorten chemotherapie te evalueren. Na de introductie van 
platinum-bevattende chemotherapie is de overlevingskans drastisch verbeterd, en werd de 
combinatie chemotherapie bestaande uit “Bleomycine, Etoposide and Platinum” de gouden 
standaard in de behandeling van uitgezaaide zaadbalkanker.16  Nadien is er veel aandacht 
besteed aan het optimaliseren van dit chemotherapie schema,17-19 daarentegen is er maar 
weinig aandacht besteed aan de rol van follow-up. 
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In hoofdstuk acht wordt de rol van routinematige follow-up in detectie van een recidief testis 
carcinoom bekeken. De kans op recidiverende ziekte blijkt afhankelijk van de ingezette 
primaire behandeling en de therapierespons op deze behandeling. Dit suggereert een 
“response-to-treatment” gerelateerde benadering van het follow-up schema. Een CT-scan van 
thorax en abdomen heeft geen toegevoegde waarde voor patiënten die behandeld zijn met 
radiotherapie of chirurgie voor zaadbalkanker stadium I of IIa en nadien vervolgd met 
röntgenfoto’s van de longen. Voor deze groep van patiënten lijkt de follow-up duur van twee 
jaar voldoende. Daarnaast lijkt er maar een beperkte rol voor follow-up weggelegd voor die 
groep van patiënten die 1) nadat de kwaadaardige lymfklieren zijn verwijderd en aanvullend 
behandeld zijn met chemotherapie (nonseminoom IIA) of die groep van patiënten die 2) eerst 
chemotherapie hebben gekregen voor uitgezaaide ziekte en vervolgens een chirurgische 
verwijdering van wat naar achteraf bleek niet pathologische restmassa. In beide 
patiëntgroepen werd geen recidiverende ziekte ontdekt. 
Hoewel deze gegevens een mindere stringent follow-up schema suggereren, denk ik dat alleen 
prospectieve gerandomiseerde studies of simulatie analyse een “response-to-treatment” 
gerelateerd follow-up schema kunnen rechtvaardigen. 
In hoofdstuk 9 wordt de effectiviteit van verschillende “wait and see” schema’s in klinisch 
stadium I nonseminoom geëvalueerd ten aanzien van levensverwachting (LV) en 
ziektespecifieke sterfte (ZSS). Om de ware effectiviteit van follow-up te evalueren is een 
gerandomiseerd onderzoek nodig wat follow-up versus geen follow-up met elkaar vergelijkt. 
Maar dit stuit op ethische bezwaren aangezien follow-up niet bewezen ineffectief is. 
Bovendien vereist zo’n onderzoek compliante patiënten. Als alternatief kunnen computer 
modellen (simulatie analyse) gebruikt worden, die het effect van verschillende schema’s 
kunnen nabootsen zonder belemmerd te worden door bovengenoemde nadelige effecten van 
gerandomiseerd onderzoek. Een Markov model werd ontwikkeld en gebruikt om de 
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effectiviteit van verschillende “wait and see” schema’s met elkaar te kunnen vergelijken: 
schema van “the European Association of Urology” (EAU) versus schema van “Het 
Nederlands kanker Instituut/Antoni van Leeuwenhoek ziekenhuis” (NKI/AvL) versus een 
hypothetisch minimaal follow-up protocol gedurende de eerste twee jaar. 
Het intensievere NKI/AvL schema (ZSS: 1.81%; LV: 53.9 jaar) leidt tot een 1.2% lagere 
ziektegerelateerde sterfte en een 6 maanden langere levensverwachting vergeleken met het 
EAU schema (ZSS: 3.05%; LV: 53.3 jaar). Het hypothetische minimaal follow-up protocol 
heeft een ZSS van 6.83% en een LV van 51.4 jaar. Concluderend, het voordeel van mindere 
intensive follow-up volgens de EAU, in vergelijking met NKI/AvL, moet worden afgewogen 
tegen een stijging van ziektespecifieke sterfte van 2% naar 3%. Follow-up alleen de eerste 
twee jaar heeft een onacceptabel hoog ziektespecifieke sterfte tot gevolg. Totdat 
gerandomiseerde onderzoeken zijn verricht, geeft dit model een indicatie van wat de gevolgen 
kunnen zijn van een veranderd follow-up schema in “wait and see” beleid van klinisch 
stadium I nonseminoom. 
 
Het laatste gedeelte van dit proefschrift behelst fertiliteitaspecten bij zaadbalkanker. 
Doordat veruit de meeste patiënten genezen van zaalbalkanker worden ziekte- en 
behandelingsgerelateerde complicaties, zoals infertiliteit, steeds belangrijker. Een saillant 
detail is dat vele studies semenanalyse hebben gebruikt als indicator voor (in)fertiliteit bij 
patiënten met zaadbalkanker, terwijl volgens de “American Society of Andrology” infertiliteit 
wordt gedefinieerd als het onvermogen om binnen één jaar zwanger te raken bij onbeschermd 
seksueel contact. De prevalentie van infertiliteit onder de algemene bevolking varieert tussen 
de 20 en 28%.20 
In hoofdstuk tien wordt de prevalentie van infertiliteit voor en na behandeling van 
zaadbalkanker geschat. Vóór de behandeling rapporteerde 34% van de patiënten infertiliteit, 
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tegen 57% na de behandeling. De infertiliteit na behandeling bleek onafhankelijk van 
behandelingskeuze. Na behandeling gebruikte 18% van de mannen ingevroren zaad voor 
bevruchting. In overeenstemming met literatuurgegevens werd er onder de nakomelingen van 
patiënten met zaadbalkanker geen verhoogd percentage aangeboren afwijkingen gevonden. 
Kortom, aangezien het niet mogelijk is te voorspellen welke patiënt fertiliteitproblemen zal 
hebben na de behandeling van zaadbalkanker, dient elke patiënt de mogelijkheid te worden 
geboden om van tevoren zaad te laten invriezen. 
In het laatste hoofdstuk wordt de kwaliteit van geëjaculeerd sperma (inclusief serum 
hormoon analyse, routinematige en computergestuurde zaadanalyse (CKIA), sperma DNA 
schade en sperma DNA condensatie) voor en na de behandeling met platinum-bevattende 
chemotherapie met elkaar vergeleken. Tevens werden de uitkomsten vergelijken met de 
zaadkwaliteit van gezonde controlepersonen.   
Verhoogd concentratie LH zorgt voor een compensatoir gelijkblijvende testosteron 
concentratie, en een verhoogde FSH waarde suggereert epitheelschade aan de gezonde 
contralaterale bal. Routinematige zaadanalyse en morfometrie volgens CKIA lieten geen 
veranderingen in zaad kwaliteit zien voor en na chemotherapie. Hoewel er een verbetering in 
chromatine condensatie van het zaad werd gevonden, was er geen afname in DNA 
beschadigde cellen. In vergelijking met zaad van gezonde controle personen blijft de sperma 
DNA kwaliteit matig. Het is onduidelijk of de verbeteringen in sperma DNA kwaliteit alleen 
het gevolg zijn van verwijdering van kwaadaardige cellen of dat er nog op andere niveaus 
schade aan sperma DNA aanwezig is dat we niet gedetecteerd hebben. 
Niettemin lijkt het raadzaam om sperma ook op DNA niveau te bekijken met name in geval 
van geassisteerde voorplanting, aangezien de externe karakteristieken van sperma, gemeten 
bij routinematige zaadanalyse, niet overeenkomen met de interne karakteristieken (DNA 
analyse). 
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De prognose voor patiënten met zaadbalkanker is enorm verbeterd in de afgelopen 25 jaar, 
waarbij bijna 100% van de patiënten met een laag stadium en 80% van de patiënten met een 
vergevorderd stadium de ziekte overleeft. Toekomstig onderzoek is gericht op enerzijds het 
vergroten van de totale overleving en anderzijds het verminderen van bijwerkingen van 
behandeling. 
 
Een belangrijk aspect van de vermindering van de bijwerkingen van behandeling vormt de 
juiste keuze tot behandeling. De huidige controverse met betrekking tot behandeling van laag 
stadium zaadbalkanker wordt met name veroorzaakt door beperkingen in visuele 
diagnostiek, zoals het onvermogen om micro-uitzaaiingen te detecteren. Dertig procent van de 
patiënten met een klinisch stadium I nonseminoom blijkt stadium IIa te hebben. Aangezien de 
sensitiviteit van huidige beeldvormende diagnostiek omgekeerd evenredig gerelateerd is aan 
tumorvolume, zijn andere vormen van diagnostiek ontwikkeld om micro-uitzaaiingen op te 
sporen.  
Het principe van 18Fluor-Deoxy-Glucose Positron Emissie Tomografie (18FDG-PET) is 
gericht op detectie van verhoogde stofwisselingsactiviteit nog voordat structurele 
veranderingen, zoals toename in weefselgrootte, plaatsvindt. Helaas bleek in laag stadium 
nonseminoom geen meerwaarde voor PET-scanning boven de conventionele CT-scan 
aanwezig. De meerwaarde van andere ontwikkelde tracers dan 18FDG in PET-scanning zijn 
nog niet getest in primaire diagnostiek van laag stadium nonseminoom.1 
Een andere niet invasieve stadieringmethode, die met succes ontwikkeld is om micro-
uitzaaiingen van prostaat en blaaskanker op te sporen, is de combinatie van MRI en 
intraveneuze injectie van extreem kleine super paramagnetische ijzeroxide partikels.2 Deze 
methodiek is nog niet toegepast bij zaadbalkanker. 
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Ongeacht welke klinische stadieringsmethode wordt gebruikt, denk ik dat het niet mogelijk is 
om microscopische ziekte te visualiseren. Ook heden ten dage blijft verwijderen van 
lymfeklieren en aansluitend histopathologisch onderzoek onder de microscoop de meest 
accurate stadieringsmethode. In een poging om de morbiditeit van open lymfeklierdissectie te 
verminderen, zijn een aantal centra begonnen met laparoscopische verwijdering van deze 
lymfeklieren, de zogenaamde kijkoperatie.3-6 Om de betreffende afwijkende klier nog 
nauwkeuriger te kunnen opsporen wordt bovendien door een enkeling radioactieve stof in de 
primaire tumor gespoten wat vervolgens wordt opgenomen door de drainerende lymfeklier. 7,8 
Hoewel laparoscopie de open chirurgie kan vervangen als stadieringsmethode, is het 
onduidelijk of het even effectief is in therapeutische zin. In alle tot nu toe uitgevoerde studies 
werd na de detectie van micro-uitzaaiingen een aanvullende behandeling met chemotherapie 
gegeven. 3-6 Het is bekend dat behandeling van stadium II zaadbalkanker goed te behandelen 
is met chemotherapie alleen, zoals blijkt uit de “wait and see” studies. Met andere woorden, 
als het de bedoeling is om pathologische lymfeklieren te behandelen met chemotherapie, 
waarom dan geen “wait and see” beleid voeren en chemotherapie starten in geval van klinisch 
bewezen uitzaaiing? De toekomst zal uitwijzen wat de rol van laparoscopie in laag stadium 
nonseminoom zal zijn. 
Een andere methode om de huidige stadiering te verfijnen is het analyseren van verschillende 
prognostische markers in de primaire tumor. Deze manier van analyse stoelt op het concept 
dat primaire tumoren vaak al in een vroeg stadium van ontwikkeling alle eigenschappen 
bezitten die nodig zijn om te metastaseren. De aanwezigheid van met name vaatinvasie leidt 
tot een 50% kans op micro-uitzaaiingen. Veel reeds verrichte studies herbergen een selectie 
en interobserver bias. Om de definitieve rol van prognostische markers in laag stadium 
nonseminoom vast te stellen is een prospectieve studie nodig. Bovendien is het niet duidelijk 
of patiënten met een verhoogde kans op micrometastasen een slechtere prognose hebben 
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wanneer primair agressief behandeld (lymfeklierdissectie of chemotherapie) in vergelijking 
met het “wait and see” beleid. 
Zolang we niet in staat zijn om patiënten op klinische gronden accuraat te onderscheiden in 
stadium I en II, zal controverse in behandeling blijven voortbestaan. De beste keuze van 
behandeling zal dan alleen tot uitdrukking kunnen komen door een gerandomiseerde trial 
waarin “wait and see”, lymfeklierdissectie en primaire chemotherapie onderling worden 
vergeleken op grond van levensverwachting, prognostische markers, bijwerkingen, kosten, en 
kwaliteit van leven. 
 
Herstadiering na chemotherapie blijft ook een uitdaging. Aangezien het op radiologische 
gronden niet mogelijk is kwaadaardig restweefsel van niet-kwaadaardig restweefsel te 
onderscheiden, is er geen ander alternatief mogelijk dan bij alle patiënten het restweefsel te 
verwijderen. Een grote winst zou het opleveren wanneer we de responders van de non-
responders konden onderscheiden. In dit proefschrift werd de aanvullende waarde van 18FDG-
PET in monitoring de response op chemotherapie bekeken. Hoewel 18FDG-PET response kan 
meten, had het geen aanvullende waarde ten opzichte van de CT-scan. Misschien dat het 
enige waarde heeft in agressievere vormen van zaadbalkanker (dwz. zaadbalkanker met hoge 
concentratie serum tumormarkers of met uitgebreide uitzaaiingen). Hopelijk kunnen de 
nieuwe 18F-gelabelde tracers de stadiering van zaadbalkanker verbeteren.1  
 
Follow-up na behandeling van kanker wordt in het algemeen als nuttig ervaren. De vraag is 
echter, wat is de waarde van follow-up na behandeling van zaadbalkanker. Zoals eerder in dit 
proefschrift is beschreven is de effectiviteit van follow-up niet voor elke patiënt hetzelfde. De 
effectiviteit hangt vooral af van de soort en het stadium van de ziekte en de daarop toegepaste 
behandeling. Maar ook in dezelfde categorie van ziekte (bijvoorbeeld laag stadium 
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nonseminoom) blijkt verandering in follow-up schema, gesimuleerd door een computer- 
programma, grote invloed te hebben op de mortaliteit. Met andere woorden er is genoeg reden 
om een prospectief gerandomiseerd onderzoek te verrichten naar de effectiviteit van follow-
up schema’s, vooral in de groep van laag stadium nonseminoom en in de groep van complete 
responders na chemotherapie. Bovendien is het nuttig om eens prospectief de psychologische 
stress te evalueren van follow-up na zaadbalkanker, aangezien dit vaak wordt verondersteld 
maar nooit is bewezen. 
 
Het is bekend dat zaadbalkanker en de behandeling ervan fertiliteitproblemen kunnen 
veroorzaken. Juist daarom moeten wij als artsen, ons ertoe dwingen patiënten niet alleen 
informatie te geven over de ziekte zelf maar ook over de fertiliteit aspecten en de 
mogelijkheid tot cryopreservatie. Door de toegenomen mogelijkheden van geassisteerde 
voortplanting denk ik dat we zaadbalkanker meer multidisciplinair moeten benaderen. Nu 
wordt nog de ziekte door de uroloog en de fertiliteitproblematiek door de gynaecoloog 
behandeld. 
Daarnaast is het nog steeds niet duidelijk of er nu een verhoogde kans op afwijkingen 
aanwezig is bij het nageslacht van patiënten, die behandeld zijn voor zaadbalkanker. De 
onderzoeken, die tot nu toe zijn verricht, tonen geen verhoogd risico aan, maar daarbij dient 
de kanttekening te worden gemaakt, dat het kleine studies zijn met een korte follow-up tijd. 
Kortom, nader onderzoek is gewenst. 
 
In de nabije toekomst zal voortschrijdend inzicht in biologie en genetica van zaadbalkanker 
mogelijk leiden tot een nieuwe therapeutische benadering en behandeling. Wanneer de 
lokalisatie van veranderingen in het DNA van zaadbalkanker kan worden opgespoord, is het 
misschien ook mogelijk nieuwe moleculaire markers en zelfs gentherapie te ontwikkelen. 
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Nieuwe markers zouden een bijdrage kunnen leveren aan risicogerelateerde behandeling en 
gentherapie is misschien minder belastend maar net zo effectief als de huidige chemotherapie. 
 
Mijn conclusie luidt dat in de laatste drie decennia grote stappen voorwaarts zijn gemaakt in 
het management van zaadbalkanker, waarschijnlijk zullen de stappen in de toekomst kleiner 
zijn om het management te optimaliseren.  
Ongeacht het feit dat zaadbalkanker relatief weinig voorkomt en het overgrote deel van de 
patiënten overleeft, moeten we onderzoek voortzetten om het management van deze ziekte 
verder te maximaliseren. Het management en de ontwikkeling van behandelingstrategie van 
deze ziekte kan als voorbeeldfunctie dienen voor de behandeling van andere tumoren. Daarom 
moedigen we financiële ondersteuning voor toekomstig onderzoek aan. 
Het zaad des doods is geworden tot zaad vol met zorg en zal weer worden tot zaad des 
…levens? 
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Promoveren betekent letterlijk voortbewegen, voortgaan ( pro – movere). De reis die ik heb 
gemaakt begon in 2000 en heeft me langs vele illustere personen gevoerd. Zij hebben mij 
kortere of langere tijd vergezeld en hen wil ik bedanken voor de geboden hulp, raad en 
levenswijsheid om dit boekje tot stand te brengen. 
 
Prof. dr. J.A. Witjes, beste Fred, jij bent de grondlegger geweest van dit boekje. De twaalf 
losse regels die je me overhandigde op een half A viertje, met daarop enkele gedachtespinsels 
heb ik gekoesterd alsof het de twaalf geboden waren. En zie hier het resultaat: een elftal 
artikelen. Dank!  
De reis die we samen maakten heeft ons langs Nijmegen by Night gevoerd. Samen op 
stap een drankje drinken en een hapje eten bij de Mc Donalds: De bediende vroeg als eerste 
aan mij “wat mag het zijn?”, waarop ik antwoordde: “Voor mij graag een Big Mac en voor 
mijn vader ook één”. 
Prof. dr. L.A.L.M. Kiemeney, beste Bart, ik heb je als de best denkbare criticaster en 
ondersteunende begeleider ervaren, wanneer jij (uiteindelijk) goedkeuring gaf aan het 
manuscript streepte ik weer een van de twaalf geboden door. 
Beste Bart, met jou heb ik een reis gemaakt op zoek naar de puurheid van het 
onderzoek waarbij jouw begrip en verstand van zaken zoveel sneller zijn dan het mijne, dat ik 
nog wel eens dreigde te verdwalen in het duistere woud van de statistiek. Dank! 
Prof. dr. W.J.G. Oyen, beste Wim, we hebben vele vruchtbare gesprekken gevoerd over de rol 
van PET scanning bij testis tumor. Ondanks de indrukwekkende stapels werk op je bureau en 
de gecorrigeerde artikelen, die je nog moest verwerken, had je altijd tijd voor me.   
De reis die we hebben gemaakt bestond uit spaarzame minuten relaxend, de boel de 
boel latend, achterover leunend in de stoel genieten van een dikke pluim. Vo. 
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Prof. dr. S. Horenblas, beste Simon, dank voor de interesse in mijn onderzoek en beoordeling 
van het manuscript. 
Terwijl we buiten in de zon op een stoepje zaten en een tweetal uur over de 
behandeling van stadium I nonseminoma hadden gepraat, sprak je voor mij de memorabele 
woorden:  “onderzoek:  the less the much” (Horenblas, EAU Brussel, 2000). 
Dr. J. van Moorselaar, beste Jeroen, jouw interesse in en enthousiasme voor de urologie 
werken aanstekelijk.  
Ik waardeer zeer de moeite die je hebt genomen om naar Nijmegen te komen om ons 
onderzoek de laatste push te geven die het nodig had en ik zal de keren niet vergeten dat ik je 
bezocht in Utrecht met de zoveelste versie van mijn artikel: we begonnen met koffie en 
eindigden met filosoferen over de urologie en het gecorrigeerde artikel ontving ik enkele 
dagen later per post. Gezellig. 
Aswin Hoffmann, dank voor de onvoorwaardelijke hulp bij het ontwikkelen van het follow-
up model. Het project zou 3 weken gaan duren, maar door ons perfectionisme het zo 
realistisch mogelijk overeen te laten komen met de werkelijkheid, heeft het 2 jaar geduurd.  
Ontspannend en vooral verhelderend waren de voettochten door de bossen van 
Malden; uiteindelijk werden daar de meeste analyse problemen geattackeerd. 
Beste UIC/BME-ers: Tommy, Michiel, John, Jos, Bennie, Mark, Tjerk, Pim, Reza en Floor, 
dank voor de ontspannende lunches en voor jullie frisse kijk op aardse zaken. 
Tommy wanneer gaan we op reis? De congresbezoeken aan Brussel en Genève 
bezorgen me nu nog hoofdpijn.  
Michiel, bedankt dat ik in je kielzog mocht meeliften naar eindbestemming promotie 
(mijn vervoersmiddel had een lagere maximum snelheid). 
De dames en heer van het fertiliteitslaboratorium: beste Liliana, Hanny, Leonie en Alex, ook 
al doet mijn naam vermoeden dat ik er verstand van heb, door jullie ben ik beter gaan 
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begrijpen wat sperma precies betekent: “een kiemcel op wereldreis”. Dank voor de vele 
zaadanalyses. 
Marc Kicken en Bob Gosselt, de dinsdagavonden in het café “St. Anneke” hebben een 
ontspannend en geestverruimend karakter gehad. Top! 
Ik vraag me nog steeds af hoe we achter de bar zijn beland, de muziek regelden en de 
tap toucheerden. De gordijnen gingen dicht, de echte klanten naar huis, het café werd aan 
kant gemaakt en wij……wij bleven de tap toucheren. Galant hebben we de smeekbeden 
aangehoord en verlieten als Heeren de bar om 04:45. Memorabel. 
Fredrik Ebbens, beste Fredje, ik ben je zeer dankbaar voor de coverpainting “Struggle for 
life”. Does the germ cell become malignant or will it come alive, that is the question? Een 
perfecte samenvatting van dit proefschrift. 
De Dom was een mooie beklimming (maakt de cover alleen maar mooier!). 
De ‘Paranifmen’: Steven van Gaalen en Max van Leyenhorst. Heeren, ik weet hoe het voelt 
om aan jullie zijde getuige te mogen zijn, en ben zeer verheugd om nu door jullie geflankeerd 
te worden.  
Lieve Ouders en Ouders, Broers en Broers, Zus en Zusjes. Jacques, Renee, Jan, Marianne, 
Jacco, Boaz, Mark, Erik, Naomi, Albertine en Luz Elena. Jullie zijn altijd een grote steun 
geweest en zullen dat ook blijven. Sinds 10 September is letterlijk alles verdubbeld. Het voelt 
verdomd goed. Hoop vanaf nu weer meer tijd met jullie te kunnen doorbrengen. 
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Lieve Niekje. Ik hou van jou. En dit gevoel van liefde is alleen maar meer geworden. 
 
Frommel de pommel was de eerste bijnaam die ik je gaf, aangezien je zo knuffelgek bent. Ik 
hoop dat je elke dag tot in lengte der dagen het ritueel blijft herhalen dat wanneer we samen 
eten jij op mijn schoot komt zitten wanneer jij je bord als eerste leeg hebt.  
 
Handyman noemde ik je wanneer je weer eens iets kapot liet vallen of iets omstootte of 
wanneer je het ei pelde en vervolgens het ei weggooide en de eierschaal deeltjes nog in je 
hand had. Niek ik hou van je en blijf je steunen in voor- en tegenspoed.  
 
Chef noemde ik je, want je bent een perfectionist en je volhardt tot het naar je zin is. Ik 
bewonder dat als een groot goed. 
 
Niek ik hou van je zodanig dat ik wil je vragen of  ik je huidige bijnaam: Mijn kleintje……… 
………10 september 2005…………..het was een superdag. Ik ben gelukkig. 
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